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Antibodies are indispensable tools in many research, diagnostic, and clinical 
applications. Current methods for producing immunoglobulin G (IgG) antibodies in 
engineered cells often require refolding steps or secretion across one or more 
biological membranes. In this work, we describe a robust expression platform for 
biosynthesis of full-length IgG antibodies in the Escherichia coli cytoplasm. IgGs with 
clinically relevant antigen- and effector-binding activities are readily produced in the 
E. coli cytoplasm by grafting antigen-specific variable heavy and light domains into a 
cytoplasmically stable framework and remodeling the fragment crystallizable domain 
with amino acid substitutions that promote binding to Fcγ receptors. The resulting 
cytoplasmic IgGs —named “cyclonals”— effectively bypass the potentially rate-
limiting steps of membrane translocation and glycosylation. Standard antibody 
discovery techniques often require multiple labor intensive and technically challenging 
steps that limit the pace at which valuable antibodies can be developed. We addressed 
this challenge by adapting the cyclonal platform for identification of specific antibody-
antigen binding by implementing two different survival selections. Finally, we 
describe isolation of high-affinity full-length IgGs from combinatorial libraries after 
just a single round of selection. Taken together, these results show that our E. coli-
based platform constitutes a simple yet powerful alternative for rapidly engineering 
full-length IgG antibodies. 
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  CHAPTER 1 
CHALLENGING THE BOUNDARIES OF MONOCLONAL ANTIBODY 
ENGINEERING  
Introduction 
Over the last century researchers have sought to develop technologies and 
applications using the special properties of antibodies.  As a tool for molecular 
detection and identification, antibodies have virtually unmatched diversity and can 
possess exquisite specificity. Specificity, immunological function, and the ability to 
modulate these characteristics continue to increase the importance of antibodies to 
modern therapeutics. The widespread use and continued growth of these antibody-
based applications continues to drive innovation in antibody discovery, antibody 
engineering, and antibody production. In this chapter, the basic principles of 
antibodies will be introduced and the seminal advances in antibody-based technology 
will be presented. The groundbreaking research that provides the theoretical context 
for the work in this dissertation will also be reviewed. Additionally, the current 
challenges facing antibody engineering and discovery will be assessed providing 
motivation for the chapters to follow. 
Natural antibodies  
Natural antibodies, also known as immunoglobulins or Ig, are globular proteins 
that are produced by a host’s immune system to help eliminate pathogens. Antibodies 
bind to unique molecules called antigens, such as membrane proteins or 
oligosaccharides, to elicit an immune response[1]. The specific part of an antigen that 
an antibody recognizes is called the epitope. Antibodies can confer immunity by 
preventing pathogens from interacting with host cells, targeting pathogens to immune 
cells called phagocytes for destruction, or activating complement pathways that 
enhance immune responses[2, 3]. 
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Antibodies are found in two forms; as membrane bound antigen receptors 
(BCRs) on B lymphocytes or B cells, and as soluble proteins secreted by terminally 
differentiated B cells known as plasma B cells. Polyclonal antibodies are those 
produced in response to pathogens and  have been secreted by many different B cell 
clones[1]. These antibodies recognize a number of different epitopes. Monoclonal 
antibodies are those that are produced from one single B cell clone. Monoclonal 
antibodies (mAbs) recognize only one particular epitope[2].  
All immunoglobulins are constructed similarly from paired heavy and light 
polypeptide chains. There are two types of light chains, λ and κ, that are functionally 
identical and can pair with any of the 5 isotypes of heavy chain[2]. However, any 
particular immunoglobulin can only have one type of light chain.  There are 5 different 
classes or isotypes of Igs, namely IgA, IgD, IgE, IgG, and IgM. These isotypes differ 
by the identity of their heavy chains. IgG is the isotype generated with the highest 
specificity. IgGs are extremely effective opsonins, molecules that mark pathogens for 
phagocytosis. IgGs are also effective at activating the complement pathway. As a 
result, IgGs provide the main source of antibody based immunity and thusly are the 
isotype used in most mAb therapeutic formulations.  
Immunoglobulin G antibodies, or simply IgG, are the most abundant antibody 
class found in mammalian serum. The IgG class accounts for about ~75-80% of 
circulating antibody and is one of the most abundant proteins in the blood serum [1, 
4]. 
IgGs are assembled from two light chains and two heavy chains. Two disulfide 
bonds covalently link the two heavy chains in the hinge region. A light chain is 
covalently linked to each heavy chain by an inter-chain disulfide bond forming a 
tetrameric full-length IgG antibody (Figure 1.1a). The IgG light chain (LC) is 
composed of two domains: a variable light (VL) domain located at N terminus, and a 
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constant light domain (CL) located at the C terminus (Figure 1.1a). The IgG heavy 
chain is composed of 4 domains: the variable heavy domain (VH), at the N terminus, 
and 3 constant domains (VH-CH1-CH2-CH3) (Figure 1.1a). The heavy chain CH1 
domain is connected to the CH2 domain by a flexible linker region called the hinge. 
The light chain (VL-CL) together with the VH and CH1 domains form a fragment 
known as the antigen-binding fragment (Fab) ((Figure 1.1b). A homodimer of the 
CH2 and CH3 domains form the Fc or crystallizable fragment. In mammalian cells, an 
oligosaccharide is covalently linked to a conserved asparagine residue (N297) in CH2, 
a post-translational modification called glycosylation (Figure 1.1b) [5]. Glycosylation 
in the Fc fragment is integral for an IgG to be recognized by cells of the immune 
system (effector cells) through binding of the Fc by Fc receptors displayed on the 
surface of these cells [2]. Fc receptor binding can initiate phagocytosis, antibody-
dependent cell-mediated cytotoxicity (ADCC), and complement dependent 
cytotoxicity (CDC). ADCC and CDC are two mechanisms by which antibodies 
facilitate the destruction of pathogen-infected and abnormal host cells. Evidence 
suggests that therapeutic IgG antibodies also utilize the ADCC and CDC mechanisms 
to potentiate the destruction of tumor cells [5]. 
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Figure 1.1. Structure of a Full-length IgG antibody. (a) Antibodies are comprised 
of two identical heavy (H) chains (blue) and two identical light (L) chain (orange), 
linked by interchain disulfide bonds (-SS-). Intradomain disulfide bonds are also 
indicated for the variable regions of the H and L chains (VH and VL), which carry the 
antigen-recognition regions of the antibody (the antibody combining site). The L 
chains possess one constant (CL) domain and the H chains contain three. (b) Schematic 
indicating the Fab (VH-CH1 of the heavy chain; VL-CL of the light chain) and Fc 
regions (CH2-CH3) of the antibody. Glycosylation sites at asparagine 297 (Asn-297) in 
CH2 domains are indicated by hexagons. The general structure of N-linked 
glycosylation is shown inset; core structures indicated by solid lines and variable 
structures by dotted lines comprising of Fucose (Fuc), N-Acetylglucosamine 
(GlcNAc), Mannose (Man), Galactose (Gal) or N-Acetylneuraminic acid (Neu5Ac). 
(c) Linear depiction of the VH and VL domains. The three CDRs of each domain are 
the hypervariable sequences that are the key contributors to antibody diversity. Images 
adapted from Lobato and Rabbitts[6] and Elgundi[7]. 
 
The antigen binding properties of IgGs are localized within the VL and VH 
domains of the antibody (Figure 1.1c). The amino acid sequence varies the greatest 
between IgGs in these domains. However, within both the VH and VL domains, the 
sequence varies the greatest within three flexible loops. These loops are commonly 
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called the complementarity determining regions (CDRs) or hyper variable regions 
(HVs). The VL and VH CDRs that are brought together by the pairing of heavy and 
light chains form the antigen-binding site[2]. CDR3 is the most variable in both VL 
and VH. However, CDR3 of the VH domain exhibits the highest variability of the six 
CDRs in the antigen-binding site (Figure 1.1c). Consequently, this CDR is often the 
most critical for high-affinity antigen binding. 
Each domain of the heavy and light chain contains an intra-chain disulfide 
bond. Altogether, a full-length IgG requires 16 disulfide bonds to achieve its native 
structure (Figure 1.2). 
 
 
Figure 1.2 Disulfide bond connectivity of Full-length IgG antibodies. Schematic 
representation of the native disulfide bonds of a correctly folded IgG antibody. Light 
chain (blue) participates in an intermolecular bond with a heavy chain (gray). Each 
heavy chain makes two intermolecular disulfide bonds with the other heavy chain. 
Each domain has a stabilizing intramolecular disulfide bond. Redox state of cysteines 
(yellow balls) are indicated (oxidized = ball + stick). Figure adapted from Robinson et 
al[8]. 
 
 
Disulfide bonds in proteins 
Disulfide bonds in proteins are post-translational modifications formed through 
the oxidation of two sulfhydryl or thiol groups (– SH) from individual cysteine 
residues. Biologically, formation of these covalent linkages is vital to the stability, 
structure, and activity of many proteins. Because of the increased stability disulfide 
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bonds provide, they are often found in proteins secreted out of the cell, such as 
antibodies[9]. Understanding the nature of disulfide bonds and their formation has 
long been a highly active area of research.  
Disulfide bonds are most often formed and broken (reduced) in vivo via the 
thiol-disulfide exchange mechanism. Thiol-disulfide exchange reactions are initiated 
by thiol oxidoreductases or small thiol containing molecules, such as glutathione[10]. 
These reactions proceed by an exchange of electrons between free thiol groups and an 
existing disulfide bond. Proteins belonging to the thiol disulfide oxidoreductase class 
often share a conserved Cys-X-X-Cys (where X is any amino acid) active site motif 
located in a domain structurally homologous to the ubiquitous protein thioredoxin[9].  
Most organisms in each domain of life have evolved reducing pathways in the 
cytoplasm. Therefore, proteins do not normally acquire stable disulfide bonds within 
the cytosol. As a result, proteins needing disulfide bonds are transported to extra-
cytoplasmic compartments where the machinery for catalysis of disulfide bond 
formation resides[11]. In eukaryotes, proteins are targeted to the endoplasmic 
reticulum to acquire stable disulfide bonds. Gram-negative bacteria, such as E. coli, 
transport proteins to the periplasm if they must be modified with disulfide bonds[10]. 
Disulfide bonding in the periplasm of E. coli 
The periplasm of Gram-negative bacteria is a compartment located between 
the inner membrane which surrounds cytoplasm and the outer membrane which is 
exposed to the extracellular environment. In E. coli, stable disulfide bond formation is 
catalyzed in the periplasm in two stages: (1) oxidation and (2) isomerization. The Dsb 
(Disulfide bond formation) proteins are responsible for these two tasks [12, 
13](Figure 1.3).   
Stage 1, the oxidation of disulfide bonds, is catalyzed by the DsbAB pathway. 
DsbA is a soluble periplasmic protein and is the primary catalyst of disulfide bond 
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formation in E. coli [14]. DsbA catalyzes the formation of disulfide bonds by donating 
its oxidized disulfide to a substrate protein (Figure 1.3). After donating its disulfide 
bond, DsbA is in its reduced form and must be reoxidized in order to catalyze another 
thiol-disulfide exchange[15]. DsbB, an integral membrane protein, performs the 
reoxidation of DsbA and transfers the electrons to a quinone [16-18](Figure 1.3). The 
electrons are in turn transferred along the electron transport chain to a terminal 
election acceptor (e.g. molecular oxygen) [18, 19]. 
DsbA introduces disulfide bonds into proteins non-specifically, most often in a 
consecutive manner[20]. Therefore, DsbA often incorrectly oxidizes proteins that 
require non-consecutive disulfide bonds. Disulfide bonds that are misoxidized are 
corrected (isomerized), during stage (2) by the DsbCD pathway [21, 22](Figure 1.3). 
Contrary to DsbA, the active site cysteines of DsbC must be in a reduced state to 
perform its function as an isomerase [23, 24]. To be regenerated after acting on a 
substrate, DsbD, a second Dsb integral membrane protein, reduces DsbC[23]. 
Ultimately, the reducing power of DsbD originates in the cytoplasm as it is reduced by 
thioredoxin[24](Figure 1.3). 
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Figure 1.3 Disulfide bonding in the periplasm. (1) A substrate protein which 
requires disulfide bonds for its folding is exported to the periplasm in its reduced non-
disulfide bonded state (ProtRED), usually via the sec pathway. (2) DsbA forms a 
disulfide-bonded complex with its reduced substrate resulting in the formation of a 
disulfide bond in the substrate protein (ProtOXI) and the reduction of DsbA’s active 
site cysteines. (3) DsbA is reoxidized by the inner membrane protein DsbB, which 
donates the electrons it has received from DsbA either to ubiquinone (UQ) in aerobic 
conditions or to menaquinone (MQ) in anaerobic conditions. (4) If the substrate 
protein is misoxidized (ProtMIS-OXI) by DsbA, the misfolded protein is recognized 
by DsbC and is either isomerized to its native state or reduced, allowing DsbA to have 
another chance at correctly oxidizing the protein. (5) DsbC is maintained in its active 
reduced state by the inner membrane protein DsbD. (6) DsbD receives its electrons 
from the cytoplasmic thioredoxin (TrxA) which ultimately receives its electrons from 
the cytoplasmic pool of NADPH. Cysteines are represented as yellow balls in their 
reduced state or as sticks in their disulfide-bonded state. Grey arrows show products 
obtained after each step, whereas red arrows represent oxidation/reduction reactions. 
Figure taken from Berkmen[9]. 
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Thiol reduction pathways in the cytoplasm of E. coli 
In E. coli, cysteines in cytoplasmic  proteins are maintained in a reduced state 
by the two main thiol reduction pathways, the thioredoxin and glutaredoxin pathways 
[25](Figure 1.4). There are two thioredoxins natively expressed in the cytoplasm of E. 
coli, thioredoxin 1 (encoded by trxA), and thioredoxin 2 (encoded by  trxC) [26]. 
Thioredoxins reduce disulfide bonds formed in a number of cytoplasmic enzymes 
during their catalytic cycles, thereby regenerating them for another round of catalysis 
[26, 27]. Ribonucleotide reductase is an essential substrate of the thioredoxin pathway 
as it is an enzyme that is involved in nucleotide synthesis.  During the reduction of a 
substrate protein, thioredoxin is converted to its oxidized state with its active site 
cysteines paired in a disulfide bond[28]. The oxidized form of thioredoxin cannot 
perform its normal functions and must be reduced by a second oxidoreductase, 
thioredoxin reductase, encoded by trxB. Thioredoxin reductase ultimately derives its 
oxidizing power from the cofactor NADPH [27, 28](Figure 1.4). 
In the glutathione/glutaredoxin pathway, glutathione oxidoreductase (gor) 
reduces two enzymes, GshA and GshB, which are responsible for the synthesis of 
glutathione, a small sulfhydryl-containing tripeptide (Glu-Cys-Gly) (Figure 1.4). Gor 
also uses a NADPH as a cofactor (Figure 1.4). Glutathione reduces the four known 
glutaredoxins: glutaredoxin 1 (grxA), glutaredoxin 2 (grxB), glutaredoxin 3 (grxC), 
and glutaredoxin 4(grxD) [27, 29]. The glutaredoxins in turn reduce their protein 
substrates in the cell[30]. Similar to the thioredoxins, the active site cysteines in 
glutaredoxins must be reduced in order to act on their native substrates[25]. 
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Figure 1.4 The Thioredoxin and Glutaredoxin pathways in the E. coli cytoplasm. 
The thioreductases glutathione oxidoreductase (Gor) and thioredoxin reductase (TrxB) 
reduce glutathione (GSH/GSSG) and thioredoxins, respectively. Glutaredoxins 2 and 4 
are not shown. The solid arrows indicate reduction. The dashed arrows indicate 
oxidation. Redox state of cysteines (yellow balls) are indicated (oxidized = ball + 
stick; reduced = ball). 
 
E. coli strains with an oxidizing cytoplasm 
Through pioneering studies in the lab of Dr. Jon Beckwith at Harvard, 
mutations in the E. coli genome that permit stable formation of disulfide bonds in the 
cytoplasm were isolated. Derman et al., found that mutation of trxB allowed for 
cytoplasmic accumulation of active Alkaline Phosphatase, a native E. coli protein that 
requires two disulfide bonds for proper folding and activity[31]. The authors 
hypothesized that trxB mutants accumulate oxidized thioredoxin in their cytoplasm 
and that oxidized thioredoxins catalyze the formation of disulfide bonds. E. coli strains 
that allow for stable disulfide bond formation in their cytoplasm are often called 
oxidizing strains[31]. 
Mutating glutathione oxidoreductase (gor) was subsequently found to allow 
cytoplasmic accumulation of proteins that require disulfide bonds, indicating that 
disruption of either pathway results in the capacity to promote disulfide bonding in the 
cytoplasm[26]. In this case, oxidized glutaredoxins promote the formation of disulfide 
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bonds. 
 
 
Figure 1.5 Disulfide bond formation in the cytoplasm of trxB gor ahpC* cells 
Schematic representation of the redox pathways involved in the formation of disulfide 
bonds in the cytoplasm of trxB gor ahpC* cells. AhpC* gains the ability to reduce 
Grx1. Reduced Grx1 can catalyze the reduction of proteins. Accumulation of oxidized 
thioredoxins such as Trx1 catalyzes the formation of disulfide bonds. Disabled protein 
interactions are represented by dotted lines. For simplicity, other reductases (Grx2, 
Grx3 and Trx2) are omitted and only the redox state of cysteines (yellow balls) of 
Grx1 and Trx1 are indicated (oxidized = yellow balls are joined; reduced = ball). 
Figure adapted from Berkmen[9]. 
 
Double mutants (trxB gor), however, were found to grow very poorly in 
aerobic conditions as a result of their inability to reduce essential substrates (e.g. 
ribonucleotide reductase) [32]. Although these mutants grow poorly, unless in the 
presence of a reducing agent like dithiothreitol (DTT), they showed an increased 
capacity to promote the correct oxidative folding in the cytoplasm, when compared to 
the single mutant strain trxB[25]. Interestingly, the trxB gor E. coli mutants 
spontaneously acquired a growth suppressor mutation that allowed them to grow 
normally in the absence of a [25]reducing agent[25]. Later studies revealed that this 
mutation maps to the ahpC gene that codes for a peroxiredoxin. Strikingly, only a 
single codon is repeated, resulting in the insertion of a single amino acid, which 
converts AhpC from a peroxiredoxin that protects the cell from oxidative damage to a 
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disulfide reductase, AhpC*. The mutant enzyme is able to shuttle electrons through 
the glutathione/glutaredoxin pathway restoring its reducing power [33, 34](Figure 
1.5). 
The triple mutant suppressor strain (trxB gor ahpC*), FA113, has been 
demonstrated for the high level cytoplasmic production of proteins that require 
disulfide bonds for activity (Figure 1.5)[35]. It is now available commercially from 
Novagen under the trade name Origami[35].  
A number of other systems have been developed for expression of proteins 
requiring disulfide bonds in the cytoplasm. Co-expression of the yeast sulfhydryl 
oxidase Erv1p was shown to promote the accumulation of disulfide bonded proteins in 
the E. coli cytoplasm without the disruption of the glutaredoxin and thioredoxin 
pathways [36, 37]. The same group also reported engineering the DsbAB pathway, 
specifically the membrane topology of DsbB, such that DsbA can catalyze disulfide 
bond formation in the cytoplasm[38]. Overall, these developments demonstrate that 
the cytoplasm still has untapped potential as a compartment for the production of 
disulfide bonded proteins. 
History of antibody applications 
For over a century, antibodies have been used as treatments for disease. In 
1890, Emil von Behring and Kitasato Shibasaburō proved that diphtheria could be 
treated with antibody-containing serum harvested from animals immunized against the 
pathogen [39, 40]. Von Behring’s and Kitasato’s breakthrough was the first reported 
clinical success of the use of passive immunization. Serum therapies are examples of 
passive immunization, which is the administration of antibodies to prevent, treat, or 
cure a clinical indication. Passive immunization is currently used against several 
infections including tetanus, botulism, and diphtheria [40, 41]. Children with antibody 
deficiencies are treated with pooled human serum against common childhood diseases 
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to which they may be exposed [40, 41]. Human IgG are also administered as 
prophylaxis for serious viral pathogens, which include Hepatitis A, Hepatitis B, and 
Rabies [40, 41].  
The first antibody-based immunotherapies developed to treat infectious disease 
were derived from serum containing polyclonal antibodies. More recently, medical 
scientists have shifted focus to developing monoclonal antibody therapeutics to 
cancer. In a landmark study, Levy and colleagues demonstrated that immunotherapy 
with anti-immunoglobulin idiotypic antibodies results in remission in B cell 
lymphoma patients[42]. This work showed for the first time that cancer could be 
effectively treated with a targeted monoclonal antibody. Of the five most successful 
monoclonal antibodies three are approved for cancer indications [43, 44]. Herceptin 
(trastuzumab) is used to treat certain types of breast cancer [3, 45]. Avastin 
(bevacizumab), which targets vascular endothelial growth factor (VEGF), can be used 
as a part of a treatment regimen for several types of cancer including colorectal and 
lung cancer[45]. Rituxan (rituximab), which targets the B cell antigen CD20, is a 
treatment for Non-Hodgkin’s lymphoma and chronic lymphocytic leukemia [45, 46].  
Another important class of monoclonal antibodies are those developed to 
relieve symptoms associated with autoimmune disorders including rheumatoid 
arthritis (RA), Crohn’s disease, and plaque psoriasis[47]. For instance, Humira 
(adalimumab) and Remicade (infliximab) bind tissue necrosis factor alpha (TNFα) 
thereby blocking its interaction with its native receptors (TNFRs)[47, 48]. Blocking 
the TNFα and TNFR interaction disrupts the signaling cascade that leads to 
inflammation[48]. At least 47 monoclonal antibodies have been approved by the Food 
and Drug Administration (FDA) and in Europe for treatment of various disorders. 
With more than 50 monoclonal antibodies in late stage clinical trials and more than 
300 candidates in development for several different indications, monoclonal antibody 
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immunotherapy is likely to remain important in the future[44, 49]. 
Researchers and clinicians have used antibodies to develop diagnostic and 
analytical technologies. Antibodies were used to develop the Coombs test, a test for 
Rhesus (Rh) factor in blood[50].  In 1960, Rosalyn Yalow and Solomon Berson 
pioneered a radioimmunoassay used to quantify insulin in plasma[51]. Eva Engvall 
and Peter Perlman described the Enzyme-linked immunosorbent assay (ELISA) in 
1971[52]. The ELISA has since become one of the most widely used laboratory 
techniques having applications in disease diagnosis, binding studies, and molecular 
identification.  
Antibodies have a rich history for use in diagnostic, analytical, and clinical 
applications that continues to this day. Many of the techniques described are still in 
use underscoring the continuing importance of developing antibody production and 
engineering technology. As the use of antibodies continues to expand and the number 
of antibody-based applications continues to grow, techniques for efficient and cost-
effective development of new antibodies will be needed. 
Hybridoma technology  
The earliest breakthrough in monoclonal antibody technology came in 1975 
when Milstein and Kohler described the production of large quantities of mAbs using 
hybridoma technology[53]. In hybridoma technology, healthy antibody-secreting 
murine plasma B cells are immortalized by fusing them with a myeloma cell line 
creating a hybrid cell line that can proliferate indefinitely in cell culture while 
continuing to secrete monoclonal antibodies (Figure 1.6). In 1986, Muromonab-CD3  
(Orthoclone OKT3) became the first monoclonal antibody therapeutic licensed by the 
FDA. The fully mouse antibody binds the CD3 T cell receptor and was approved to 
treat allograft rejection specifically after kidney transplantation. 
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Figure 1.6 Antibody discovery via hybridoma technology. To generate hybridoma 
cells, an animal is immunized with the desired antigen (denoted in red). After spleen 
cell harvest and myeloma fusion, supernatants from hybridoma clones are screened 
and monoclonal antibodies of the desired specificity are identified with an appropriate 
functional assay. Figure adapted from Joyce et al[54]. 
 
However, mouse antibodies are often immunogenic when used in human 
therapy [55, 56] which often results in a reduction in therapeutic efficacy. Thus, it is a 
common practice to use DNA recombinant technology to replace potentially 
immunogenic mouse-derived Ig domains of an antibody with the human homologs of 
those domains in a process known as humanization. The chimeric antibody format, in 
which the constant domains of the mouse heavy (CH1-CH2-CH3) and light chains (CL) 
are replaced, and the humanized format, in which all but the CDR domains are 
replaced, are most prevalent formats used for therapeutic antibodies[57]. 
Researchers have also developed methods for generating hybridomas using 
human B cells[56]. However, isolating monoclonal antibodies using hybridoma 
systems is a technologically complex process and does not allow for engineering of 
desirable properties like antibody affinity, stability, or enhancement of effector 
function.  
In an attempt to isolate fully human antibodies while still using mice as model 
hosts, transgenic strains were developed by replacing mouse antibody coding genes 
with human antibody coding gene loci resulting in mice that generate fully human 
antibodies upon immunization with an antigen[58-60]. However, it is often difficult to 
generate effective antibodies via immunization of transgenic mice when the antigen to 
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be administered is either toxic or highly conserved (immune tolerance) thereby 
limiting the applicability of the technology [57, 61].  
To address these shortcomings, microbial systems have been developed to 
screen antibodies with enhanced functional properties from large combinatorial 
libraries. But first the challenge of expressing active antibodies in microbial systems 
had to be addressed. 
Antibody fragments expressed in microbial systems 
Expression of antibody fragments in E. coli was initially limited to the 
periplasm because of the requirement of stable disulfide bonds for folding. The 
Plückthun group reported the earliest use of recombinant DNA technology to express 
a soluble antibody fragment in E. coli [62]. Plückthun and associates expressed VL and 
VH domains as separate polypeptides that assemble via hydrophobic interactions into 
variable fragments (Fvs) (Figure 1.7). These fragments retain the antigen binding 
specificity of a full-length antibody. Later, the single-chain Fv (scFv), where the VL 
and VH antibody sequences are genetically fused by the introduction of a short linker 
sequence, was introduced as a way to stabilize the Fv fragment[63] (Figure 1.7). 
Eventually, expression of more complex antibody fragments in the E. coli periplasm 
like Fabs, dimeric antibody fragments composed of a full-length light chain (VL-CL) 
linked to the VH and CH1 domains of a heavy chain by a disulfide bond between the 
CL and CH1 domains, was also achieved [64, 65](Figure 1.7). Successful production 
of scFvs and Fabs in E. coli was soon followed by technologies for isolating high 
affinity binders from combinatorial libraries. 
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Figure 1.7 Common antibody fragments expressed in microbes. Schematic 
representation of different antibody formats, showing intact an IgG antibody along 
with Fab, Fv, and scFv fragments (sizes given in kilodaltons (kDa) are approximate). 
VL and VH domains are also depicted. Figure adapted from Holliger and Hudson[66]. 
 
Antibody engineering technology in microbial systems  
The human immune system generates billions of antibodies, all with slightly 
different specificities, in response to a pathogen. As a result, an individual’s immune 
repertoire contains antibodies that can be matured to bind virtually any substance[2]. 
To mimic this diversity, large libraries of DNA encoding VH and VL sequences are 
created to generate a rich pool of specificities to screen for antibodies against a target 
antigen. Libraries can either be immunized libraries that are biased for binders against 
a particular antigen, or naïve, which are unbiased[67]. The first libraries created for 
antibody isolation were amplified from mRNA harvested from animals immunized 
against a particular antigen[68]. Later, antibody engineers began to create de novo or 
synthetic antibody libraries. To create synthetic libraries, numerous strategies have 
been developed to introduce variation within VH and VL sequence DNA. Techniques 
that have been demonstrated for this purpose include CDR walking[69], random 
mutagenesis[70], DNA shuffling[71], or site specific recombination[72]. 
Phage display is one of the most widely used in vitro technologies for affinity 
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maturation and screening of antibody fragments from combinatorial libraries[73]. The 
Winter lab at the MRC Laboratory of Molecular Biology in Cambridge, England 
pioneered phage display as a tool for selecting specific antibodies from scFv libraries 
[74]. Concurrently, phage display was adapted for the selection of antigen-specific 
Fabs by the Lerner and Barbas labs at the Scripps Research Institute[75]. 
 
 
Figure 1.8 In vitro and microbial display technologies. Schematic representation of 
display technologies. Antibody phenotype (orange) is coupled to its genotype (wavy 
line) via a phenotype-genotype link (green) to a host (blue and purple). As a result, 
each host particle expresses (or displays) a unique antibody on its surface. Figure 
adapted from  Hoogenboom[76]. 
 
The principle behind phage display is the coupling of a genotype with a selectable 
phenotype by fusing the antibody to the surface of bacteriophages harboring DNA 
encoding the antibody. Phage libraries can be selected for binding (“panning”) against 
a target antigen and DNA from phages that bind can be recovered. Phage display has 
proved to be a powerful antibody engineering technology. The first fully human 
antibody approved by FDA for therapeutic use, Humira, was developed using this 
transformational technique. Since its approval in 2002, the anti-TNFα antibody has 
become one of the most commercially successful biologics. Alternative in vitro 
screening techniques, including ribosome[77-79] and nucleic acid display[80], operate 
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by similar principles(Figure 1.8). 
Microbial display technologies for screening antibody fragments have also 
been developed. These include yeast display [71, 81, 82] and bacterial display [70, 83, 
84] . Also, in vivo selections have been reported using E. coli that allow isolation of 
antibody fragments by simple selection strategies such as growth on antimicrobial 
agents. These strategies include the protein complementation assay (PCA) [85-87], 
which depends upon reactivation of a reporter protein via antigen-antibody 
interactions, and bacterial hitchhiker selection [88-90].  
Antibody fragments however, have proven to be of limited use in therapeutic 
applications due to their short circulating half-lives, rapid systemic clearance, and 
inability to activate the host’s immune functions[91]. As a result, antibody fragments 
isolated using the described technologies are typically converted to full-length mAbs 
and expressed in mammalian systems. Unfortunately, this process is costly and labor 
intensive. The reformatting process also often results in a loss of binding activity [92, 
93]. 
Full-length antibody expression and engineering in E. coli 
The need to convert antibody fragments to full-length antibodies after they 
have been selected could be circumvented by a strategy to directly express and select 
full-length antibodies in E. coli. In an important technological advancement, Simmons 
and colleagues at Genentech reported the first instance of soluble full-length antibody 
expression in E. coli. In this study, heavy and light IgG chains were expressed in the 
periplasm where assembly into full-length IgG is favored via disulfide bonding[94].  
The Georgiou group at the University of Texas-Austin adapted bacterial 
membrane display to screen specific IgG from an immunized library. Full-length IgG 
were captured on the E. coli inner membrane using a lipoprotein-Fc binding protein 
fusion (Figure 1.9). The outer membrane was then removed creating “spheroplasts.” 
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After incubating the spheroplasts with a fluorescently tagged antigen, the authors then 
screened the displayed IgG library by fluorescence-activated cell sorting (FACS) [93]. 
 
 
Figure 1.9 Isolation of full-length antibodies with E-clonal technology. Schematic 
representation of the E-clonal display technology. Libraries of full-length IgG 
antibodies expressed in the periplasm of E. coli are captured by an inner-membrane 
tethered NlpA-ZZ fusion protein. Following outer-membrane disruption, the inner-
membrane-captured IgG antibodies specifically bind fluorescently labeled antigen and 
are enriched by FACS. 
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Spiess and colleagues at Genentech demonstrated isolation of full-length anti-
VEGF framework variants with enhanced expression and thermostability using the 
bacterial antibody display (BAD) system[95]. The BAD method entails expressing 
full-length IgG in the periplasm followed by permeabilizing the outer membrane of 
the cells with EDTA. The permeabilized cells are then incubated with fluorescently 
labeled antigen. The antigen is able to penetrate the outer membrane of the cells and 
be captured by the expressed full-length antibodies. After antigen capture, the 
membrane integrity is restored though incubation with MgCl2. Cells that capture the 
antigen can then be screened by fluorescence-activated cell sorting (FACS). To date, 
these are the only reports of isolation of full-length IgGs expressed in E. coli. 
However, these methods require specially designed antigens, expensive equipment 
(flow cytometer), and permeabilizing the cell membrane [93, 95] (Figure 1.9). 
Additionally, the use of FACS limits the library size that can be realistically screened 
and thus would require pre-screening using a supplementary method to accommodate 
screening larger libraries[92]. 
A streamlined system for monoclonal antibody development  
While the seminal work presented in this chapter addressed significant 
obstacles faced by the field in the past, there are still challenges that remain. These 
include the long process times associated with IgG production in mammalian cells, the 
dependence of antibody discovery on immunization, and limited control over antibody 
maturation or engineering. Though use of microbial systems offers much shorter 
antibody development timelines and more control over antibody diversity and 
optimization, these systems still depend on laborious multi-step processes.  
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In this thesis, I describe a simple prokaryotic system designed to streamline 
full-length IgG antibody production and discovery processes. By basing our system on 
the prokaryote Escherichia coli, we were able to take advantage of the relative ease 
and low cost of culture, the plethora of tools available for genetic manipulation and 
recombinant protein expression, and the high doubling rate associated with this model 
organism. We achieved full-length antibody production by expressing the 
immunoglobulin G subunits in an engineered strain of E. coli called SHuffle. SHuffle 
promotes the formation of stable disulfide bonds in the cytoplasm where the heavy and 
light immunoglobulin chains are assembled into an IgG. We call these cytoplasmic 
monoclonal antibodies “cyclonals”. We demonstrated that a variety of cyclonals 
assembled efficiently and were functionally active. The binding kinetics, serum 
stability, and binding specificity of the cyclonals were extensively characterized and 
compared with IgG produced by mammalian cells. We also tested whether the binding 
specificity of a cyclonal can be readily engineered using standard DNA recombinant 
techniques. Several cyclonals with unique antigen specificities were generated by 
variable domain grafting using the framework of our model cyclonal and expressed in 
SHuffle. Furthermore, the Fc domain of aglycosylated cyclonals was remodeled to 
confer function that is essential in many cases for therapeutic efficacy.  Overall yields 
of engineered cyclonals produced in shake flask cultures were measured.  
After establishing that full-length, active IgGs could be produced at greater 
yields within the cytoplasm of E. coli, we implemented the cyclonal system for 
discovery of new IgGs. To do this, we applied our system to report intracellular 
antibody:antigen binding by implementing two distinct survival selections. In one 
approach antibody:antigen reactivity is linked to cell survival on chloramphenicol. In 
the other, a protein-fragment complementation assay (PCA) in which antibodies were 
isolated due to viability of cells on minimal media and resistance to glyphosate was 
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developed. We then examined the general applicability of both selections by testing 
whether each strategy correctly reported the binding of several known 
antibody:antigen pairs. Lastly, we isolated high affinity cyclonals from combinatorial 
libraries using one of our selection platforms. We show that the cyclonal platform 
represents a significant advancement in antibody engineering technology that could 
greatly simplify discovery, development, and production of monoclonal antibodies.  
Recently, more than 100 of the preeminent experts in the field of antibody 
engineering technology called for an effort to establish consistent standards for 
antibodies used in research and the clinic [96]. Their recommendations include that: 
(1) the sequence of all antibodies should be defined and available and (2) that 
researchers should shift toward producing antibodies recombinantly. In addition, the 
co-authors Andrew Bradbury and Andreas Plückthun, suggest that antibody scientists 
turn to methods that directly yield recombinant binding reagents that can be readily 
sequenced [96]. Techniques like our cyclonal technology are well suited to meet these 
standards. 
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CHAPTER 2 
EFFICIENT EXPRESSION OF FULL-LENGTH ANTIBODIES IN THE 
CYTOPLASM OF ENGINEERED BACTERIA1  
Introduction 
Over the past three decades, monoclonal antibodies (mAbs) have become one 
of the most useful protein tools with a myriad of diagnostic and therapeutic 
applications. For example, of the 151 unique recombinant therapeutics approved by 
the FDA, one-third of them are mAbs, with many more in research and development 
pipelines. At present, the majority of mAbs approved for therapeutic applications are 
produced in Chinese hamster ovary (CHO) cells (12 out of 28), followed by SP2/0 
(7/28) and NS0 (5/28) mouse cell lines, and hybridomas (2/28)[97]. The remaining 
two are antigen-binding fragments (Fabs) that are produced periplasmically in 
Escherichia coli.  
With this expansion in the use of mAbs has come an increased demand for 
systems that enable rapid, cost-effective production and customization using 
molecular engineering. Mammalian cell expression systems offer a number of 
potential advantages for generating mAbs including high-level expression and 
stability[98], and have recently been developed for the display of functional 
glycosylated IgGs on the cell surface[99, 100]. However, the selection of stable 
antibody-producing cell lines is very time-consuming. Additionally, despite the 
potential for high mAb yields in CHO cells (~10 g/L of culture), mammalian cell 
expression requires a long production cycle that results in higher cost of goods relative  
____________________ 
1 Adapted with permission from: Robinson, M.-P., N. Ke, J. Lobstein, C. Peterson, A. 
Szkodny, T. J. Mansell, C. Tuckey, P. D. Riggs, P. A. Colussi, C. J. Noren, C. H. Taron, M. P. 
DeLisa and M. Berkmen, Efficient expression of full-length antibodies in the cytoplasm of 
engineered bacteria. Nature Communications, 2015. 6: p. 8072. 
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to microbial expression systems that involve much faster growth rates and thus lower 
capital investment [101, 102].  
Moreover, mammalian cell surface display has been hampered by the smaller 
library sizes that can be screened and the appearance of multiple copies of antibodies 
with different specificities on a single cell surface, making it difficult to directly 
identify and isolate antibodies with a desired property from naïve libraries. 
Additionally, with the increasing demand for animal-free products, alternative 
production platforms continue to be sought. Some possibilities include in vitro cell 
free expression systems[103], algae[104], baculoviral insect[105] or plant cells[106], 
and Drosophila melanogaster[107]; however, each of these presents many of the same 
challenges faced with mammalian systems while also being much less utilized. 
E. coli on the other hand remains a system of choice, finding broad use in both 
industry and academia for bench- and large-scale production of recombinant proteins. 
A major challenge facing the use of E. coli as an antibody expression platform is the 
production of mAbs with the correct disulfide bonds. The formation of disulfide bonds 
in E. coli can be catalyzed in either the naturally oxidative periplasmic compartment 
[108] or in the cytoplasm of genetically engineered strains [35, 109]. Indeed, many 
fragments derived from mAbs such as Fab[110], single-chain Fv (scFv)[111], Fc[112], 
and an scFv-Fv fusion[113] have been expressed in the periplasm or in the cytoplasm 
of specially engineered E. coli[114, 115 , 116]. There have even been two reports 
describing expression and functional assembly of full-length IgGs in E. coli, both in 
the periplasm [93, 94]. However, periplasmic expression is thought to be limited by 
the smaller volume and the lack of ATP-dependent molecular chaperones in this 
compartment, as well as by the need for extensive optimization to efficiently secrete 
both the IgG heavy chain (HC) and light chain (LC) across the tightly sealed 
cytoplasmic membrane. To address these limitations, several groups have attempted to 
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produce soluble IgGs in the cytoplasm of E. coli; however, none have been successful 
[117-119]. At best, these efforts resulted in misfolded IgG chains within inclusion 
bodies, which required further in vitro refolding processes. 
Here, we demonstrate that biologically active IgGs can be obtained by 
expression in the engineered oxidative cytoplasm of an E. coli strain called 
SHuffle[109].  In fact, significantly higher titers of cytoplasmic IgGs named 
“cyclonals” were obtained compared to periplasmic IgG expression, suggesting that 
membrane translocation is a limiting step in bacterial IgG production. Indeed, protein 
transport across biological membranes is energetically expensive and is often 
associated with negative pleiotropic effects [120, 121]. And unlike the periplasm, 
which lacks ATP, the cytoplasm of E. coli harbors several energy-dependent folding 
chaperones (e.g. GroEL, ClpXP, Hsp90) that may promote more efficient IgG folding 
and assembly. Further, we show that simple grafting of Fv domains from previously 
isolated IgGs permits on-demand production of entirely new cyclonals that bind 
specifically to diverse antigens. One concern, however, regarding the use of the 
cytoplasm is the absence of asparagine-linked (N-linked) glycosylation, which in the 
context of IgGs is necessary for in vivo effector function via binding to cognate Fcγ 
receptors (FcγRs)[122, 123] and for circulating half-life retention time[124]. We 
addressed this concern by modifying cyclonals with previously identified Fc mutations 
that endow IgGs with the ability to bind the receptors FcγRI, FcγRIIa, FcγRIIb and 
FcγRIIIa [5, 125, 126]. The end result is an entirely cytoplasmic system for efficient 
biosynthesis of immunologically and therapeutically relevant IgGs without the need 
for membrane translocation or glycosylation. This platform not only provides a 
powerful complement to the existing antibody expression toolkit, but should open the 
door to a range of applications such as the rapid conversion of phage-displayed scFvs 
into full-length IgGs or animal-derived IgGs into humanized clones. 
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Results 
Cytoplasmic IgG production in SHuffle cells. To enable production of cyclonals in 
E. coli, the genes encoding HC (VH-CH1-CH2-CH3; CH2-CH3 is a murine γ1 constant 
region) and LC (VL-CL; CL is a murine κ constant region) were assembled into a 
synthetic, bicistronic operon under the control of a strong T7/lac promoter in plasmid 
pET21b (Figure 2.2a). Our initial construct was generated using the VH and VL 
domains of an anti-maltose-binding protein (MBP) antibody. The resulting plasmid 
was transformed in either a wild-type (wt) E. coli B strain or the isogenic trxB gor 
suppressor strain MB1731, whose cytoplasmic reductive pathways have been 
diminished, allowing the formation of disulfide bonds in the cytoplasm[35, 109] 
(Figure 2.1).  
 
 
Figure 2.1 Disulfide bond formation in the cytoplasm of SHuffle. Schematic 
diagram of the redox pathways in the cytoplasm of SHuffle cells. Disabled protein 
interactions due to the deletion of trxB and gor are represented as dotted lines. Redox 
state of cysteines (yellow balls) are indicated (oxidized = ball + stick; reduced = ball). 
(a) Heavy chain (HC) with 11 cysteines and light chain (LC) with 5 cysteines are 
reduced by Grx1 or oxidized by Trx1. (b) Misoxidized IgG is isomerized to its (c) 
native correctly folded state by DsbC. 
 
Both strains carry a genomic copy of T7 gene1, which encodes the T7 RNA 
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polymerase that permits expression of genes under the regulation of the T7 promoter. 
As expected, no IgG activity above background was observed in wt E. coli cells 
expressing the anti-MBP cyclonal (Figure 2.2b), consistent with the earlier 
observations that IgGs do not fold correctly in a normal reducing cytoplasm [117-
119]. In contrast, expression of the anti-MBP cyclonal in MB1731 cells resulted in a 
marked increase in IgG activity (Figure 2.2b), indicating that an oxidizing cytoplasm 
is sufficient for the correct folding of full-length IgG.  
 
 
Figure 2.2 Cytoplasmic expression of mouse anti-MBP cyclonals in SHuffle. (a) 
Schematic of pET21b-based vector for expression of cyclonals in E. coli. VH, variable 
heavy; VL, variable light; CH, constant heavy; CL, constant light; RBS, ribosome 
binding site. (b) ELISA signals (Abs492) for mouse anti-MBP cyclonals in lysates 
generated from the following:  wt E. coli B strain with a reducing cytoplasm 
(reducing); isogenic E. coli strains MB1731 and SHuffle engineered with oxidizing 
cytoplasms (oxi); and, in the case of SHuffle, cytoplasmic DsbC (oxi + cDsbC). The 
activity measured in MB1731 cells carrying empty pET21b served as a negative 
control (oxi control). Data are expressed as the mean ± standard error of the mean 
(SEM) of biological triplicates. 
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IgG folding and assembly processes are dependent on multiple disulfide 
bonds[127]. Hence, we hypothesized that cyclonal production could be enhanced by 
expression of E. coli DsbC, an oxidoreductase chaperone capable of enhancing 
oxidative protein folding both in its native periplasmic compartment and when 
expressed cytoplasmically[35, 114, 128]. To test this notion, SHuffle T7 express cells 
(hereafter SHuffle), which are isogenic with MB1731 but carry a copy of dsbC that 
lacks its native signal sequence and is regulated by the rrnB promoter[109], were 
transformed with the anti-MBP cyclonal-encoding plasmid. In the presence of 
cytoplasmic DsbC, cyclonal activity was measurably increased (Figure 2.2b) without 
any significant difference in growth compared to MB1731 cells expressing the same 
cyclonal construct. In addition to mouse IgG, rabbit antibodies specific for two 
different human proteins, namely β2 microglobulin (B2M) and prostate-specific 
membrane antigen (PSMA), were actively expressed in the cytoplasm of SHuffle cells 
(Figure 2.3a).  
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Figure 2.3 Antigen-binding activity of rabbit and humanized cyclonals. (a) 
Antigen-binding activity in SHuffle lysates for anti- β2 microglobulin (B2M) and anti-
prostate-specific membrane antigen (PSMA) cyclonals as indicated. ELISA signals 
(Abs492) for rabbit cyclonals (diamonds) and empty plasmid control (triangles) were 
obtained using anti-rabbit antibodies; signals for rFab/hFc cyclonals (squares) and 
corresponding empty plasmid control (asterisks) were obtained with anti-human Fc 
antibodies. (b) HER2-binding activity in lysates for cyclonal (closed circles) and E-
clonal (open circles) versions of Herceptin expressed from pMAZ360-Herceptin in 
SHuffle cells or from pSTJ4-AglycoT in the parental B strain, as well as for empty 
plasmid control (triangles). ELISA signals (Abs492) were obtained with anti-human 
HC+LC antibodies. All data are expressed as the mean ± standard error of the mean 
(SEM) of biological triplicates. 
This is significant because rabbit monoclonal antibodies are much more 
difficult to develop compared to mouse antibodies due to the lack of a stable fusion 
partner cell line for hybridoma development. Taken together, these results confirm that 
(i) full-length IgGs can be produced as soluble proteins in the bacterial cytoplasm 
when the cytoplasmic reductive pathways have been diminished and (ii) the activity of 
antibodies produced in the cytoplasm is on par with those produced recombinantly in 
mammalian cells. 
Humanizing cyclonals via domain swapping. Human, or human hybrid, antibodies 
are typically less immunogenic than those of mice[129]; therefore, it has become 
common practice to ‘humanize’ mouse antibodies. Humanizing involves combining 
the antigen-binding portions of a mouse antibody with the constant regions of a human 
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antibody using recombinant DNA techniques. To create humanized cyclonals, we re-
engineered the mouse anti-MBP cyclonal in two ways. First, the mouse anti-MBP 
Fabs were spliced onto human Fc resulting in a mouse Fab/human Fc (mFab/hFc) 
hybrid. Second, the mouse anti-MBP variable domains were fused to human constant 
domains (mouse VL to human CL and mouse VH to human CH1-CH2-CH3 for LC and 
HC, respectively) resulting in a chimeric antibody that contained only ~30% mouse 
sequence as described previously[130, 131]. Both newly engineered cyclonals were 
expressed as functional IgGs in the cytoplasm of SHuffle cells at a level that was 
comparable to that of the mouse cyclonal (Figure 2.4a). Western blot analysis under 
non-reducing conditions revealed that nearly 70% of the HC was associated with the 
LC in fully assembled, heterotetrameric IgGs (Figure 2.4b), shown for the mFab/hFc 
hybrid. Size exclusion chromatography (SEC) further confirmed the high efficiency of 
heterotrimer formation for the SHuffle-derived anti-MBP cyclonal (Figure 2.4c). 
Similar domain swapping with rabbit cyclonals resulted in rabbit Fab/human Fc 
(rFab/hFc) hybrids that bound cognate antigens as effectively as their progenitors 
(Figure 2.3a).  
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Figure 2.4 Expression of humanized cyclonals. (a) Antigen-binding activity for 
mouse, mFab/hFc hybrid, and chimeric anti-MBP cyclonals. ELISA signals (Abs492) 
for mouse cyclonal and empty plasmid control (light green triangle) samples in cell 
lysates were obtained with anti-mouse antibodies; mFab/hFc cyclonal, chimeric 
cyclonal, and corresponding empty plasmid control (dark green star) were detected in 
cell lysates with anti-human Fc antibodies. Data are expressed as the mean ± SEM of 
biological triplicates. (b) Soluble anti-MBP cyclonal in the mFab/hFc format was 
purified from cell lysates prepared from SHuffle by protein-A affinity chromatography 
and analyzed by Western blot under non-reducing (left panel) and reducing (right 
panel) conditions. Arrows indicate fully assembled cyclonal as well as other 
intermediate species. The percentage of fully assembled heterotetrameric product 
among all product was 63 ± 5% (left panel) as determined by densitometry analysis. 
(c) Representative SEC analysis of protein A-purified anti-MBP cyclonal in the 
mFab/hFc format performed using a Superdex 200 10/300 GL gel filtration column. 
Heterotetramer and other intermediate products are labeled. 
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Figure 2.5 Comparison of SHuffle- versus hybridoma-derived IgGs. (a) Antigen-
binding activity for protein A-purified hybridoma-produced anti-MBP monoclonal 
IgGs or anti-MBP cyclonals in the mFab/hFc hybrid or mouse formats. ELISA signals 
(Abs492) for all samples were obtained with anti-mouse IgG (Fab specific)-HRP 
antibodies. Data are expressed as the mean ± SEM of biological triplicates. (b) 
Western blots against purified MBP (lane 1 and 4) or MBP in crude cell lysates (lane 3 
and 6) were probed with equal amounts of either SHuffle-produced anti-MBP 
cyclonals (lanes 1-3) or hybridoma-produced anti-MBP monoclonal IgGs (lanes 4-6). 
Cell lysates lacking cytoplasmic MBP served as controls and showed no unspecific 
cross-reaction for either of the IgGs (lanes 2 and 5). Each blot was incubated with 10-
ml solution containing each antibody at a final concentration of 0.1 µg/ml. (c) Stability 
analysis for protein A-purified hybridoma-produced anti-MBP monoclonal IgGs or 
anti-MBP cyclonals in the mFab/hFc hybrid or mouse formats upon incubation in 
bovine serum. IgGs were diluted to a final concentration of 30 g/ml in 100% bovine 
serum and incubated at 37°C for the indicated time periods. Residual binding activity 
to MBP of each fraction was evaluated by ELISA. 
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Next, the bacterially produced cyclonals were compared to mammalian cell-
derived IgG produced using conventional hybridoma cell culture. With respect to 
antigen binding, purified cyclonals in the mFab/hFc and mouse formats bound soluble 
MBP in ELISA with similar avidity to the corresponding hybridoma-derived IgG 
(Figure 2.5a). Cyclonals also performed comparably to the hybridoma IgG when each 
was used in a Western blot format (Figure 2.5b). With respect to stability, we 
compared the serum stability at 37°C of cyclonals in the mFab/hFc and mouse formats 
to that of hybridoma-derived IgG. Importantly, all IgGs were equally stable, losing 
little to no binding activity over the test period of four days (Figure 2.5c). 
Variable region grafting yields new cyclonal specificities. Because of the ease with 
which new genes can be designed, cloned and expressed in E. coli, the cyclonal 
platform affords the unique opportunity for on-demand production of customized 
antibodies. To demonstrate this concept, we created a panel of new cyclonals in a 
process that required less than a week to complete. This involved first replacing the 
VH and VL genes of the anti-MBP cyclonal with the same genes from a variety of 
existing antibodies and antibody fragments including:  YMF10, a humanized IgG 
specific for proteolytically processed and heptamerized Bacillus anthracis protective 
antigen (PA-63)[93]; 26.10-IgG, a murine IgG specific for digoxin (Dig)[93]; D10, an 
scFv specific for the capsid protein D (gpD) of bacteriophage lambda[132]; anti-Gcn4 
scFv (Ω-graft variant) that binds the 47-residue bZIP domain of the yeast transcription 
factor Gcn4 (Gcn4-bZIP)[133]; and h6-4, an scFv that binds a 6-residue peptide 
derived from hemagglutinin (HAG) of influenza virus[134]. Following expression in 
SHuffle cells, cyclonals in the mFab/hFc format were observed to bind their cognate 
antigens with high affinity (Figure 2.6a).  
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Figure 2.6 Redirecting cyclonals to new antigens with swapped variable regions. 
(a) Antigen-binding activity in SHuffle lysates for anti-MBP cyclonals with swapped 
VH and VL domains with specificity for antigens as indicated. ELISA signals (Abs492) 
for mFab/hFc cyclonals (red), parental anti-MBP cyclonal (orange) and empty plasmid 
control (green) in cell lysates were obtained with anti-human Fc antibodies. Data are 
expressed as the mean ± SEM of biological triplicates. (b) Representative non-
reducing Western blot of different cyclonals in the mouse Fab-human Fc format 
following protein-A affinity purification from cell lysates prepared from SHuffle cells. 
Arrows indicate fully assembled cyclonal and other HC intermediate species. The 
percentage of fully assembled product (% heterotetrameric) among all products was 
determined for each cyclonal using densitometry analysis. Percentages are expressed 
as the mean ± SEM of biological triplicates. 
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Importantly, the parental anti-MBP cyclonal showed no significant binding activity 
against the new antigens (Figure 2.6a) and none of the grafted cyclonals recognized 
MBP (Figure 2.7), confirming a complete change in specificity by simple swapping of 
the variable domains. Western blot analysis under non-reducing conditions revealed 
fully assembled, heterotetrameric IgGs in each case with the percentage of fully 
assembled heterotetrameric product among all products ranging from 66-90% under 
the conditions tested (Figure 2.6b).  
 
 
Figure 2.7 Recognition of MBP by anti-MBP cyclonal and grafted derivatives. 
MBP-binding activity in SHuffle lysates for anti-MBP cyclonal and derivatives 
containing swapped VH and VL domains with specificity for antigens as indicated. 
ELISA signals (Abs492) for the parental anti-MBP cyclonal in the mFab/hFc format 
(red) and all derivatives in the mFab/hFc format (various colors) were obtained with 
anti-human Fc antibodies. Data are the mean ± SEM of biological triplicates. 
 
We routinely purified ~1-25 mg of highly active IgGs per liter of shake flask 
culture using affinity chromatography on a protein-A column (Figure 2.8a and b). It 
is also worth mentioning that one of the grafted cyclonals (anti-Gcn4-bZIP) and its 
progenitor scFv clone both exhibited nanomolar equilibrium dissociation constants as 
determined by Biacore analysis (Figure 2.9; Kd = 5.5 nM for cyclonal vs. 0.5 nM for 
scFv), confirming the feasibility of scFv-to-IgG reformatting in the cyclonal context.  
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Figure 2.8 Purification of cyclonals from the cytoplasm of SHuffle cells. (a) 
Representative non-reducing SDS-PAGE gels of cyclonals purified from SHuffle T7 
cells. Expression of each cyclonal was induced with 1 mM IPTG for 16 h at 30°C. 
Cyclonals were purified from cell lysate by affinity chromatography involving protein 
A columns. Molecular weight (MW) markers are shown at left. Arrows indicate fully 
assembled cyclonal IgG antibodies. (b) Representative titers for different cyclonals 
following protein-A purification strategy described in (a). 
 
 
 38 
 
Figure 2.9 Binding kinetics of cyclonal versus scFv antibodies. Biacore 
sensorgrams generated for purified scFv-Gcn4-bZIP (left) and cyclonal-Gcn4-bZIP 
(right) measured by surface plasmon resonance. Binding kinetics were monitored 
using Biacore 3000. Purified scFv-Gcn4-bZIP or cyclonal-Gcn4-bZIP was 
immobilized on CM5 chips and the response of varied concentrations of purified 
MBP-Gcn4, given in each curve, was compared with an empty flow cell. Purity of all 
recombinant proteins was assessed by SDS-PAGE. Affinity values were obtained by 
fitting the equilibrium binding responses with a 1:1 Langmuir binding model using a 
simultaneous non-linear program. Representative results are depicted.   
 
Remodeling Fc domain of cyclonals for binding to FcγRs. IgGs lacking 
glycosylation in their Fc domain, such as those produced in E. coli, are completely 
unable to bind to Fcγ receptors (FcγRs), and therefore do not induce FcγR-mediated 
effector functions[94, 135]. However, aglycosylated Fc variants that productively 
engage the receptors FcγRI (CD64), FcγRIIa (CD32a), FcγRIIb (CD32b) and FcγRIIIa 
(CD16a) with moderate to high affinity have recently been isolated[5, 125, 126]. In 
the case of FcγRI, binding was critically dependent on the amino acid substitution 
E382V, and to a lesser extent M428I, within the CH3 domain. To engineer cyclonals 
that bind FcγRs, we introduced the E382V and M428I mutations to the human Fc 
domain of the chimeric anti-PA-63 cyclonal. The wt and E382V/M428I variant 
cyclonals were each expressed in the cytoplasm of SHuffle cells and purified by 
protein A affinity chromatography. As expected, only the E382V/M428I variant 
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exhibited binding of FcγRI that was significantly above background and on par with 
the binding obtained with glycosylated IgGs produced by hybridoma cells (Figure 
2.10). These results confirm that the activity conferred by Fc remodeling is maintained 
following expression in the bacterial cytoplasm and that in vitro FcγRI binding by 
cyclonals rivals that of antibodies produced by mammalian cell culture.  
 
 
Figure 2.10 Binding of FcγRI by cyclonals with remodeled Fc domains. Antigen-
binding activity of chimeric anti-PA-63 cyclonal with either wt or mutated Fc domain 
(cyclonalFc(E382V/M428I)). Glycosylated IgGs with wt Fc were purified from hybridoma 
cultures and included as positive control. Equivalent amounts of purified E. coli 
cyclonals or hybridoma IgGs were used to coat ELISA plates and purified FcγRI was 
applied at various concentrations as indicated. Blank buffer was used as a control. 
Data are expressed as the mean ± SEM of biological triplicates. 
Comparison of cytoplasmic versus periplasmic IgG expression. It has been 
reported that secretory production of functional IgGs in the periplasm is inefficient 
and could only be achieved by lowering protein translation rates[94]. This observation 
combined with the large energetic cost associated with moving polypeptides across 
biological membranes [120] led us to hypothesize that the exceptional expression 
levels achieved in the cytoplasm of SHuffle cells might be due to the elimination of 
the membrane translocation step and/or access to ATP-dependent chaperone systems. 
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To test this hypothesis, we directly compared the accumulation of the anti-MBP IgG 
in the mFab/hFc format following expression in the cytoplasm and periplasm. For 
periplasmic expression, we generated a bicistronic construct in pET21b where the HC 
and LC of the anti-MBP IgG were both fused to the pelB signal peptide, yielding a so-
called “E-clonal”[93] specific for MBP. Unlike the periplasm of wild type cells, 
SHuffle cells overexpress a cytoplasmic version of DsbC that could unfairly bias the 
cytoplasmic versus periplasmic analysis. Therefore, for this comparison we used the 
SHuffle progenitor strain MB1731 to express all cyclonal constructs because it has an 
oxidizing cytoplasm but lacks a cytoplasmic copy of dsbC. When over-expressed from 
a T7 promoter, the antigen-binding activity for the anti-MBP E-clonal was barely 
above that measured for cells carrying an empty plasmid, regardless of whether we 
used MB1731 cells or the wt B strain that was isogenic with MB1731 but with a 
reducing cytoplasm[109] (Figure 2.11; shown for wt B strain). In stark contrast, 
expression of the anti-MBP cyclonal in isogenic MB1731cells resulted in a marked 
increase in antigen-binding activity, reaching a level that was ~10-fold greater than its 
E-clonal counterpart (Figure 2.11a). Western blot analysis indicated that the HC and 
LC of the anti-MBP cyclonal accumulated almost exclusively in the soluble fraction, 
whereas periplasmic targeting of the E-clonal HC and LC resulted in significant 
accumulation in the insoluble fraction with only slight accumulation in the soluble 
fraction (Figure 2.11b). Since expression from T7-based plasmids can often lead to 
this type of severe insoluble accumulation, we decided to test an alternative expression 
plasmid, pMAZ360, that was previously shown to be optimized for E-clonal 
production[93]. When the anti-MBP E-clonal construct was expressed from 
pMAZ360, where expression was driven from a lac promoter, a modest increase in 
activity was observed (Figure 2.11a). In line with this increased activity, we observed 
greater accumulation of the E-clonal HC and LC in the soluble fraction; however, a 
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significant amount still partitioned to the insoluble fraction (Figure 2.11b). As above, 
expression of the anti-MBP cyclonal from pMAZ360 was significantly greater than 
expression of the E-clonal from the same plasmid (Figure 2.11a). In fact, cyclonal 
expression from pMAZ360 was indistinguishable from pET-based expression.  
 
Figure 2.11 Comparison of cytoplasmic versus periplasmic IgG expression. (a) 
Antigen-binding activity of mFab/hFc anti-MBP cyclonals derived from the cytoplasm 
of MB1731 cells (closed squares) or E-clonals derived from the periplasm of parental 
B strain (open squares). Expression was either from plasmid pET21b (red) or 
pMAZ360 (dark red); signal from cells carrying empty plasmid was used as negative 
control (green). Data are expressed as the mean ± SEM of biological triplicates. (b) 
Western blot analysis of soluble (sol) and insoluble (ins) fractions derived from the 
same cells as in (a). HC, heavy chain; LC, light chain; asterisk, degraded HC. Mass 
spectrometry analysis of the degraded HC revealed that the cleavage site is in the CH1 
domain of HC, known to fold inefficiently and be the major limiting factor in the 
assembly of IgG in eukaryotic cells. This bottleneck seems to carry over to SHuffle 
cells and is likely due to site-specific cleavage of misassembled HC by cytoplasmic 
protease(s). 
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Despite this high activity, the cyclonal HC and LC accumulated in the insoluble 
fraction following pMAZ360 expression at a level that was similar to the E-clonal 
chains (Figure 2.11b). Nonetheless, soluble accumulation of the cyclonal HC and LC 
was significantly higher compared to that of the E-clonal, especially in the case of the 
HC.  
Nearly identical results were obtained when comparing cytoplasmic and 
periplasmic expression of the anti-HAG and anti-PA-63 IgGs from pET21b and 
pMAZ360 (Figure 2.12) and Herceptin from pMAZ360 (Figure 2.3b), indicating that 
the advantage of cytoplasmic expression was not confined to the anti-MBP IgG 
construct. 
 
 
Figure 2.12 Cytoplasmic versus periplasmic IgG expression. Antigen-binding 
activity of mFab/hFc IgGs specific for (a) HAG or (b) PA-63. Cyclonals (filled 
squares) were produced in the cytoplasm of K12 strain SMG96; E-clonals (open 
squares) were produced in the periplasm of the parental K12 strain. Expression was 
either from plasmid pET21b (red squares) or pMAZ360 (dark red squares); signal 
from cells carrying empty plasmid was used as negative control (green). Data are 
expressed as the mean ± SEM of biological triplicates. 
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Discussion  
We report the first soluble expression of active, full-length IgGs in the 
cytoplasm of SHuffle E. coli cells, a feat that was previously unattainable using wt E. 
coli cells whose cytoplasmic compartments were not engineered for disulfide bond 
formation [117-119]. This advance taps the wealth of knowledge and comprehensive 
tools (e.g., tightly regulated promoters, chaperone co-expression systems) available for 
this host, making it possible to produce large quantities of recombinant antibodies for 
in vitro diagnostic techniques as well as in vivo therapeutic applications. Moreover, we 
show that expression in the SHuffle cytoplasm can be combined with standard 
molecular engineering strategies such as grafting alternative epitope recognition 
domains, humanizing[129-131] and Fc engineering[94, 135] to rapidly (~1 week or 
less) create custom mouse, rabbit or humanized antibodies exhibiting clinically 
relevant properties. These results are in direct agreement with the recent observation 
that engineered biophysical properties can be readily transferred between different 
antibody formats and expression systems[136]. Hence, we anticipate that the cyclonal 
expression technology described here will find use in several applications such as 
rapidly converting phage-displayed scFvs into full-size IgGs or molecular reformatting 
mouse- or rabbit-derived IgGs into humanized analogs.  
A significant limitation in the therapeutic use of IgGs expressed from 
prokaryotes is the lack of post-translational glycosylation of the Fc domain. 
Specifically, N-linked glycosylation at the conserved N297 residue is necessary for 
efficient binding of the Fc domain with its cognate Fcγ receptors. Upon binding, 
effector function is activated resulting in antibody-dependent cell-mediated 
cytotoxicity (ADCC) or antibody-dependent cell-mediated phagocytosis (ADCP) or 
complement dependent cytotoxicity (CDC)[123]. We have bypassed this limitation by 
remodeling cyclonal Fc domains with previously discovered mutations (e.g., 
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E382V/M428I) that permit efficient binding of aglycosylated IgG to Fcγ receptors [5]. 
The result is a synthetic pathway, entirely in the E. coli cytoplasm, for producing IgGs 
that bind specific antigens and also engage FcγRs with the potential to activate 
immune cells. In fact, bacterially produced cyclonals equaled the performance of the 
same IgGs produced using conventional mammalian cell culture (i.e., hybridomas) in 
both antigen- and FcγR-binding properties. 
A major advantage of cytoplasmic expression is the elimination of the 
membrane translocation step, which is a prerequisite for soluble antibody production 
in all other cell-based systems. By circumventing the physical membrane barrier, we 
observed much greater soluble accumulation and activity for two different cyclonals, 
independent of the plasmid backbone choice, compared to their periplasmic 
counterparts. In particular, the expression of cyclonals but not periplasmic IgGs was 
harmonious with pET-based plasmids, which are well known for their high levels of 
protein expression. It should be noted that this high level of expression was achieved 
following direct cloning into the multi-cloning site of standard plasmids and did not 
require any additional gene-level optimization, even in the face of major changes to 
variable and framework regions. In contrast, to achieve soluble IgG expression in the 
E. coli periplasm required screening of a panel of translation initiation regions (TIRs) 
to balance expression of each polypeptide chain and lower the protein translation 
rate[94]. The lower translation rate is thought to decrease protein load on the Sec 
pathway and also ensure that protein substrates remain unfolded for efficient secretion. 
Indeed, although not reported for IgGs specifically, when large amounts of complex 
hybrid proteins (e.g., the signal sequence of outer membrane protein LamB fused to 
LacZ) are made, rapid folding of the hybrid in the cytoplasm can cause a lethal 
jamming of the Sec translocase [137]. Importantly, all of these secretion-related 
problems are avoided with cytoplasmic expression. 
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Another major advantage to expressing proteins in the cytoplasm is the 
presence of the many energy-dependent chaperones that facilitate correct folding of 
proteins, which are absent in the periplasm (e.g., GroEL/S, ClpXP, DnaKJ systems). 
Such chaperone systems may be responsible for the significant cyclonal titers (~1-24 
mg/L) observed here. By way of comparison, yields of periplasmically-expressed IgGs 
produced in shake flasks rarely exceed 1 mg of assembled full-length antibodies per 
liter of culture with literature values of 0.004-0.008 mg/L[138], 0.1-1.3 mg/L[93], and 
1-4 mg/L[139]. In fact, cyclonal titers were typically greater than other less complex 
immunoglobulin formats regardless of the whether they were expressed in the 
periplasm (e.g., 0.2 mg/L Fv[62]; 2 mg/L Fab[140]) or the cytoplasm of redox-
engineered E. coli (e.g., 1-2 mg/L scFv[114]; 3-4 mg/L Fab[115]). This may be due to 
the cytoplasmic copy of DsbC in SHuffle cells that was absent in earlier cytoplasmic 
expression systems. Indeed, levels of active cyclonal increased by ~70% when 
expressed in the presence of cytoplasmic DsbC compared to an isogenic strain that 
lacked cytoplasmic DsbC (see Figure 2.2). Taken together, our findings confirm the 
capacity of the cytoplasm as a compartment for high-titer IgG production. 
Looking forward, many remaining factors known to be important for IgG 
expression and folding in other systems remain to be optimized for cyclonals. For 
example, we co-expressed a set of helper proteins that were previously shown to 
improve the production of disulfide bonded proteins in SHuffle cells[109]. Several of 
these helpers including the yeast PDI homolog (MPD1) and a mutant thioredoxin with 
an altered active site (CPHC) enhanced the levels of active cyclonal (Table 2.1). In 
light of these preliminary results, we suspect that co-expression of other ER folding 
factors could further augment the accumulation of full-length cyclonals. Another 
strategy for improving cyclonal production titers is to toggle the ratio of light and 
heavy chains in the cytoplasm in a manner that favors the formation of fully 
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assembled IgGs. Such toggling could be achieved by either modifying the sequences 
that control heavy and light chain expression (e.g., translation initiation regions 
(TIRs), promoters) or altering the primary sequence of the IgG directly through the 
use of alternative frameworks and/or constant region sequences (i.e., IgG isotypes). In 
one notable example, Yansura and colleagues showed that heavy and light chain levels 
in the E. coli periplasm could be more efficiently assembled using different strength 
TIRs for light and heavy chains[94]. It is therefore conceivable that even higher titers 
of cyclonals can be reached in the future following further host and process 
optimization. 
Materials and Methods 
Bacterial strains and growth conditions. The bacterial strains used in this study are 
listed in Table 2.2. A single colony of SHuffle T7 Express transformed with one of the 
pMAZ360-cIgG expression vectors was used to inoculate 5 mL Luria-Bertani (LB; 10 
g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl, NaOH to pH 7.2) supplemented with 
100 μg/mL carbenicillin (Carb) and 25 μg/mL spectinomycin (Spec), and grown 
overnight at 30ºC. The next day, 300 mL of fresh LB supplemented with 100 μg/ml 
carbenicillin was inoculated 1/100 with the overnight culture and cells were grown at 
30ºC until reaching an absorbance at 600 nm (A600) of 0.7. At this point, cyclonal 
expression from the pMAZ360-cIgG vector was induced by addition of 1.0 mM 
isopropyl β-D-thiogalactopyranoside (IPTG), after which cells were incubated an 
additional 16 h at 30ºC. Cells were harvested by centrifugation prior to preparation of 
lysates or purification of IgGs.  
Immunization, cell fusion and selection of hybridoma. A protein fusion consisting 
of bacteriophage M13 pIII (residues 259-406) and MBP was constructed in the pMAL 
expression system, expressed and purified according to manufacturer’s protocols 
(New England Biolabs). Two female BALB/c mice (Jackson Laboratories) were 
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immunized intraperitoneally over a period of 4 months with a primary injection 
containing 50 µg antigen emulsified in Freund’s complete adjuvant, followed by three 
subsequent boosts in Freund’s incomplete adjuvant. A final tail vein injection 
containing 25 µg of antigen in 50 µL of sterile saline was administered three days 
prior to removing the spleen and fusion of splenocytes with X63Ag8.653 parental 
myeloma cells[141]. Splenocytes were fused with X63Ag8.653 myelomas using the 
ClonaCell-HY hybridoma cloning kit (StemCell Technologies Inc.). Hybridoma 
tissue culture supernatants (TCS) were screened initially by ELISA with MBP as 
antigen. The isotype of monoclonal antibodies was determined using an antigen-
capture ELISA. Wells were coated with anti-mouse immunoglobulin antibody 
(American Qualex International). Undiluted hybridoma TCS was used for isotyping. 
The isotype of each captured mAb was then determined using goat anti-isotype-
specific alkaline phosphatase conjugated antibodies (Caltag).  
Plasmid construction. A list of plasmids used in this study is given in Table 2.2. To 
generate the initial anti-MBP IgG construct, total RNA was isolated from 4x107 
hybridoma cells using Qiagen RNeasy kit with the following modifications: 4x107 
cells were resuspended in 600 μL RLT buffer, homogenized with hand-held 
homogenizer for 2 min followed by the addition of 1800 μL RLT buffer (2400 total, 
600 μL per 1x107 cells), mixed, separated into 4x600 μL aliquots and homogenized 
for another 30 s. Total RNA for each sample was purified separately according to 
protocol, eluted 2x30 μL for each sample and pooled (240 μL total). A mixture of 
degenerate forward primers (Deg1 to Deg7, Table 2.3) was designed from κ chain 
sequences in the Kabat database[142] and used with 3’ reverse primer LC-9 (Table 
2.3) to amplify the cDNA sequence of the IgG κ LC gene. 50-μL PCR mixtures for κ 
LC cDNA amplification with Deep Vent DNA polymerase (New England Biolabs) 
contained buffer supplied by the manufacturer supplemented with 200 μM dNTPs, 0.8 
 48 
μM forward primer mixture, 4 μM reverse primer, and ~300 ng cDNA. Thermocycling 
consisted of incubation at 94°C for 5 min followed by 30 cycles of successive 
incubations at 94°C for 30 s, 55°C for 30 s and 72°C for 60 s. After thermocycling, a 
final extension was performed at 72°C for 10 min. The amplified product was digested 
with EcoRI and cloned between the EcoRI-SmaI sites of pNEB193, resulting in 
plasmid pNEB-LC-MBP. To amplify the cDNA sequence of the IγG HC, a degenerate 
primer pair (Kabat-F and Kabat-R, Table 2.3) were designed from IgG2A-chain 
sequences from the Kabat database[142]. PCR mixtures for IγG HC cDNA 
amplification with Taq DNA Polymerase (New England Biolabs) contained buffer 
supplied by the manufacturer supplemented with 200 μM dNTPs, 4 μM each of 
forward and reverse primers, and ~300 ng cDNA. Thermocycling consisted of 
incubation at 94°C for 5 min, 80°C for 60 s, followed by 30 cycles of successive 
incubations at 94°C for 30 s, 52°C for 30 s and 72°C for 2 min. After thermocycling, a 
final extension was performed at 72°C for 10 min.  The amplified product was 
digested with EcoRI and NotI and cloned between the EcoRI-NotI sites of pNEB193, 
resulting in plasmid pNEB-HC-MBP. Sequencing of this plasmid was used to design a 
synthetic HC gene in pUC57 (GenScript; pUC57-HC-MBPsyn) that was modified 
with unique internal restriction sites for future cloning.  
The construction of all bacterial IgG expression plasmids and the reagents used 
in their construction (e.g., DNA templates, primers, restriction enzymes) are described 
in Tables 2.3 and 2.4. Briefly, the anti-MBP HC and LC lacking native export signals 
were PCR-amplified from pNEB-LC-MBP and pUC57-HC-MBPsyn, respectively, 
and subsequently assembled as a bicistronic operon using overlap extension PCR. This 
operon was initially cloned in plasmid pMAZ360-IgG[93] and then subcloned into 
pET21b. The resulting plasmid, pET21b-cyclonal-MBP, placed expression of the HC 
and LC under the control of the strong T7/lac promoter (Figure 2.2a). Construction of 
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pET21b-cyclonal-MBP(mFab/hFc) involved double digestion of pET21b-cyclonal-
MBP with AscI/XhoI to remove the mouse CH2 and CH3 domains followed by ligation 
of DNA encoding human CH2 and CH3 domains between the same sites. Construction 
of pET21b-cyclonal-MBP (chimeric) involved double digestion of pET21b-cyclonal-
MBP (mFab/hFc) with SalI/HindIII to remove the mouse CL followed by ligation of 
DNA encoding human CL between the same sites. To generate mFab/hFc cyclonals 
with new antigen specificity, VL domain sequences from existing antibodies and 
antibody fragments [93, 132-134] were amplified by PCR, while in parallel, mouse CL 
region DNA was also amplified by PCR. During PCR, engineered sequence overlaps 
were introduced into both the VL and CL sequences. The two PCR products were 
combined by overlap extension PCR and the resulting product was cloned between 
NdeI/HindIII of pET21b-cyclonal(mFab/hFc). Corresponding VH domain sequences 
from the same existing antibodies and antibody fragments were amplified by PCR, 
while in parallel, mouse CH1 region DNA was also amplified by PCR. During PCR, 
engineered sequence overlaps were introduced into both the VH and CH1 sequences. 
The two PCR products were combined by overlap extension PCR and the resulting 
product was cloned between NheI/AscI of pET21b-cyclonal(mFab/hFc). For chimeric 
constructs with new antigen specificity, PCR amplified VL domain sequences from 
existing antibodies and antibody fragments were cloned directly between NdeI/SalI of 
pET21b-cyclonal(chimeric). Corresponding VH domain sequences were assembled 
with human CH1 region DNA by overlap extension PCR and the resulting products 
were cloned between NheI/AscI of pET21b-cyclonal(chimeric). The E382V Fc 
mutation28 was introduced into the CH3 sequence of the chimeric anti-PA-63 HC by 
overlap extension PCR followed by a nested PCR using a mutagenic reverse primer to 
generate the M428I Fc substitution28. The resulting mutant HC was ligated between 
NheI/XhoI of pET21b-cyclonal-PA-63(chimeric). To construct E-clonal expression 
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plasmids, DNA encoding the E. carotovora pectate lyase signal peptide (spPelB) was 
fused to the 5’ end of the HC and LC genes from anti-MBP (mFab/hFc) using nested 
PCR. An RBS was introduced upstream of the spPelB-HC fusion in the same manner. 
The resulting spPelB-HC and spPelB-LC sequences were cloned between the 
NdeI/HindIII and HindIII/XhoI sites, respectively, of pET21b-cyclonal-MBP, yielding 
pET21b-E-clonal-MBP(mFab/hFc). All subsequent periplasmic constructs were 
synthesized by inserting the appropriate LC and HC pairs into pET21b-E-clonal-
MBP(mFab/hFc) using the NcoI/HindIII and NheI/XhoI sites, respectively. To 
generate additional pMAZ360 expression constructs, a synthetic multi-cloning site 
was cloned between NdeI/AscI of pMAZ360[93] such that the same restriction sites 
used in synthesizing the bicistronic pET21-cyclonal and pET21-E-clonal plasmids 
could also be used to generate pMAZ360-cyclonal and pMAZ360-E-clonal expression 
vectors coding for any of the different IgGs. For construction of rabbit antibodies, HC 
and LC genes from rabbit anti-PSMA and anti-B2M clones (kindly provided by Cell 
Signaling Technologies) were PCR amplified and cloned between NcoI/BamHI of 
pETDuet-1 (Novagen). Construction of rFab/hFc hybrids in pETDuet-1 was 
performed using overlap extension PCR as described above for mFab/hFc cyclonals. 
Construction of Herceptin in the cyclonal format was performed by first PCR 
amplifying the gene encoding the LC from pSTJ4-AglycoT [5] and cloning the PCR 
product between the NdeI/HindIII sites of pMAZ360-cIgG-aMBP. Next, DNA 
encoding the HC was amplified from pSTJ4-AglycoT and cloned between the 
NheI/XhoI sites of pMAZ360-cIgG resulting in the vector pMAZ360-cIgG-Herceptin. 
Genes encoding the target antigens bacteriophage lambda gpD[132], the 47-residue 
bZIP domain of the yeast transcription factor Gcn4[133]; and 6-residue peptide 
derived from hemagglutinin (HAG) of influenza virus[134] were each cloned into 
pET28a(+), which introduced a 6x-His tag to the N terminus of each antigen. Due to 
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their relatively small sizes, Gcn4-bZIP and HAG were fused to the C terminus of 
glutathione S-transferase (GST). All plasmids constructed in this study were 
confirmed by sequencing. 
Preparation of soluble and insoluble fractions. SHuffle cells expressing cyclonals 
were harvested by centrifugation at 13,000xg and 4°C for 30 min. Harvested cells 
were resuspended in a volume of PBS, 1x SigmaFAST™ protease inhibitor cocktail 
(EDTA free), and 5 mM EDTA equal to one tenth of the original culture volume. Cells 
were ruptured by passage through an Emulsiflex-C5 High Pressure Homogenizer at 
16,000-18,000 psi. The cell lysate was then clarified by centrifugation at 30,000xg and 
4°C. The supernatant containing soluble cytoplasmic proteins was recovered as the 
soluble fraction and then passed through a 0.2-μm sterile membrane filter. Insoluble 
pellets were washed 3 times in 50 mM Tris-HCl, 1 mM EDTA (pH 8.0) and then 
resuspended in PBS supplemented with 2% SDS. Inclusion bodies were solubilized by 
heating at 100oC for 10 min. The solubilized mixture was centrifuged at 16,000xg for 
10 min and the supernatant was collected as the insoluble fraction. 
Protein purification. For cyclonal purification, protein A-agarose resin was 
equilibrated with 10 mL PBS and then mixed with the filtered soluble lysate fraction. 
The resin-soluble lysate fraction mixture was incubated at room temperature with end-
over-end mixing for 2 h. The mixture was then applied to a polypropylene gravity 
column and the soluble lysate was allowed to completely pass through the column. 
After settling in the column, the protein A-agarose was washed with 25 mL PBS. 
Cyclonals were eluted from the column with 0.1 M glycine-HCl (pH 3.0) in 1-mL 
fractions and neutralized with 100 μL 1 M Tris (pH 9.0). Purified fractions were 
resolved by SDS-PAGE under non-reducing conditions and either visualized by 
staining with Coomassie Blue G-250 or further processed for Western blot as 
described below. 
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Western blot analysis. For SDS-PAGE analysis under non-reducing conditions, 
samples were diluted 1:1 in 2x Laemmli sample buffer. For reducing conditions, 
samples were diluted 1:1 in 2x Laemmli sample buffer supplemented with 2.5% 2-
mercaptethanol. In both cases, samples were heated at 100oC for 10 min and then 
loaded on 4-20% Tris-Glycine gels (Bio-Rad). All samples were normalized by total 
protein, as determined by Bradford assay. Following electrophoresis, resolved proteins 
were transferred to polyvinylidene fluoride membranes (Millipore). Membranes were 
rinsed with PBS and then blocked with 5% milk (w/v) in PBS containing 0.05% 
Tween-20 (PBST) for 1 h. After 3 washes with PBST, membranes containing 
mFab/hFc or chimeric IgGs were probed with 1:7,500-diluted anti-human Fc-HRP 
conjugate antibodies (Thermo scientific) plus 1:10,000-diluted anti-mouse Igκ chain-
HRP conjugate antibodies (Jackson ImmunoResearch) in 2% milk (w/v)-PBST for 1 
hr. After washing 6 more times with PBST, membranes were incubated with Immun-
star HRP substrate (Bio-Rad) and then visualized using a Bio-Rad Chemidoc XRS+ or 
by exposing membranes to X-ray film. 
ELISA. Costar 96-well ELISA plates (Corning) were coated overnight at 4°C with 50 
μL of 4-10 μg/mL antigen in 0.05 M sodium carbonate buffer (pH 9.6). Antigens used 
were MBP5 (New England Biolabs), digoxin-BSA (Fitzgerald Industries), PA-63 
(Calbiochem), as well as gpD, GST-Gcn4, and GST-HAG that were each expressed in 
E. coli T7 express cells and purified by standard Ni-NTA purification. After blocking 
with 3% (w/v) milk in PBST for 1-3 h at room temperature, the plates were washed 4 
times with PBS buffer and incubated with serially diluted purified IgG samples or 
soluble fractions of crude cell lysates for 1 h at room temperature. IgG-containing 
samples were quantified by Bradford assay and an equivalent amount of total protein 
(typically 8-64 µg) was applied to the plate. After washing 4 times with the same 
buffer, 50 µL of the following antibodies in 3% PBST was added to each well for 1 hr:  
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1:4,000-diluted goat anti-mouse IgG (H+L)-HRP conjugate (Promega) or anti-mouse 
IgG (Fab specific)-HRP conjugate (Sigma) for mouse IgGs; 1:5,000-diluted rabbit 
anti-human IgG (Fc) antibody-HRP conjugate (Pierce) for chimeric and mFab/hFc 
IgGs; 1:5000-diluted goat anti-rabbit IgG (H+L)-HRP conjugate (Pierce) for rabbit 
IgGs; and 1:5000 anti-human IgG (H+L)-HRP conjugate (Abcam) for Herceptin. 
Plates were washed and developed using standard protocols. FcγR-binding assays 
were performed as described elsewhere [5] except that 50 µL of 5 µg/mL of cyclonals 
with wt and mutant Fc domain (cyclonalFc(E382V/M428I)) both purified from SHuffle cells 
and wt IgG purified from hybridoma cells were diluted in 0.05 M Na2CO3 (pH 9.6) 
buffer and used to coat 96 well polystyrene ELISA plates overnight at 4°C. Following 
blocking, the plate was incubated with serially diluted recombinant human 
FcγRI/CD64 (R&D Systems) at room temperature for 1 h. After washing, 1:20,000-
diluted rabbit anti-6x-His tag antibody-HRP conjugate (Abcam) was added and plates 
were washed and developed using standard protocols 
Gel filtration. Protein A-purified cyclonals were analyzed by SEC using a Superdex 
200 10/300 GL gel filtration column and the ÄKTA Purifier FPLC system. The 
Superdex 200 was equilibrated with 60 mL (~2 CV) of PBS gel filtration buffer (50 
mM phosphate buffer, 150 mM NaCl, pH 7.0) at 0.5 ml/min. 300 μL of protein A-
purified sample concentrated to 1 mg/mL was loaded onto and passed through the 
column at 0.25 ml/min with gel filtration buffer. Absorbance at 280 nm (Abs280) was 
measured and recorded using UNICORN 5.1 software. Apparent molecular weights 
(MW) were calculated by interpolation using the elution volume at the maxima of 
each major absorption peak and a calibration curve generated using gel filtration high 
MW standards (GE healthcare). 
Serum stability. Protein A-purified IgGs from SHuffle or hybridoma cell culture were 
diluted to a final concentration of 30 µg/ml in 100% fetal bovine serum (FBS; Sigma) 
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and incubated at 37°C for 4 days. Residual binding activity to MBP was evaluated by 
ELISA as described above. 
Surface plasmon resonance (SPR). Equilibrium binding affinity measurements were 
made using a Biacore 3000 system. Cyclonal IgG or scFv antibodies were covalently 
linked to the surface of a CM5 sensor chip through amine coupling chemistry. First, 
the surface of the CM5 sensor chip was activated using N-hydroxysuccinimide (NHS) 
and N-ethyl-N-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (GE 
Healthcare). Purified anti-Gcn4 cyclonals or scFvs diluted to 50 μg/mL in 10 mM 
sodium acetate pH 4.0 were immobilized to the surface of the CM5 chip with a target 
level of 900 response units (RU). Unreacted sites on the chip surface were 
subsequently blocked with 1 M ethanolamine hydrochloride. Serial dilutions of the 
antigen, MBP-TEV-Gcn4, prepared in 10 mM HEPES, pH 7.4, 150 mM NaCl, 3mM 
EDTA, 0.005% polysorbate-20 (HBS-EP buffer, GE Healthcare) at concentrations 
ranging from 0.5-32 nM were injected over the chip using the same buffer at a flow 
rate of 30 μl/min (2 min injection time, 5 min dissociation). The surface of the chip 
was regenerated between the injections of each serial dilution with 10 mM glycine, pH 
2.0 (2 min injection time, 2 min stabilization time). Kinetic parameters (ka, kd, and KD) 
were determined by fitting the response curves with a Langmuir 1:1 binding model 
within the BIAevaluation software. 
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Tables 
 
Table 2.1. Effects of helper protein co-expression on cyclonal production 
Description Helper Normalized activity1   
 pBAD33 1.0   
 
 
 
 
 
Redox active helpers 
    
AaDsbC 1.4   
DsbC 1.2   
TrxACGPC 1.1   
TrxACPYC 1.3   
TrxACPHC 1.5   
AaPDO 1.2   
QSOX 1.2   
PDI 1.2   
EUG1 1.1   
MPD1 1.7   
MPD2 1.2   
Chaperone helpers MalE 1.2   Skp 0.9   
 
Oxidative stress helpers 
KatG 1.4   
AhpC, AhpF 1.1   
AhpC*, 
AhpF 
0.9   
1Activity of anti-MBP cyclonal in crude cell lysates derived from SHuffle cells was 
quantified by ELISA. All samples were normalized according to total protein as 
determined by Bradford assay and the activity data was normalized to the activity for 
cells expressing empty vector alone (pBAD33). Bold font indicates the five best 
helpers in terms of fold improvement. 
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Table 2.2. List of E. coli strains and plasmids used in this study 
Strain or plasmid Relevant genotype or features Source 
Strain 
NEB express T7 
 
BL21 fhuA2 lacZ::T7 gene1 [lon] ompT gal 
sulA11 R(mcr-73::miniTn10--TetS)2 [dcm] 
R(zgb-210::Tn10--TetS) endA1 Δ(mcrC-
mrr)114::IS10 
 
NEB 
MB1731 NEB express T7 ΔtrxB Δgor ahpC* Ref.[109] 
SHuffle T7 express MB1731 λatt::pNEB3-r1-cDsbC (SpecR, lacIq)  NEB 
 
Plasmid 
  
pBAD33-cAaPDO Gene encoding Aquifex aeolicus oxido-
reductase (PDO) in plasmid pBAD33 
Ref.[109] 
pBAD34-cAaDsbC Gene encoding A. aeolicus DsbC homolog 
devoid of signal peptide in plasmid pBAD34 
Ref.[109] 
pBAD33-cDsbC Gene encoding E. coli DsbC devoid of signal 
peptide in plasmid pBAD33 
Ref.[109] 
pBAD33-TrxACGPC Gene encoding E. coli thioredoxin A (TrxA) 
with wt active site (CGPC) in plasmid pBAD33 
Ref.[109] 
pBAD33-TrxACPYC Gene encoding E. coli TrxA with grx active site 
(CPYC) in plasmid pBAD33 
Ref.[109] 
pBAD33-TrxACPHC Gene encoding E. coli TrxA with dsbA active 
site (CPHC) in plasmid pBAD33 
Ref.[109] 
pBAD33-QSOX Gene encoding human quiescin sulphydryl 
oxidase in plasmid pBAD33 
Ref.[109] 
pBAD34-MalE Gene encoding E. coli maltose binding protein 
(MBP) devoid of signal peptide in plasmid 
pBAD34 
Ref.[109] 
pBAD34-PDI Gene encoding yeast protein disulfide 
isomerase (PDI) in plasmid pBAD34 
Ref.[109] 
pBAD34-EUG1 Gene encoding yeast PDI homolog (EUG1) in 
plasmid pBAD34 
Ref.[109] 
pBAD34-MPD1 Gene encoding yeast PDI homolog (MPD1) in 
plasmid pBAD34 
Ref.[109] 
pBAD34-MPD2 Gene encoding yeast PDI homolog (MPD2) in 
plasmid pBAD34 
Ref.[109] 
pBAD34-KatG Gene encoding E. coli catalase (KatG) in 
plasmid pBAD34 
Ref.[109] 
pBAD33-AhpCF Genes encoding E. coli wt peroxidase pair 
(AhpC and AhpF) in plasmid pBAD33 
Ref.[109] 
pBAD33-AhpC*F Genes encoding E. coli mutant peroxidase pair 
(AhpC* and AhpF) in plasmid pBAD33 
Ref.[109] 
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pBAD34-Skp Gene encoding E. coli periplasmic chaperone 
Skp devoid of signal peptide in plasmid 
pBAD34 
Ref.[109] 
pMAZ360-IgG 
Bicistronic expression of IgGs in the E. coli 
periplasm; HC and LC each carries N terminal 
PelB signal peptide 
Ref.[93] 
pMAZ360-26.10-IgG Bicistronic expression of 26.10-IgG in the E. 
coli periplasm 
Ref.[93] 
pMAZ360-YMF10-IgG Bicistronic expression of YMF10-IgG in the E. 
coli periplasm 
Ref.[93] 
pHK19 Gene encoding Gcn4-specific scFv antibody Ref.[133] 
pHK38 Gene encoding HAG-specific scFv antibody Ref.[134]  
pHK49 Gene encoding gpD-specific scFv antibody Ref.[132] 
pET21b-cyclonal-MBP 
Mouse anti-MBP HC and LC genes lacking 
export signals in pET21b; bicistronic 
expression 
This 
study* 
pET21b-cyclonal-
MBP(mFab/hFc) 
Mouse anti-MBP Fab spliced onto human Fc in 
pET21b; bicistronic expression 
This 
study* 
pET21b-cyclonal-
MBP(chimeric) 
Mouse anti-MBP variable domains fused to 
human constant domains (mouse VL to human 
CL and mouse VH to human CH1-CH2-CH3 for 
light and heavy chains, respectively) in 
pET21b; bicistronic expression 
This 
study* 
pET21b-cyclonal-
Dig(mFab/hFc) 
pET21b-cyclonal-MBP(mFab/hFc) but with VH 
and VL from murine 26-10-IgG that binds 
digoxin[143] 
This 
study* 
pET21b-cyclonal-
Dig(chimeric) 
pET21b-cyclonal-MBP(chimeric) but with VH 
and VL from murine 26-10-IgG that binds 
digoxin[143] 
This 
study* 
pET21b-cyclonal-
Gcn4(mFab/hFc) 
pET21b-cyclonal-MBP(mFab/hFc) but with VH 
and VL from anti-GCN4 scFv that binds Gcn4-
bZIP domain[133] 
This 
study* 
pET21b-cyclonal-
Gcn4(chimeric) 
pET21b-cyclonal-MBP(chimeric) but with VH 
and VL from anti-GCN4 scFv that binds Gcn4-
bZIP domain[133] 
This 
study* 
pET21b-cyclonal-
gpD(mFab/hFc) 
pET21b-cyclonal-MBP(mFab/hFc) but with VH 
and VL from D10 scFv that binds bacteriophage 
lambda gpD[132] 
This 
study* 
pET21b-cyclonal-
gpD(chimeric) 
pET21b-cyclonal-MBP(chimeric) but with VH 
and VL from D10 scFv that binds bacteriophage 
lambda gpD[132] 
This 
study* 
pET21b-cyclonal-
HAG(mFab/hFc) 
pET21b-cyclonal-MBP(mFab/hFc) but with VH 
and VL from the h6-4 scFv that binds 6-residue 
HAG peptide[134] 
This 
study* 
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pET21b-cyclonal-
HAG(chimeric) 
pET21b-cyclonal-MBP(chimeric) but with VH 
and VL from the h6-4 scFv that binds 6-residue 
HAG peptide[134] 
This 
study* 
pET21b-cyclonal-PA-
63(mFab/hFc) 
pET21b-cyclonal-MBP(mFab/hFc) but with VH 
and VL from M18.1 Hum-IgG that binds B. 
anthracis PA-63[93] 
This 
study* 
pET21b-cyclonal-PA-
63(chimeric) 
pET21b-cyclonal-MBP(chimeric) but with VH 
and VL from M18.1 Hum-IgG that binds B. 
anthracis PA-63[93] 
This 
study* 
pET21b-cyclonal-
PA63(FcE382V/M428I) 
pET21b-cyclonal-PA-63(chimeric) but with 
E382V and M482I mutations in Fc domain 
This 
study* 
pET21b-E-clonal-
MBP(mFab/hFc) 
Mouse Fab/human Fc anti-MBP IgG in 
pET21b; PelB signal peptides on heavy and 
light chains 
This 
study* 
pMAZ360-cyclonal-
MBP(mFab/hFc) 
Mouse Fab/human Fc anti-MBP cyclonal in 
pMAZ360-IgG 
This 
study* 
pMAZ360-E-clonal-
MBP(mFab/hFc) 
Mouse Fab/human Fc anti-MBP IgG in 
pMAZ360-IgG; PelB signal peptides on heavy 
and light chains 
This 
study* 
pET21b-E-clonal-
HAG(mFab/hFc) 
Mouse Fab/human Fc anti-HAG IgG in 
pET21b; PelB signal peptides on heavy and 
light chains 
This 
study* 
pMAZ360-cyclonal-
HAG(mFab/hFc) 
Mouse Fab/human Fc anti-HAG cyclonal in 
pMAZ360-IgG 
This 
study* 
pMAZ360-E-clonal-
HAG(mFab/hFc) 
Mouse Fab/human Fc anti-HAG IgG in 
pMAZ360-IgG; PelB signal peptides on heavy 
and light chains 
This 
study* 
pET21b-E-clonal-PA-
63(mFab/hFc) 
Mouse Fab/human Fc anti-PA-63 IgG in 
pET21b; PelB signal peptides on heavy and 
light chains 
This 
study* 
pMAZ360-cyclonal-
PA-63(mFab/hFc) 
Mouse Fab/human Fc anti-PA-63 cyclonal in 
pMAZ360-IgG 
This 
study* 
pMAZ360-E-clonal-
PA-63(mFab/hFc) 
Mouse Fab/human Fc anti-PA-63 IgG in 
pMAZ360-IgG; PelB signal peptides on heavy 
and light chains 
This 
study* 
pET28a-gpD gpD cloned in pET pET28a(+), which 
introduced a 6x-His tag to the N terminus 
This study 
pET28a-GST-Gcn4 
Gcn4-bZIP domain cloned as GST fusion in 
pET pET28a(+), which introduced N terminal 
6x-His tag 
This study 
pET28a-GST-HAG 
6-residue HAG peptide cloned as GST fusion in 
pET pET28a(+), which introduced N terminal 
6x-His tag 
This study 
*Construction of plasmids described in Table 2.3 
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Table 2.3. Construction of plasmids used in this study. 
Plasmid Template Primer pair Restriction Enzymes 
pMAZ-cyclonal-
MBP 
pNEB-LC-MBP 
pUC57-HC-MBPsyn* 
PCR (cLC + cHC) 
52-53 (= PCR cLC) 
50-51 (= PCR cHC) 
52-51 (= PCR cLH) 
PCR cLH 
NdeI/AscI 
pET21b-cyclonal-
MBP pMAZ-cyclonal-MBP 123-124 NdeI/XhoI 
pET21b-cyclonal-
MBP(mFab/hFc) pUC57-mFab/hFcsyn* AscI/XhoI fragment AscI/XhoI 
pET21b-cyclonal-
MBP(chimeric) 
pET21b-cyclonal-
MBP(mFab/hFc) 
pUC57-hLCsyn* 
pET21b-cyclonal-
MBP(mFab/hFc) 
pUC57-hHCsyn* 
PCR (A + B + C + D) 
160-161 (= PCR A) 
162-163 (= PCR B) 
164-165 (= PCR C) 
166-167 (= PCR D) 
160-167 (= PCR E) PCR E 
NdeI/AscI 
pET21b-cyclonal-
Dig(mFab/hFc) 
pMAZ360-26.10-IgG 
pET21b-cyclonal-
MBP(mFab/hFc) 
pMAZ360-26.10-IgG 
pET21b-cyclonal-
MBP(mFab/hFc) 
PCR (A+B) 
PCR (C+D) 
201-202 (= PCR A) 
203-216 (= PCR B) 
204-205 (= PCR C) 
206-220 (= PCR D) 
201-216 (= PCR E) 
204-220 (= PCR F) 
 
 
 
 
PCR E 
NdeI/HindII
I 
PCR F 
NheI/AscI 
pET21b-cyclonal-
Gcn4(mFab/hFc) 
pHK19 (anti-GCN4 
scFv) 
 pET21b-cyclonal-
MBP(mFab/hFc) 
pHK19 (anti-GCN4 
scFv)  
pET21b-cyclonal-
MBP(mFab/hFc) 
PCR (A+B) 
PCR (C+D) 
207-208 (= PCR A) 
209-216 (= PCR B) 
210-211 (= PCR C) 
212-220 (= PCR D) 
207-216(= PCR E) 
210-220 (= PCR F) 
 
 
 
 
PCR E 
NdeI/HindII
I 
PCR F 
NheI/AscI 
pET21b-cyclonal-
gpD(mFab/hFc) 
pHK49 (anti-gpD scFv, 
D10) 
pET21b-cyclonal-
MBP(mFab/hFc) 
pHK49 (anti-gpD scFv, 
D10) 
pET21b-cyclonal-
MBP(mFab/hFc) 
PCR (A+B) 
213-214 (= PCR A) 
215-216 (= PCR B) 
217-218 (= PCR C) 
219-220 (= PCR D) 
213-216 (= PCR E) 
217-220 (= PCR F) 
 
 
 
 
PCR E 
NdeI/HindII
I 
PCR F 
NheI/AscI 
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PCR (C+D) 
pET21b-cyclonal-
HAG(mFab/hFc) 
pHK38 (anti-Hag scFv) 
pET21b-cyclonal-
MBP(mFab/hFc) 
pHK38 (anti-Hag scFv) 
pET21b-cyclonal-
MBP(mFab/hFc) 
PCR (A+B) 
PCR (C+D) 
221-222 (= PCR A) 
223-216 (= PCR B) 
224-225 (= PCR C) 
226-220 (= PCR D) 
221-216 (= PCR E) 
224-220 (= PCR F) 
 
 
 
 
PCR E 
NdeI/HindII
I 
PCR F 
NheI/AscI 
pET21b-cyclonal-
PA63(mFab/hFc) 
pMAZ360-YMF10-IgG 
pET21b-cyclonal-
MBP(mFab/hFc) 
pMAZ360-YMF10-IgG 
pET21b-cyclonal-
MBP(mFab/hFc) 
PCR (A+B) 
PCR (C+D) 
227-228 (= PCR A) 
229-216 (= PCR B) 
230-231 (= PCR C) 
232-220 (= PCR D) 
227-216 (= PCR E) 
230-220 (= PCR F) 
 
 
 
 
PCR E 
NdeI/HindII
I 
PCR F 
NheI/AscI 
pET21b-cyclonal-
Dig(chimeric) 
pMAZ360-26.10-MBP 
pMAZ360-26.10-MBP 
pET21b-cyclonal-
MBP(chimeric) 
PCR (B+C) 
201-233 (= PCR A) 
204-234 (= PCR B) 
235-245 (= PCR C) 
204-245 (= PCR D) 
PCR A 
NdeI/SalI 
 
 
PCR D 
NheI/AscI 
pET21b-cyclonal-
Gcn4(chimeric) 
pHK19 (anti-GCN4 
scFv) 
pHK19 (anti-GCN4 
scFv) 
pET21b-cyclonal-
MBP(chimeric) 
PCR (B+C) 
207-236 (= PCR A) 
210-237 (= PCR B) 
238-245 (= PCR C) 
210-245 (= PCR D) 
PCR A 
NdeI/SalI 
 
 
PCR D 
NheI/AscI 
pET21b-cyclonal-
gpD(chimeric) 
pHK49 (anti-gpD scFv, 
D10) 
pHK49 (anti-gpD scFv, 
D10) 
pET21b-cyclonal-
MBP(chimeric) 
PCR (B+C) 
213-239 (= PCR A) 
217-240 (= PCR B) 
241-245 (= PCR C) 
217-245 (= PCR D) 
PCR A 
NdeI/SalI 
 
 
PCR D 
NheI/AscI 
pET21b-cyclonal-
HAG(chimeric) 
pHK38 (anti-Hag scFv) 
pHK38 (anti-Hag scFv) 
pET21b-cyclonal-
MBP(chimeric) 
PCR (B+C) 
221-242 (= PCR A) 
224-243 (= PCR B) 
244-245 (= PCR C) 
224-245 (= PCR D) 
PCR A 
NdeI/SalI 
 
 
PCR D 
NheI/AscI 
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pET21b-cyclonal-
PA63(chimeric) 
pMAZ360-YMF10-IgG 
pMAZ360-YMF10-IgG 
pET21b-cyclonal-
MBP(chimeric) 
PCR (B+C) 
227-267 (= PCR A) 
230-265 (= PCR B) 
266-245 (= PCR C) 
230-245 (= PCR D) 
PCR A 
NdeI/SalI 
 
 
PCR D 
NheI/AscI 
pET21b-cyclonal-
PA63(FcE382V/M428I) 
pET21b-cyclonal-
PA63(chimeric) 
pET21b-cyclonal-
PA63(chimeric) 
PCR B 
PCR C 
PCR (A+D) 
230-246 (= PCR A) 
247-248 (= PCR B) 
247-249 (= PCR C) 
247-250 (= PCR D) 
230-250 (= PCR E) 
 
 
 
 
PCR E 
NheI/XhoI 
pMAZ360-
cyclonal-
MBP(mFab/hFc) 
pET21b-cyclonal-
MBP(mFab/hFc) 
264-263 NdeI/MluI 
pMAZ360-
cyclonal-
HAG(mFab/hFc) 
pET21b-cyclonal-
HAG(mFab/hFc) 
221-263 NdeI/XhoI 
pMAZ360-
cyclonal-
PA63(mFab/hFc) 
pET21b-cyclonal-
PA63(mFab/hFc) 
227-263 NdeI/XhoI 
pET21b-E-clonal-
HAG(mFab/hFc) 
pET21b-cyclonal-
HAG(mFab/hFc) 
PCR A 
257-216 (= PCR A) 
258-256 (= PCR B) 
259-256 (= PCR C) 
PCR A 
NcoI/HindII
I 
 
PCR C 
NheI/XhoI 
pET21b-E-clonal-
MBP(mFab/hFc) 
pET21b-cyclonal-
MBP(mFab/hFc) 
PCR A 
pET21b-cyclonal-
MBP(mFab/hFc) 
PCR C 
PCR D 
251-261 (= PCR A) 
252-261 (= PCR B) 
253-256 (= PCR C) 
254-256 (= PCR D) 
255-256 (= PCR E) 
 
PCR B 
NdeI/HindII
I 
 
 
PCR E 
HindIII/Xho
I 
pET21b-E-clonal-
PA63(mFab/hFc) 
pET21b-cyclonal-
PA63(mFab/hFc) 
pMAZ360-YMF10-IgG 
pET21b-cyclonal-
MBP(mFab/hFc) 
PCR (B+C) 
260-216 (= PCR A) 
262-231 (= PCR B) 
232-220 (= PCR C) 
262-220 (= PCR D) 
PCR A 
NcoI/HindII
I 
 
 
PCR D 
NheI/AscI 
pMAZ360-E- pET21b-E-clonal- 262-263 NdeI/XhoI 
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clonal-
HAG(mFab/hFc) 
HAG(mFab/hFc) 
pMAZ360-E-
clonal-
MBP(mFab/hFc) 
pET21b-E-clonal-
MBP(mFab/hFc) 
263-263 NdeI/XhoI 
pMAZ360-E-
clonal-
PA63(mFab/hFc) 
pET21b-E-clonal-
PA63(mFab/hFc) 
262-263 NdeI/XhoI 
pETDuet-cyclonal-
PSMA 
CST-rLC-PSMA 
CST-rHC-PSMA 
NK438-NK397 
NK440-NK399 
NcoI/BamH
I 
pETDuet-cyclonal-
B2M 
CST-rLC-B2M 
CST-rHC-B2M 
NK438-NK397 
NK440-NK399 
NcoI/BamH
I 
pETDuet-cyclonal-
PSMA(rFab/hFc) 
CST-rLC-PSMA 
CST-rHC-PSMA  
pUC57-mFab/hFcsyn* 
PCR A + B 
NK438-NK397 
NK440-NK400 (= 
PCR-A) 
NK401-NK402 (= 
PCR-B) 
Gibson Assembly 
NdeI/EcoR
V 
pETDuet-cyclonal-
B2M(rFab/hFc) 
CST-rLC-B2M 
CST-rHC-B2M 
pUC57-mFab/hFcsyn* 
PCR A + B 
NK438-NK397 
NK439-NK400 (= 
PCR-A) 
NK401-NK402 (= 
PCR-B) 
Gibson Assembly 
NdeI/EcoR
V 
*Gene synthesis, GenScript 
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Table 2.4. List of primers and the sequences used in construction of plasmids. 
 
Name                              Sequence (5’ to 3’) 
50 TATATATATATATATATTCTAGAGAAGGAGATATACACATGCA
GGTCCAACTGCAGCAACCTGGG 
51 TATGCGGCGCGCCTTATTATTTACCCGGAGTCCGGGAGAAGC 
52 ATATACATATGGACATTGTGATGACACAGTCTCC 
53 GTGTATATCTCCTTCTCTAGAATATATATATATATATATTAACA
CTCATTCCTGTTGAAGC 
123 ATATACATATGGACATTGTGATGAC 
124 ATGCCTCGAGTTATTTACCCGGAGTCCGGGAGAAGCTC 
160 ATATACATATGGACATTGTGATGAC 
161 CCGTACGTTTCATGTCGACTTTGGTCCCCCCCCCGAACGTGTA
CGGAG 
162 CTCCGTACACGTTCGGGGGGGGGACCAAAGTCGACATGAAAC
GTACGG 
163 GGTTGCTGCAGTTGGACCTGCATGGCTAGCTCTCCTTCTCTAG
AATA 
164 TATTCTAGAGAAGGAGAGCTAGCCATGCAGGTCCAACTGCAG
CAACC 
165 GGTACCCTGGCCCCAGTATTTAAATAACCCTCTTGTACAGTAA
TAGACCGCAGA 
166 TCTGCGGTCTATTACTGTACAAGAGGGTTATTTAAATACTGGG
GCCAGGGTACC 
167 ACGGTGGGCATGTGTGAGTTTTGTCGGCGCGCCCTTTCGGTTC
AACTTTT 
NK397 GCCGAGCTCGAATTCGTTAACAGTCACCCCTATTGAAGC 
NK399 CGCGTGGCCGGCCGATTTATTTACCCGGAGAGCG 
NK400 GTTTTGTCGGCGCGCCCGCATGTCGAGGGCG 
NK401 TGCGCCCTCGACATGCGGGCGCGCCGA 
NK402 CGCGTGGCCGGCCGATTTATTTACCCGGAGACAGGG 
NK438 CTTTAAGAAGGAGATATACATGGCCGTGCTGACCC 
NK439 GTATAAGAAGGAGATATACAATGCAGTCGGTGGAGGAGTCC 
NK440 GTATAAGAAGGAGATATACAATGCAGTCGCTGGAGGAGTCC 
Deg1 GGGAATTCCACCATGGASACAGACACACTCCTGCTATGG 
Deg2 GGGAATTCCACCATGGATTTTCWRGTGCAGATYTTCAG 
Deg3 GGGAATTCCACCATGRAKTCACAKRCYCAGGTYYTYAT 
Deg4 GGGAATTCCACCATGAKKNHYTCWSCTCAGYTYYTKGG 
Deg5 GGGAATTCCACCATGAAGTTGCCTGTTAGGCTGTTG 
Deg6 GGGAATTCCACCATGGACATRAGKRCYCYYGCTCAG 
Deg7 GGGAATTCCACCATGCATCAGAYCAGCATGGGCWTCAAG 
LC-9 GCGCCGGTCGACATTAACACTCATTCCTGTTGAAGC 
Kabat-
F 
GGGAATTCCACCATGGRATGSAGCTGKGTMATSCTC 
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Kabat-
R 
GTGGGGCGGCCGCTCATTTACCCGGAGTCCGGGAGAAGC 
201 TTTTTTCATATGGCGGACATAGTACTGACCCAGTC 
202 GATGGATACAGTTGGTGCAGCATCAGTGGCCGATTTGATCTCG
AGCTTG 
203 CAAGCTCGAGATCAAATCGGCCACTGATGCTGCACCAACTGT
ATCCATC 
204 TTTTTTGCTAGCCATGGCGGAGCTGCAGCAGTC 
205 CCGATGGGGCTGTTGTTTTGGCAGAGCTCACAGTAACACTAGC
ACCATG 
206 CATGGTGCTAGTGTTACTGTGAGCTCTGCCAAAACAACAGCCC
CATCGG 
207 TTTTTTCATATGCGAGATATCGTTATGACCCAATCTC 
208 GATACAGTTGGTGCAGCATCAGCGCGCTTAAGCTCCACTTTGG
TTC 
209 GAACCAAAGTGGAGCTTAAGCGCGCTGATGCTGCACCAACTG
TATC 
210 TTTTTTGCTAGCCATGGAAGTCAAACTTCTTGAGTCAGGTG 
211 GTTGTTTTGGCTGCAGAGACAGTAACCAGCGTGCCCTGC 
212 GCAGGGCACGCTGGTTACTGTCTCTGCAGCCAAAACAAC 
213 TTAAATCATATGGATATCGAACTGACCCAGCCG 
214 CCCGTTTTATTTCCAGCTTGGTGCCGCCGCCAAACACAG 
215 CTGTGTTTGGCGGCGGCACCAAGCTGGAAATAAAACGGG 
216 TTTTTTAAGCTTTTAACACTCATTCCTGTTGAAGCTC 
217 ATTAATGCTAGCCATGGAAGTGCAATTGGTGGAAAGCG 
218 GATGGGGCTGTTGTTTTGGCTGCGCTAACCGTCACCAGGGTGC 
219 GCACCCTGGTGACGGTTAGCGCAGCCAAAACAACAGCCCCAT
C 
220 GTGGGCATGTGTGAGTTTTGTC 
221 AAAAAACATATGGATATCGTTATGACCCAGTCACCG 
222 GATGGATACAGTTGGTGCAGCATCAGCGCGCTTAAGTTCCAGT
TTG 
223 CAAACTGGAACTTAAGCGCGCTGATGCTGCACCAACTGTATCC
ATC 
224 ATTAATGCTAGCCATGGAAGTTCAACTAGTTGAATCCGGTGGT
G 
225 CGATGGGGCTGTTGTTTTGGCAGCTGAAACGGTAACCAGGGT
AC 
226 GTACCCTGGTTACCGTTTCAGCTGCCAAAACAACAGCCCCATC
G 
227 TTTTTTCATATGGCGGATATTGTGATGACCCAGTC 
228 GATGGATACAGTTGGTGCAGCATCAGTACGATTCAGCTCCAGC
TTGG 
229 CCAAGCTGGAGCTGAATCGTACTGATGCTGCACCAACTGTATC
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CATC 
230 TTTTTTGCTAGCCATGGCGGAGGTCCAGCTTC 
231 CCGATGGGGCTGTTGTTTTGGCTGAGGAGACTGTGAGAGTGGT
G 
232 CACCACTCTCACAGTCTCCTCAGCCAAAACAACAGCCCCATCG
G 
233 TTTTTTGTCGACCTTGGTCCCCGAGCCGAAC 
234 CACCAGGGTACCCTGGCCCCAATAATCCATGGCCCATTTGTTA
CCAG 
235 CTGGTAACAAATGGGCCATGGATTATTGGGGCCAGGGTACCC
TGGTG 
236 TTTTTTGTCGACTTTGGTTCCTTGACCAAATACCCAGTG 
237 CAGGGTACCCTGGCCCCAGTAGTCGAAAAGTCCTGTCACGCA
G 
238 CTGCGTGACAGGACTTTTCGACTACTGGGGCCAGGGTACCCTG 
239 TTTTTTGTCGACCTTCGTGCCGCCGCCAAACAC 
240 CACCAGGGTACCCTGGCCCCAATAATCCATACCAGAAACATA
AGAAAAACGC 
241 GCGTTTTTCTTATGTTTCTGGTATGGATTATTGGGGCCAGGGTA
CCCTGGTG 
242 TTTTTTGTCGACTTTGGTGCCACCACCGAAGGTC 
243 CAGGGTACCCTGGCCCCAGTAGGCGAAACCGTTTTCGTCATAA
C 
244 GTTATGACGAAAACGGTTTCGCCTACTGGGGCCAGGGTACCCT
G 
245 TATATAGGCGCGCCCGCAGCTTTTCGGTTCAACTTTTTTATCCA
CTTTCG 
246 CTGCCCATTGCTCACCCACTCCACGGC 
247 GCCGTGGAGTGGGTGAGCAATGGGCAG 
248 GAGCCTCGTGGATCACGGAGC 
249 GAGAGGCTCTTCTGCGTGTAGTGGTTGTGCAGAGCCTCGTGGA
TCACGGAGCATGAGAAG 
250 CTCAGC CTCGAG 
TCATTTACCCGGAGACAGGGAGAGGCTCTTCTGCGTGTAGTGG 
251 TGGATTGTTATTACTCGCGGCCCAGCCGGCCATGGCGGACATT
GTGATGACACAGTCTCC 
252 CTCAGT CATATG 
AAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCG
CGGC 
253 CCGCTGGATTGTTATTGCTAGCGGCTCAGCCGGCAATGGCGCA
GGTCCAACTGCAGCAAC 
254 AGGAGAGAATTCCATGAAATACCTATTGCCTACGGCAGCCGC
TGGATTGTTATTGCTAGC 
255 CTCATG AAGCTT 
TATATATATATATATATTCTAGAGAAGGAGAGAATTCCATGAA
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ATACCTATTG 
256 CTCAGT CTCGAG TCATTTACCCGGAGAC 
257 TTTTTTCCATGGCGGATATCGTTATGACCCAGTCACCGTC 
258 GCAATGGCGGAAGTTCAACTAGTTGAATCCGGTGGTG 
259 TATAATGCTAGCGGCTCAGCCGGCAATGGCGGAAGTTCAACT
AGTTG 
260 GATTCA CCATGG CGGATATTGTGATGACC 
261 GAACTT AAGCTT TTAACACTCATTCCTGTTGAAGCTCTTGAC 
262 CTCAGTTCTAGAATGAAATCCCTATTGCCTACGGC 
263 AATATTACGCGTGTACTCGAGTTATCATTTACCCGGAGACAGG
GAG 
264 TATATT CATATGGACATTGTGATGACACAGTC 
265 GACGGGCCTTTGGTGCTGGCTGAGGAGACTGTGAGAGTGGTG 
266 CACCACTCTCACAGTCTCCTCAGCCAGCACCAAAGGCCCGTC 
267 TTAATTGTCGACCTTGGTCCCAGCACCGAAC 
*Engineered restriction sites are underlined.   
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CHAPTER 3 
A FUNCTIONAL SELECTION FOR FULL-LENGTH ANTIBODIES IN THE 
CYTOPLASM OF ENGINEERED BACTERIA  
Introduction 
Monoclonal antibodies have become ubiquitous tools in biological and medical 
research. Many protein detection methods, e.g. imaging techniques and binding 
assays, depend on the existence and availability of reliable antibodies. In medicine, 
monoclonal antibodies are both the largest and fastest growing class of protein 
therapeutics[44]. Despite the number of advancements in antibody engineering 
technology, development of antibodies for research and therapeutic applications 
remains challenging and expensive.  
Currently, most antibodies are developed using methods that require 
immunization including hybridoma technology[53] and  immunization of wild-type 
and transgenic animals[58-60]. These technologies offer several advantages including 
harnessing the natural immune repertoire, using natural mechanisms of clonal 
selection, and selection of full-length antibodies with important post-translational 
modifications. However, immunization-based discovery methods are both time-
consuming and labor intensive making them technically challenging to perform and 
poorly suited for developing antibodies against multiple antigens in parallel. In 
addition, the applicability of hybridoma technology and transgenic animals is limited 
by a poor immune response against proteins that are well conserved (immune 
tolerance) and the inability to directly control antibody sequence diversity. These 
limitations make it difficult to enhance desired properties like affinity, stability, 
solubility, and expression level.  
Display technologies including phage[74, 75], ribosome[77], bacterial[84], and 
yeast display[71, 81], have become increasingly popular for the isolation and 
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engineering of antibodies. The genetic tractability of display systems allows near 
complete control of the antibody sequence diversity [144]. Furthermore, the ease of 
propagation of model microbes allows for the screening of large combinatorial 
libraries in a relatively short period of time[76].  In the past, these systems were 
limited to isolation of antibodies in single-chain Fv (scFv) or Fab formats, which lack 
the effector functions and long circulating serum persistence of full-length antibodies. 
However, full-length antibodies have recently been engineered using creative 
adaptations of bacterial [93], yeast [145, 146], and phage display[92]. Although 
microbial based display systems have been used to address the drawbacks of 
hybridoma technology and animal immunization, there are also several disadvantages 
to microbial based display including the requirement for multiple labor-intensive 
steps, and specialized equipment. Moreover, display technologies typically require 
several rounds of screening before a suitable lead antibody is isolated. Furthermore, 
display technologies like immunization based methods usually require purification, 
immobilization, special preparation, and/or modification of the target antigen.  
Genetic selections have been employed for decades to elucidate biological 
phenomena as well as to evolve and engineer proteins, cells, and pathways [31, 147, 
148]. Genetic selections are attractive as they are designed to link a desired property to 
the fitness of the host organism; requiring minimal interference in the isolation 
process. Selections are high-throughput strategies for isolating desirable traits as large 
libraries can be subjected to explicit selection conditions, and most cells that survive 
should exhibit the desired property. On the other hand, screens require every member 
of a library be analyzed making the process of identifying beneficial mutations much 
more labor intensive.  E. coli is often the host of choice for engineering recombinant 
proteins due to its fast doubling time and ease of genetic manipulation. E. coli based 
survival selections for isolating antibody fragments have been reported in several 
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cases. One strategy based on reconstitution of split antibiotic resistance enzymes 
facilitated by antibody:antigen binding, has been used to report known 
antibody:antigen interactions and to select antibody fragments from combinatorial 
libraries [85-87, 149, 150]. This strategy, however, has been limited to selecting 
antibody fragments and has not been demonstrated for full-length antibodies. 
The use of antibiotics in genetic selections is widespread especially given the 
vast range of targets whether aimed at transcription, translation, or cell wall synthesis. 
One well studied antibiotic is chloramphenicol (Cm), which inhibits cell growth by 
arresting protein synthesis in the cytoplasm by interacting with the 23s rRNA of the 50 
S subunit of the ribosome. A natural countermeasure towards chloramphenicol is the 
production of an enzyme called chloramphenicol acetyltransferase (CAT). CAT 
inhibits the action of chloramphenicol by covalently adding an acetyl group to 
chloramphenicol preventing it from binding to ribosomes and allowing protein 
synthesis to continue in the cell. Since translation is catalyzed by ribosomes in the 
cytoplasm, CAT must also be present the cytoplasm in order to deactivate 
chloramphenicol [151, 152]. We formulated a strategy to link cell survival to the 
subcellular localization of CAT using the twin-arginine translocation (Tat) pathway. 
There are two distinct pathways in E. coli for the translocation of proteins to the 
periplasm: the general secretory pathway or Sec pathway and the Tat pathway. The E. 
coli twin arginine translocation (Tat) pathway consists of a complex of proteins, 
TatABC, which preferentially export folded proteins carrying an N terminal Tat signal 
peptide across the inner membrane to the periplasmic space.  
 70 
 
Figure 3.1. CAT selection for engineering antigen specific cytoplasmic IgG 
antibodies. Schematic representation of the Tat-CAT assay for identifying 
intracellular binding between specific cyclonal antigen pairs. A fusion protein 
consisting of CAT and a target antigen modified with a Tat signal peptide at its N 
terminus. In the absence of a binding partner the fusion protein is freely exported to 
the periplasmic space where it cannot deactivate chloramphenicol resulting in Cm 
sensitive cells. When a cyclonal that binds the target antigen is present, the interaction 
retains the CAT fusion protein in the cytoplasm where it can deactivate 
chloramphenicol thereby conferring resistance (Cm resistant).  
Recently we reported the expression of active full-length IgG antibodies within 
the cytoplasm (cyclonals) of E. coli cells[8]. We achieved this by co-expressing heavy 
and light chains in trxB gor aphC* E. coli cells that promote stable disulfide bond 
formation in the cytoplasm. Building upon this work, we developed a genetic selection 
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strategy to isolate functional full-length antibodies against an antigen fused to CAT 
(CAT-Ag) and relying on the Tat pathway to select for higher affinity binders that 
keep CAT-Ag in the cytoplasm conferring resistance to chloramphenicol, while weak 
or non-binders allow CAT-Ag to be exported to the periplasm. When a full-length 
antibody is coexpressed in the cytoplasm with its antigen fused to CAT carrying an N 
terminal Tat signal peptide (spTorA-CAT), antibody:antigen binding impedes export 
thereby retaining CAT in the cytoplasm where it can confer resistance to 
chloramphenicol (Figure 3.1). We hypothesize that by this blocking mechanism 
specific antigen binding in the cytoplasm will be linked to a simple growth phenotype. 
Using this strategy, we demonstrate for the first-time isolation of antigen-specific full-
length antibodies by genetic selection. 
Results 
Cytoplasmic retention of CAT is a selectable phenotype. We hypothesized that the 
cytoplasmic reporter CAT fused to an antigen of interest (CAT-Ag) exported to the 
periplasm via the Tat pathway would render cells sensitive to chloramphenicol. This 
would allow a selection based upon Tat mediated translocation of the CAT-Ag 
substrate. To determine whether we could select for Tat export of CAT-Ag, we 
constructed a vector encoding a Tat-specific signal peptide (spTorA) genetically fused 
to the N terminus of CAT followed by a target antigen fused to the CAT with a 7 
amino acid (Gly- Thr-Ser-Ala-Ala-Ala-Gly) flexible linker (spTorA-CAT-Ag).  CAT 
exists as a trimer in vivo composed of identical monomers all approximately 25 kDa in 
size [153]. As such, we hypothesized that antigens that are relatively small in size 
would reduce the probability that inefficient CAT-Ag transport would be a 
complicating factor in developing the selection. Therefore, HAG peptide[134], c-Myc 
epitope tag[154], and the basic-region leucine zipper domain of S. cerevisiae 
Gcn4[155], all relatively small polypeptides, were each cloned into the target antigen 
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position of the reporter construct to generate spTorA-CAT-HAG, spTorA-CAT-c-
Myc, and spTorA-CAT-Gcn4, respectively. SHuffle cells expressing the spTorA-
CAT-Ag hybrid proteins were evaluated for resistance to chloramphenicol. Regardless 
of the antigen fused to CAT, cells expressing spTorA-CAT-Ag fusions grew poorly on 
media supplemented with chloramphenicol (Figure 3.2). Having observed that 
translocation of the CAT fusions resulted in chloramphenicol sensitivity; we predicted 
that blocking the export of the CAT reporter would result in the restoration of 
chloramphenicol resistance. If so, we would have the ability to select for attenuated 
Tat export of the CAT-Ag reporter. In order to determine whether blocking Tat 
translocation of spTorA-CAT-Ag could restore chloramphenicol resistance, we 
replaced the wild-type spTorA signal sequence with one in which the twin-arginine 
motif RR had been mutated to KK (spTorA(KK)). The RR to KK mutation has been 
shown to abolish Tat export [156, 157]. Without exception, cells carrying plasmids for 
spTorA(KK)-CAT-Ag were more resistant to chloramphenicol than those expressing 
CAT-Ag hybrids with functional Tat signal peptides (RR) (Figure 3.2).  
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Figure 3.2 CAT selection for Tat export. Selective spot plating of SHuffle cells with 
plasmids for CAT-antigen fusions (spTorA-CAT-Ag)  and CAT-antigen fusions with 
a defective Tat signal peptide that impedes translocation (spTorA(KK)-CAT-Ag)  are 
indicated. SHuffle cells were serially diluted in LB media and 5 µl was plated on LB-
agar supplemented with 0 or 10 µg/ml chloramphenicol, 0.4 % arabinose, and 1mM 
IPTG. 
These results suggest that when grown in the presence of Cm, blocking CAT-Ag 
translocation to the periplasm and thereby retaining the putative cytoplasmic reporter 
within the cytosol, is a selectable phenotype. Therefore, we built a selection strategy 
based upon disrupting the export of spTorA-CAT-Ag reporter hybrids. 
Antibody:Antigen reactivity promotes cell viability in CAT assay. Rodrigue et al 
described the “hitchhiker” transport mechanism by which proteins lacking a N 
terminal Tat signal peptide can be cotransported provided it is part of a complex in 
which at least one of the proteins possesses a functional signal peptide[158]. We 
speculated that increasing the size of the spTorA-CAT-Ag reporter by coexpressing an 
antibody (Ab) specific for spTorA-CAT-Ag would impede efficient export. The export 
of the spTorA-CAT-Ag:Ab complex would be poor relative to that of the smaller 
unbound spTorA-CAT-Ag reporter (or blocked all together) resulting in higher 
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concentration of CAT in cytoplasm.  This should allow selection for complex 
formation in the cytoplasm on Cm.  To test this theory, we cloned plasmids for 
cytoplasmic expression of two scFvs, namely scFv-HAG, specific for the 18 amino 
acid HAG peptide, and scFv-gpD (D10)[149], specific for the phage coat glycoprotein 
D. We chose the scFv format as it provides the simplest case of Ab:Ag interaction. 
SHuffle cells expressing scFv-HAG and spTorA-CAT-HAG showed resistance to 
chloramphenicol while cells expressing scFv-gpD (D10) with spTorA-CAT-HAG 
showed no detectable growth (Figure 3.3).  These observations suggest that the 
binding interaction between CAT-HAG and scFv-HAG impedes Tat export.  
Single-chain Fvs are one of the simplest models for antibody binding as the VL 
and VH binding domains are expressed as a single polypeptide linked covalently 
through a flexible linker. Furthermore, scFv-HAG and scFv-gpD are “intrabodies”, 
which are antibody fragments evolved to retain their function in the absence of 
structural disulfide bonds so as to be functional in intracellular (reducing) 
environments. Next, we tested whether a more complex antibody fragment could 
provide a similar selective advantage to cells cultured on Cm. Fab antibody fragments 
have similar binding specificity to scFvs but are expressed as two chains each linked 
to an antibody constant domain. Importantly, Fab fragments require five structural 
disulfide bonds for correct assembly and activity (i.e. must be assembled via bonding).   
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Figure 3.3 CAT selection for antibody fragments that bind antigens. Selective 
spot plating of SHuffle cells with plasmids for expressing scFv, Fab (cyFAB), and 
CAT-antigen fusions as indicated. SHuffle cells carrying plasmids for the CAT-
antigen fusions with a defective Tat signal peptide (spTorA(KK)-CAT-Ag) that 
impedes translocation were plated as negative controls. SHuffle cells were serially 
diluted in LB media and 5 µl was plated on LB-agar supplemented with 0 or 20 µg/ml 
chloramphenicol, 0.4 % arabinose, and 1mM IPTG. 
To create a vector for the anti-HAG Fab antibody the VL domain of scFv-HAG 
was fused to the CLκ domain of mouse IgG2a (VL- mCLκ), while the VH domain was 
fused to CH1 domain of mouse IgG2a (VH-mCH1), and cloned into a two-promoter 
vector for coexpression of the two chains in the cytoplasm. Expression of the anti-
HAG Fab in the cytoplasm with spTorA-CAT-HAG conferred resistance to 
chloramphenicol on SHuffle cells (Figure 3.3). Cells coexpressing the Fab and its 
specific antigen grew nearly as well as the positive control in which CAT-HAG export 
is blocked (Figure 3.3). On the contrary, SHuffle cells expressing an anti-MBP Fab 
and spTorA-CAT-HAG showed much lower tolerance for Cm compared with cells 
that express the binding pair. We observed similar phenomena when we challenged 
cells expressing another Fab:Ag pair, anti-Gcn4 and Gcn4, with chloramphenicol 
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(Figure 3.3). This suggests that the selective advantage conferred by antibody binding 
is a general phenomenon and not specific to the Ag in the fusion provided that it is 
sufficiently exported by Tat. Our results indicate that specific binding of the spTorA-
CAT-Ag hybrid within the cytoplasm offers a similar selective advantage to cells as 
blocking export of the reporter via Tat. 
 
 
Figure 3.4. CAT selection for cyclonals that bind antigens. Selective spot plating of 
SHuffle cells with plasmids for expressing cyclonals and CAT-antigen fusions as 
indicated. SHuffle cells carrying plasmids for the CAT-antigen fusion alone and the 
CAT-antigen fusion with a defective Tat signal peptide that impedes translocation 
were plated as negative controls. Shuffle cells were serially diluted in LB media and 5 
µl was plated on LB-agar supplemented with 0 or 10 µg/ml chloramphenicol, 0.4 % 
arabinose, and 1mM IPTG. 
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Cyclonal:Antigen reactivity promotes cell viability in CAT assay. Having 
determined that binding of the spTorA-CAT-Ag reporter by specific antibody 
fragments results in a selectable phenotype, we hypothesized that the selection could 
be extended to isolating binding interactions with full-length IgG. To adapt the 
selection to full-length IgGs we cloned the anti-HAG mFab/hFc cyclonal created in 
previous work into the two-promoter vector constructed for Fab expression. We also 
chose the cyclonal against E. coli maltose binding protein (MBP)[8], a cyclonal 
against Gcn4[8], and a mFab/hFc cyclonal we generated against the c-Myc epitope tag 
by grafting the VL and VH sequences from a previously reported scFv, scFv-3DX, onto 
the mFab/hFc framework as additional test cases [154]. SHuffle T7 Express cells were 
transformed with plasmids expressing specific antigen:antibody pairs and plated on 
varying concentrations of chloramphenicol. In each case, cells carrying plasmids for 
cognate antigen:antibody pairs possessed an observable fitness advantage over cells 
co-producing non -specific pairs (Figure 3.4).   
We also tested whether the binding specificity of CDR-H3 variants of the anti-
Gcn4 scFv (scFv-Gcn4(GLF)) would be faithfully reported in the context of our assay.  
These scFv variants differ within the third hypervariable region of the variable heavy 
chain domain (VH) and were chosen from two previous studies. In one study 
conducted by the Plückthun group [155]and the other from our group[88], scFvs with 
randomized CDR-H3 were selected from synthetic libraries for both intracellular 
binding activity and stability in yeast and E. coli, respectively. We selected a panel of 
4 scFvs, isolated between the two reports, scFv-Gcn4(ALF) and scFv-Gcn4(GLQ), 
scFv-Gcn4(GLH), and scFv-Gcn4(GLM) and grafted them into our two-promoter 
cyclonal expression plasmid. A fifth scFv, scFv-Gcn4(GFA), was grafted as a negative 
control as it was shown to be non-specific for Gcn4.  SHuffle cells expressing each 
specific variant with the spTorA-CAT-Gcn4 hybrid showed higher resistance to Cm 
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than cells expressing the non-reactive variant GFA (Figure 3.5).  
Each variant confers similar levels of resistance to Cm when compared with 
cells expressing the anti-Gcn4 cyclonal. As expected, the non-binding cyclonal variant 
anti-Gcn4(GFA) did not grow well under the selective conditions of assay. These 
results corroborate findings of both Plückthun and coworkers and Waraho and DeLisa, 
providing further evidence that our assay is functioning successfully as an intracellular 
antigen:antibody binding reporter. 
 
Figure 3.5 Performance of anti-Gcn4 variant cyclonals in CAT selection. Selective 
spot plating of SHuffle cells with plasmids for expressing anti-Gcn4 variant cyclonals 
and CAT-antigen fusions as indicated. Selected CDR-H3 residues are indicated in 
parenthesis cyclonal(XXX). SHuffle cells carrying plasmids for the non-specific 
cyclonal [cyclonal(GFA)] and parent cyclonal [cyclonal(GLF)] were plated as 
negative and positive controls, respectively. SHuffle cells were serially diluted in LB 
media and 5 µl was plated on LB-agar supplemented with 0 or 20 µg/ml 
chloramphenicol, 0.4 % arabinose, and 1mM IPTG. 
CAT selection of specific antibodies from synthetic cyclonal library. Next, we 
examined whether our strategy could be employed to select antigen specific binders 
from a library composed of cyclonals with randomized CDR-H3 sequences. Structural 
studies indicate that the third complementarity determining region of the IgG heavy 
chain typically forms crucial interactions with the bound antigen [159-162]. We chose 
the basic leucine zipper domain of Gcn4 as it has been used as a model antigen to test 
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other antibody selection strategies [133].  The CDR-H3 of the published anti-Gcn4 
cyclonal variants consists of 5 residues (e.g. GLFDY, ALFDY). We elected to 
construct an IgG library similar to the scFv libraries selected against Gcn4 in Waraho 
and DeLisa. In order to generate an IgG library, we randomized the first three residues 
of the heavy chain CDR3 of the non-binding anti-Gcn4 cyclonal, anti-Gcn4(GFA) 
leaving the last two residues (DY) constant. Two libraries were constructed: one in 
which the NDT codon was used to randomize the CDR-H3, and a second where the 
NNK degenerate codon was used for random mutagenesis of CDR-H3. SHuffle cells 
carrying the spTorA-CAT-Gcn4 reporter were cotransformed with each library. To 
isolate Gcn4 binders, a total of ~2.8x107 clones from each library were selected on LB 
agar supplemented with 10 µg/ml Cm. SHuffle cells coexpressing spTorA-CAT-Gcn4 
and anti-Gcn4(GFA) were plated similarly as a negative control. After 72 h, 20 clones 
were selected at random from each library plate (NDT and NNK). The growth 
phenotype was confirmed by retransforming SHuffle cells carrying the Gcn4 reporter 
with plasmids isolated from the 20 clones and plating under selective conditions. A 
total of 20 positive clones, 10 from the NDT and 10 from the NNK library, were then 
sequenced. Of those clones, 19 were unique. To verify Gcn4 specificity, the 19 unique 
cyclonal clones were expressed in SHuffle cells and soluble extract from these clones 
was measured for Gcn4 binding activity. Four of the clones, anti-Gcn4(GLF), anti-
Gcn4(SLF), anti-Gcn4(GIN), anti-Gcn4(GTK) exhibited Gcn4 binding activity 
(Figure 3.6).  
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Figure 3.6. Confirmation of Gcn4 binding activity of selected clones from 
randomized 3-residue libraries. Soluble extracts prepared from SHuffle T7 express 
cells expressing clones selected from the 3-residue NNK and NDT libraries were 
assayed for binding activity against Gcn4 by ELISA. Extracts containing GLF and 
GFA cyclonals were used as positive and negative controls, respectively. Extracts 
were serially diluted 2-fold in PBS buffer. Absorbance was measured at 492 nm. 
Binding was detected with a peroxidase-conjugated anti-human Fc IgG. 
 
The observed binding activity confirmed the authenticity of the selected 
sequences. Of those clones, three (GLF, SLF, and GIN) were selected from the NDT 
library and the other (GTK) from the NNK library. It is noteworthy that the only 
sequence we isolated that is identical to one selected in the previous studies is GLF. 
However, this is not surprising as GLF is the original anti-Gcn4 sequence isolated by 
ribosome display in an earlier work by the Plückthun group[78]. The other three 
sequences are unique to our study. However, an equally interesting observation is that 
the hits still adhere to a similar pattern to those selected in previous studies. For 
instance, GIN and GTK both contain glycine in the first position, which is consistent 
with all hits selected by Waraho and DeLisa and with a majority of those selected by 
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de Maur et al [88, 155]. The GIN clone in particular shares not only glycine in the first 
position with the hits selected by Waraho and DeLisa, but, also a similar amino acid 
isoleucine (I) in the second position. Each hit isolated by Waraho and DeLisa 
contained leucine (L) in the second position within the three-amino acid CDR-H3 in 
addition to glycine in the first position. Similarly, SLF shares the identity of the amino 
acids in the second and third position with the wild-type sequence GLF. Clones GIN 
and SLF support the findings of both studies that there is a strong preference for a 
straight chain hydrophobic amino acid (Isoleucine or Leucine) at the second position. 
Noting that in vivo, CDR-H3 sequences frequently vary in length, we tested 
whether cyclonals could be directly selected from a library with a longer randomized 
CDR-H3. We chose to insert an additional randomized position into CDR-H3 again 
leaving the final two residues constant. The result was a library with four total 
randomized positions within the CDR (NDT4). To construct the NDT4 library, four 
residues within the expanded CDR-H3 of anti-Gcn4(GFA) were randomized with the 
NDT codon. The NDT4 library was screened using the SHuffle reporter strain on LB 
agar supplemented with 10-20 µg/ml Cm. A total of ~2.8x107 clones were plated and 
cultured for 72 hrs. Twenty positive clones were verified by retransforming the 
SHuffle reporter strain and confirming antibiotic resistance. Ten clones were tested for 
binding activity against Gcn4 and one clone (GLLD) specifically bound the antigen 
with high affinity (Figure 3.7).     
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Figure 3.7. Confirmation of Gcn4 binding activity of selected clones from 
randomized 4-residue libraries. Soluble extracts prepared from SHuffle T7 express 
cells expressing selected positive cyclonal clones were assayed for binding activity 
against Gcn4 by ELISA. Extracts containing GLF and GFA cyclonals were used as 
positive and negative controls, respectively. GIN cyclonal was previously selected 
from the NDT3 library. Extracts were serially diluted 5-fold in PBS buffer. Data 
shown are the anti-Gcn4 binding activity for 2 µg total protein extract (0.04 µg/ml). 
Absorbance was measured at 652 nm. Binding was detected with a peroxidase-
conjugated anti-human Fc IgG. 
Interestingly, the identities of the selected CDR-H3 residues of this clone 
strictly follow the pattern observed in the two previous works [88, 133]. In fact, the 
GLLD clone is nearly identical to the 3-residue CDR-H3 clone GLL selected in both 
studies. In summary, we have demonstrated the potential of our CAT reporter assay as 
a tool for isolating functional antigen-specific full-length IgG antibodies. 
Discussion 
In this chapter, we report a novel strategy for direct selection of functional full-
length IgGs in bacteria cells. Our simple genetic selection is based upon inhibiting Tat 
mediated secretion of a hybrid cytoplasmic reporter to the periplasm. It is made 
possible by building upon previous work in which we achieved soluble expression of 
full-length antibodies within the cytoplasm of engineered E. coli cells, which is not 
possible using wild-type E. coli cells. The CAT reporter selection bypasses the need 
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for the costly and time-consuming step of immunization.  
We first showed that we could select for attenuated export via the Tat pathway 
of three-part fusions, consisting of Tat signal peptide, followed by the CAT enzyme 
and an antigen of interest (spTorA-CAT-Ag). The selective advantage, resistance to 
Cm, was observed for several antigens.  Blocked export due to a deficient Tat signal 
peptide presumably leads to a higher concentration of the spTorA(KK)-CAT-Ag 
reporter within the cytoplasm; however, further experiments must be performed to 
confirm this. We also showed that the effect of blocked reporter export could be 
observed by coexpressing antibody fragments that specifically bind the CAT reporter. 
Exploiting this phenomenon, we demonstrated that by simply observing a growth 
phenotype under appropriate selective conditions cognate antigen:antibody could be 
identified from non-cognate ones. Conferral of chloramphenicol resistance was 
observed using both scFv and Fab antibody fragments, the latter proving that the assay 
is compatible with formats that require disulfide bonds for proper assembly. 
Additionally, we proved that the specificity of a scFv could be reported with the 
spTorA-CAT-Ag reporter strategy suggests that the assay might be used as a general 
protein-protein interaction reporter for proteins as small as ~28 kDa. 
The spTorA-CAT-Ag selection method was further extended to report specific binding 
between a full-length IgG and its target. As with the antibody fragments, this method 
proved to be applicable across a number of different antigen:antibody interactions. 
Furthermore, we demonstrated that the CAT reporter assay could be used for selection 
of functional antibodies from a synthetic antibody library. Five specific clones that 
bind Gcn4 were selected from 3 different libraries demonstrating the potential for 
using CAT hybrid selection as a tool for antibody engineering (Table 3.1). Clone 
GTK is a notable case, as it does not have a leucine or isoleucine in the second 
position of its CDR-H3. Although GTK was found to have measurable binding 
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activity against Gcn4, it is less active than the other selected clones, GIN and SLF. 
The GTK clone differs the most from the hits selected in the two previous works, and 
therefore warrants further characterization and study. The selection of the GTK clone 
over expected clones is intriguing, and further characterization of this clone could 
provide some insight into the mechanism of selection.  
 
Table 3.1. Comparison of CDR-H3 sequences of confirmed anti-Gcn4 hits to 
previous studies. CDR-H3 sequences of confirmed anti-Gcn4 hits are aligned with 
hits from previous studies. The study and the strategy used to diversify the library 
from which the hit was isolated are indicated in the first two columns. Conserved 
residues before and after CDR-H3 are shown in the second row. Amino acid positions 
are numbered according to the system devised by Kabat [163]. 
 
It is noteworthy that we do not completely understand the mechanism by 
which our selection works as the Tat translocation mechanism itself is not well-
understood. For instance, we observed that the size of the antigen component of the 
reporter is important. Each antigen that worked well within the context of the assay 
was very small in size with the largest compatible antigen being the Gcn4 leucine 
zipper. This is not surprising given that CAT has a molecular weight of ~25 kDa and 
is a known trimer[153]. Thus, even when expressed as a fusion to a small 10 kDa 
protein, this results in a ~105 kDa CAT-Ag complex. As a result, the CAT-Ag hybrid 
may be poorly exported due to its size. At this juncture care must be taken when 
choosing an appropriate antigen for use in the assay. The effect of export efficiency of 
the reporter on the efficacy of the selection is worth investigating so as to better 
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understand the parameters of the method. 
While there are a handful of genetic selections that have been reported for 
isolating functional antibodies, none has been adapted for full-length IgG antibodies. 
All currently reported genetic selections have only been demonstrated for scFvs and 
similar antibody fragment formats [85, 88, 89, 132, 164].  Furthermore, these 
strategies require the modification of the antibody, with either a signal peptide or 
reporter fragment, to be compatible with the selection. On the other hand, our CAT 
reporter selection requires no modification of the IgG and therefore the selected 
plasmid can be used directly for functional IgG expression without sub cloning. 
Therefore, the process is streamlined from selection to expression for end use or 
further characterization. 
Our strategy also offers several advantages over microbial display methods 
that have been developed in the past decade. First, it does not require purification or 
immobilization of the target antigen. Furthermore, to use the CAT-Ag selection there 
is no need for labeling of the antigen (e.g. fluorophore) as is required for the 
fluorescence-activated cell sorting (FACS) based screening technologies developed 
for isolating full-length IgG including the BAD and E-clonal systems [93, 95]. In 
addition, successful performance of the CAT reporter selection does not require the 
use of expensive or specialized equipment. Our selection system alleviates the need 
for laborious washing steps and time-consuming panning steps associated with plate 
and bead based screens. Another advantage is that selection is conducted with viable 
cells that can be recovered and amplified after selection. This is in contrast to most 
bacterial display screens in which the cells are non-viable after permeabilization of the 
outer membrane.  
Though further development is needed, the CAT reporter assay is possibly the 
simplest method for engineering full-length antibodies reported to date. 
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Materials and Methods 
Bacterial Strains and Plasmids. SHuffle T7 Express (New England Biolabs) was 
used for all library selections, and cyclonal expression experiments.  DH5alpha was 
used for all cloning experiments, plasmid construction, and library construction. 
Protein antigens for immunoassays were expressed in T7 Express (New England 
Biolabs) and BL21 (DE3) (Novagen) strains. The vector pCOLA-Duet cIgG 
(Novagen) was purchased from EMD Millipore and this vector was used to express all 
antibody fragments and cyclonals. The vector pBAD24[165] was used for expression 
of spTorA-CAT-Ag reporter fusions. The GST-Gcn4 antigen was expressed from the 
plasmid pET28a-GST-Gcn4 in E. coli T7 express cells (NEB).  
Plasmid construction. The gene encoding scFv-HAG was amplified using primers 
that added a 5’ NcoI site and 3’ SalI site by PCR using the plasmid pHK38[134]as a 
template. FLAG epitope DNA sequence was constructed by annealing complementary 
phosphorylated oligonucleotides that added a SalI overhang to the 5’ end and an XhoI 
overhang at the 3’ end. The scFv-HAG PCR product and pCOLA-Duet were digested 
using NcoI and SalI. The FLAG oligonucleotide dimer and scFv-HAG gene was 
inserted by double ligation into the NcoI/XhoI site of pCOLA-Duet generating 
pCOLA-Duet-scFv-HAG-FLAG. DNA for scFv-gpD was PCR amplified from 
pHK49 adding an NcoI and SalI to the 5’ and 3’ ends, respectively. The resulting 
product and pCOLA-Duet-scFv-HAG-FLAG were double digested by NcoI and SalI 
and ligated to produce pCOLA-Duet -scFv-gpD-FLAG. To construct plasmids for Fab 
expression, the light chain genes (VL-mCLκ) for anti-HAG and anti-Gcn4 Fab were 
PCR-amplified from the pMAZ360-cIgG-aHAG-mFab/hFc and pMAZ360-cIgG-
aHAG-mFab/hFc vectors, respectively using primers that added an NcoI site upstream 
and a downstream NotI. After digesting pCOLA-Duet and the light chain genes with 
NcoI and NotI, the digestion products were ligated resulting in pCOLA-Duet –cIgL-
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aHAG and pCOLA-cIgL-aGcn4. The genes coding for heavy chain Fab fragment (VH-
mCH1) were also amplified by PCR using pMAZ360-cIgG-aHAG-mFab/hFc and 
pMAZ360-cIgG-aHAG-mFab/hFc as templates during which NdeI and AscI 
restriction sites were introduced at the 5’ and 3’ ends of the product. DNA coding for 
the FLAG epitope tag was assembled by annealing complementary phosphorylated 
oligonucleotides that added a 5’ AscI and a 3’ XhoI overhang to the gene fragment. 
Separately, the intermediate vector products pCOLA-Duet –cIgL-aHAG and pCOLA-
cIgL-aGcn4 were digested with NdeI and XhoI. The PCR amplified anti-HAG heavy 
chain Fab fragment was digested using NdeI and AscI, and double ligated with FLAG 
and pCOLA-Duet –cIgL-aHAG to create pCOLA-Duet –cFAB-aHAG-Mus-FLAG. 
Similarly, the PCR amplified anti-Gcn4 heavy chain Fab fragment was digested using 
NdeI and AscI, and double ligated with FLAG and pCOLA-cIgL-aGcn4 to generate 
the final product pCOLA-Duet –cFAB-aGcn4-Mus-FLAG. The anti-MBP Fab 
expression vector was cloned by first inserting the murine light chain, into the NcoI/ 
NotI site pCOLA-Duet –cFAB-aHAG-Mus-FLAG and subsequently ligating VH-mCH1 
genes from pMAZ360-cIgG-aMBP-mFab/hFc into the NdeI/AscI site of the get the 
final product pCOLA-Duet –cFAB-aMBP-Mus-FLAG. 
For the expression of cyclonals, the mFab/hFc heavy chain genes (VH-mCH1-
hFc) for anti-HAG, anti-Gcn4, and were PCR-amplified from vectors pMAZ360-
cIgG-aHAG-mFab/hFc, pMAZ360-cIgG-aGcn4-mFab/hFc, and pMAZ360-cIgG-
aMBP-mFab/hFc, respectively. 5’ NdeI and 3’XhoI restriction sites were introduced 
during the amplification of each heavy chain product. The heavy chain PCR products 
and associated pCOLA-Duet –cFAB vectors were digested with NdeI and XhoI and the 
digestion products were ligated to produce pCOLA-Duet –cIgG-aHAG-mFab/hFc, 
pCOLA-Duet –cIgG-aGcn4-mFab/hFc, pCOLA-Duet –cIgG-aMBP-mFab/hFc. 
Anti-Gcn4 CDR-H3 cyclonal variants (ALF, GFA, GLH, GLM, and GLQ) 
 88 
were generated by site-directed mutagenesis of the original anti-Gcn4 cyclonal heavy 
chain (GLF) [133] by overlap extension PCR. For each anti-Gcn4 variant, the VH 
sequence was amplified with a common forward primer that introduced a 5’ NdeI site 
and a unique reverse primer that encoded the 9-nucleotide CDR-H3 sequence of the 
specific variant. In parallel, the DNA sequence for the constant domains of the 
mFab/hFc heavy chain, mCH1-hFc, was amplified using a forward primer that 
introduced a sequence that overlaps with the end of the VH gene. Full-length heavy 
chains (VH-mCH1-hFc) were produced by fusing each VH PCR product encoding a 
CDR-H3 variant with the mCH1-Fc product by overlap extension PCR. The full-length 
CDR-H3 variants were digested with NdeI and XhoI and ligated into the NdeI/XhoI 
site of pCOLA-Duet-cIgG-aGcn4 yielding pCOLA-Duet-cIgG-aGcn4(ALF), pCOLA-
Duet-cIgG-aGcn4(GFA), pCOLA-Duet-cIgG-aGcn4(GLH), pCOLA-Duet-cIgG-
aGcn4(GLM), and pCOLA-Duet-cIgG-aGcn4(GLQ). 
For cytoplasmic expression of the anti-c-Myc IgG, VL domain sequence was 
amplified from scFv-3DX[154] while using primers that added a 5’ NcoI site and a 
sequence overlapping with the mouse constant light chain kappa domain (mCLκ). In a 
parallel PCR, the mCLκ sequence was amplified with primers that introduced a 5’ 
sequence overlap with the VL of scFv-3DX and a 3’ NotI site. The two PCR products 
were fused by overlap extension PCR producing the full-length anti-c-Myc light chain, 
VL-3DX- mCLκ. Similarly, the VH domain sequence for anti-c-Myc was amplified 
from scFv-3DX using primers that added a 5’ NdeI site and a sequence overlapping 
with the mFab/hFc heavy chain constant domains. At the same time, the mFab/hFc 
constant heavy chain domains were amplified with primers that introduced a 5’ 
sequence overlap with the VH of scFv-3DX and a 3’ XhoI site. The two PCR products 
were combined by overlap extension PCR creating the full-length anti-c-Myc heavy 
chain, VH-3DX- mCH1-hFc. The full-length light chain and full-length heavy chain 
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products were cloned into the NcoI/NotI and NdeI/XhoI sites of pCOLA-Duet-cIgG, 
respectively to produce pCOLA-Duet-cIgG-3DX-mFab/hFc. 
To generate the CAT-Ag reporter vectors, spTorA-JunLZ-FLAG, DNA, 
encoding the signal peptide of E. coli TorA (spTorA) fused to the N terminus of the c-
Jun leucine zipper was amplified using pBAD18-spTorA-JunLZ-FLAG[88] as a 
template with  5’ NheI and 3’HindIII restriction sites. The digested PCR product was 
cloned into pBAD24 that had been previously digested by NheI and HindIII yielding 
pBAD24-spTorA-JunLZ-FLAG. The gene for chloramphenicol acetyl transferase 
(CAT) was PCR-amplified from pACYC-Duet with a 5’ XbaI site and downstream 
DNA coding for a flexible linker (GTSAAAG) flanked by SalI and SpeI restriction 
sites. The GCN4(7P14P) gene, encoding a double proline mutant of the bZIP domain 
of transcription factor Gcn4 that reduces its propensity for homodimerization, was 
amplified from pBAD33-GCN4(7P14P)-Bla[88] inserting the same flexible linker 
sequence at the 5’ end and a 3’HindIII restriction site. The genes for CAT and 
GCN4(7P14P) were fused by overlap extension PCR. The overlap extension PCR 
product was digested by XbaI and HindIII and ligated into XbaI-HindIII digested 
pBAD24- spTorA-JunLZ-FLAG yielding pBAD24-spTorA-CAT- GCN4(7P14P). 
Genes for HAG peptide and c-Myc epitope tag (EQKLISEEDL) were constructed by 
annealing complementary oligonucleotides. HAG and c-Myc were cloned in the place 
of GCN4(7P14P) after digestion of pBAD24-spTorA-CAT- GCN4(7P14P) with SpeI 
and HindIII yielding plasmids pBAD24-spTorA-CAT- HAG and pBAD24-spTorA-
CAT- c-Myc. 
Selective growth assays. Chemically competent SHuffle cells were transformed with 
pCOLA-Duet encoding antibody expression and pBAD24-spTorA-CAT-Ag plasmids, 
spread on Lysogeny Broth (LB)-Agar plates supplemented with 25 μg/ml 
spectinomycin (Spec), 25 μg/ml kanamycin (Kan), and 50 μg ampicillin (Amp), and 
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cultured overnight at 37°C. The next day, 3 mL LB with 25 μg/ml spectinomycin, 25 
μg/ml kanamycin, and 50 μg ampicillin was inoculated with three freshly transformed 
colonies and incubated at 30°C for 12-18 h. Cells carrying the pCOLA-Duet and 
pBAD24-spTorA-CAT-Ag plasmids were normalized to a cell density of A600=2.5 
(2.5x109 cells/mL) as measured by a spectrophotometer. Cells were then serially 
diluted ten-fold in LB medium typically. 5 μl of each dilution was spotted on selective 
induction plates with 25 μg/ml spectinomycin, 25 μg/ml kanamycin, and 50 μg/ml 
ampicillin, 1 M IPTG, 0.2% arabinose, and varying concentrations of 
chloramphenicol. The plates were then incubated at 30°C for 24-48 h.  
Library construction. The first anti-Gcn4 library was generated by random 
mutagenesis of the first three residues of CDR-H3 using the NDT codon (NDT3). The 
resulting library encoded anti-Gcn4 heavy chain CDR-H3 variants of the form 
XXXDY, where X can be any of the 12 amino acids encoded by the NDT codon (X = 
G, V, L, I, C, S, R, H, D, N, F, or Y). The NDT codon degeneracy (12 codons/12 
amino acids) theoretically results in no codon bias at the randomized positions and 
zero probability of the occurrence of a premature stop codon. Also, the balanced mix 
of amino acids encoded by the NDT codon is representative of the chemical and 
structural diversity within the entire group. Finally, smaller number of possible 
members requires fewer transformants for full library coverage. Random mutagenesis 
of the CDR-H3 was achieved by amplifying the entire pCOLA-Duet-cIgG-
aGcn4(GFA)-mFab/hFc plasmid by inverse PCR with a reverse primer encoded the 
three randomized codons within CDR-H3. The resulting linear PCR product was 
circularized by blunt end ligation producing the plasmid library pCOLA-Duet-cIgG-
aGcn4(XXXDY). The circularized product was used to transform electrocompetent 
DH5alpha cells. The transformed cells were cultured overnight in 100 mL LB and 50 
μg/ml kanamycin. Plasmid DNA was purified by maxiprep from the overnight culture 
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for selection experiments. A second library (NNK3) was created in a nearly identical 
manner with the only change being that the first three residues of CDR-H3 were 
randomized using the NNK codon instead of the NDT codon. 
To create the NDT4 library, the first three residues of CDR-H3 of the anti-
GCN4(GFA) were replaced with 4 randomized residues by mutagenesis PCR 
featuring a reverse primer that encodes 4 amino acids, each with the NDT codon. The 
PCR product, VH-aGcn4(XXXXDY), was fused to the constant domains of the 
mFab/hFc heavy chain (mCH1-hFc) to generate a full-length heavy chain product. The 
heavy chain product was ligated into the NdeI/XhoI site of pCOLA-Duet-cIgG-aGcn4 
yielding pCOLA-Duet-cIgG-aGcn4(XXXXDY). The ligation product was used to 
transform electrocompetent DH5alpha cells. The transformed cells were cultured 
overnight in 100 mL LB and 50 μg/ml kanamycin. Plasmid DNA was purified by 
maxiprep from the overnight culture for selection experiments. 
Library selection. To perform library selections, electrocompetent SHuffle T7 cells 
carrying the pBAD24-spTorA-CAT-Gcn4 reporter plasmid were transformed with the 
purified anti-Gcn4 mFab/hFc cyclonal libraries. Transformants were incubated in SOC 
media at 37 C for 1 hr without antibiotics and then cultured overnight in LB 
supplemented with 100 µg/ml Carb, 50 µg/ml Kan, and 0.2% glucose. The next day, 
overnight cells were normalized to A600 = 2.5 and serially diluted to 10-3, 10-4, and 10-
5. A total volume of 225 µl of each dilution was plated on LB-agar supplemented with 
15-30 μg/ml Cm 0.2% Arabinose and 1 mM IPTG and cultured at 30°C for 72 hrs. At 
the same time, cells transformed with anti-Gcn4(GFA) and pBAD24-spTorA-CAT-
Gcn4 were treated in an identical manner as library cells and used as a negative 
control. Clones that appeared on selective plates were picked at random and resistance 
to Cm was verified by selective spot plating. Plasmid DNA was isolated from positive 
clones and sequenced. 
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Expression of cytoplasmic IgGs. A single colony of SHuffle T7 Express 
transformed with one of the pCOLA-Duet-cIgG expression vectors was used to 
inoculate 2 ml Lysogeny Broth (10 g/L 1 tryptone, 5 g/L yeast extract, 5 g/L NaCl and 
NaOH to pH 7.2) supplemented with 50 µg/mL kanamycin and 25 µg/mL 
spectinomycin, and grown overnight at 30 °C. The next day, 5 ml of fresh LB 
 supplemented with 50 µg/mL kanamycin was inoculated 1/100 with the overnight 
culture and cells were grown at 30 °C until reaching an absorbance at 
 600 nm (A600) of 0.7. At this point, cyclonal expression from the pCOLA-Duet-cIgG 
vector was induced by addition of 0.1 mM isopropyl β-D-thiogalactopyranoside, 
 after which cells were incubated an additional 16 h at RT or 30 °C. Cells were 
harvested by centrifugation before preparation of lysates. 
Preparation of soluble cell extracts. Cells expressing recombinant proteins were 
harvested by centrifugation (4,000 x g, 4°C) and resuspended in PBS and 5 mM 
EDTA. Cells were lysed in an ice-water bath by sonication using a Branson sonifier 
450 (Duty cycle 30% Output control 3) using four repetitions of 30 s each. The 
insoluble fraction was removed by centrifugation (21,000g, 4°C) and the supernatant 
collected as the soluble fraction. 
Enzyme-linked immunosorbent assay (ELISA).  Costar 96-well ELISA plates 
(Corning) were coated overnight at 4°C with 50 µl of 10 µg/ml GST-Gcn4, in 0.05 M 
sodium carbonate buffer (pH 9.6). The antigen GST-Gcn4 was expressed in E. coli T7 
express cells and purified by standard nickel-charged affinity resin (Ni-NTA) 
purification. After blocking with 3% (w/v) milk in PBST (PBSTM) for 1–3 h at room 
temperature, the plates were washed four times with PBS buffer and incubated with 
serially diluted soluble fractions of crude cell lysates for 1 h at room temperature. IgG-
containing samples were quantified by the Bradford assay and an equivalent amount 
of total protein (typically 8–64 mg) was applied to the plate. After washing four times 
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with the same buffer, 50 µl of 1:5,000-diluted rabbit anti-human IgG (Fc) antibody–
HRP conjugate (Pierce) antibodies in PBSTM was added to each well for 1 h. The 96 
well Plates were then washed six times with PBST. After the final wash, 200 µl 
SigmaFAST™ OPD solution (Sigma-Aldrich) was added and incubated within each 
well in the dark for 30 min. The HRP reaction was then terminated by the addition of 
50 µl 3 M H2SO4 to the wells. Following reaction quenching, the absorbance of each 
well was measured at 492 nm. To develop plates with TMB, 50 µl 1-Step™ Ultra 
TMB-ELISA Substrate Solution (Thermofisher Scientific) was added and incubated 
within each well for 15 min. The absorbance of each well was measured at 652 nm 
and 370 nm. 
Acknowledgements 
We thank Dr. Mehmet Berkmen at New England Biolabs and Dr. Andreas Plückthun 
for kindly providing plasmids encoding genes for this study. We also thank Matt 
Chang for technical support in performing library selections and selective spot plating. 
We also thank Xiaolu Zheng for help in generating the NNK library. 
 
 94 
CHAPTER 4 
AN IN VIVO SPLIT-PROTEIN REPORTER FOR ANTIBODY:ANTIGEN 
INTERACTIONS 
Introduction 
In Chapter 3, we showed that microbial based genetic selections are viable 
options for isolation of antibodies from large combinatorial libraries. The goal of 
genetic selection strategies for antibody isolation is to couple fitness to intracellular 
reactivity between an antibody and its target. Techniques of this nature are attractive 
as they offer advantages over both display and traditional methods because they (1) do 
not require purification or elaborate preparation of the antigen and (2) greatly reduce 
the resources, expertise, and equipment required to successfully isolate and engineer 
antibodies. However, while we were successful in isolating full-length antibodies 
using our CAT selection, that strategy is potentially limited to smaller antigens. 
Therefore, in this chapter we developed a selection that can be applied to a more 
diverse set of targets. 
The protein-fragment complementation assay (PCA), a strategy originally 
designed for studying protein-protein interactions (PPIs) [148, 166, 167], has been 
modified for the purpose of engineering antibody:antigen interactions. PCA strategies 
involve a reporter protein that is dissected into two inactive fragments. The two 
fragments are expressed as fusions to either an antigen of interest or its corresponding 
antibody. The activity of the reporter is restored when the antigen:antibody interaction 
brings the two fragments close enough to non-covalently reassemble into a native-like 
structure (Figure. 4.1). Although, several reporter proteins have been adapted for PCA 
including GFP, YFP, Luciferase, and β-galactosidase[168], PCAs designed for 
engineering binding interactions have most often leveraged murine Dihydrofolate 
reductase (mDHFR) or  β-lactamase within the context of an E. coli survival 
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selection[86, 87, 169]. E. coli based PCAs using both enzymes have been used 
successfully to isolate antigen specific antibodies from naïve libraries [85, 149].  
 
 
Figure 4.1 Principle of the protein fragment complementation assay.  A reporter 
protein is expressed as two inactive polypeptide fragments F1 and F2. The fragments 
are then fused genetically to proteins of interest (X and Y) that potentially interact. If 
X and Y interact the fused fragments are brought into close enough contact to 
reconstitute enzymatic activity. Figure taken from Remy[170]. 
 
While there have been reports of isolating functional antibody fragments by 
survival selection, no study to date has described a genetic selection for specific full-
length IgG antibody binding. This is partly because full-length IgG expression in E. 
coli had only been achieved by exporting the light and heavy chain polypeptide 
subunits to the periplasm where disulfide bonds can readily form. This requirement 
does not permit the use of cytoplasmic based reporters and would complicate 
implementation of a selection based on periplasmic reporters. However, recently we 
overcame this hurdle by proving that full-length monoclonal IgG antibodies 
(cyclonals) can in fact be expressed within the cytoplasm of bacteria engineered to 
permit cytoplasmic disulfide bonding. This finding opens up the possibility that a 
cytoplasmic reporter could be used to develop a selection for specific antibody:antigen 
binding. 
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Figure 4.2 Enzyme catalyzed synthesis of EPSP. (a) The synthesis of 5-
enolpyruvyl-shikimate-3-phophate (EPSP) is catalyzed by the product of the aroA 
gene. EPSP synthase facilitates the conversion of shikimate-3-phosphate (S3P) and 
phosphoenolpyruvate (PEP) generating EPSP and releasing a phosphate (b) Chemical 
structure of EPSPS substrate PEP and competitive inhibitor glyphosate N-
phosphonomethylglycine. 
 
In this study, we developed a genetic selection for reporting the binding of a 
full-length antibody to its target antigen within the cytoplasm of engineered bacterial 
cells based upon functional complementation of 5-Enol-pyruvl-shikimate-3-phosphate 
synthase (EPSPS). EPSPS is an enzyme produced natively in many plants, fungi, and 
other microorganisms that catalyzes the synthesis of 5-enol-pyruvl-shikimate-3-
phosphate (EPSP) from shikimate-3-phosphate (S3P) and phosphoenolpyruvate (PEP) 
[171-174](Figure 4.2a). EPSP is an important precursor to the aromatic amino acids 
phenylalanine, tyrosine, and tryptophan[175]. E. coli lacking a functional copy of the 
aroA gene, the native gene that codes for the EPSPS, are auxotrophic with respect to 
aromatic amino acids and thus do not grow on minimal media[175]. 
Glyphosate (N-phosphonomethylglycine), a competitive inhibitor of EPSPS, is 
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broadly effective against plants, bacteria, and most organisms that utilize the shikimate 
pathway [176-178] (Figure 4.2b). It is the active ingredient of the herbicide Roundup 
(Monsanto) which is widely used in agriculture. As a result, several groups 
investigated protein fragment complementation as a means to engineer glyphosate 
tolerance in valuable crops while preempting lateral gene transfer of glyphosate 
resistance to other unwanted plants [179-181]. E. coli is often used as model system in 
several of these studies to test glyphosate resistance. For example, Synechocystis sp. 
PCC6803 DnaE split intein was shown to reconstitute a glyphosate tolerant version of 
S. typhimurium EPSPS from split fragments and confer growth on minimal media 
supplemented with glyphosate to an E. coli aroA knockout strain [179]. In another 
study, Dai et al. identified potential split sites within E. coli EPSPS using 
computational prediction methods to predict stable circular permutation mutants and 
then tested the ability of the most stable mutants to confer survival on aroA deficient 
cells cultured on minimal media[180]. Predicted split sites were confirmed by 
demonstrating that the two complementary fragments created by dissection at any one 
of the given sites restored growth on minimal media if the fragments were fused to 
homodimerizing leucine zippers[180].  
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Figure 4.3 Structure of EPSPS synthase in its open and closed conformations. (a) 
Three-dimensional representation of the crystal structure of the EPSPS in its “open” 
conformation (i.e. without bound ligands). Cartoon shows the two distinct globular 
domains of EPSPS that are composed entirely of αβ-type folding units (b) “Closed” 
conformation of EPSPS in a complex with one of its substrates S3P (yellow) and 
competitive inhibitor glyphosate (magenta) represented as “ball-and-stick” models. 
Figure taken from Schönbrunn[172]. 
 
Here, we implemented a PCA in which EPSPS is dissected into two inactive 
fragments, one of which is fused to a full-length antibody and the second fused to its 
target antigen. The antibody:antigen interaction facilitates association of the two 
fragments thereby reconstituting the activity of EPSPS in vivo. The reassembled 
EPSPS enzyme confers growth on minimal media as well as resistance to glyphosate. 
Using this strategy we are able to distinguish between ∆aroA cells coexpressing 
specific and non-specific cyclonal:antigen binding pairs. We demonstrate with three 
cognate antibody:antigen pairs that only SHuffle ∆aroA cells expressing a specific pair 
exhibit robust growth on minimal media. This allows us to distinguish those cells from 
those coexpressing a non-interacting pair by observing a simple phenotype. 
Glyphosate supplementation of the minimal media resulted in an increase of the 
stringency of the PCA further allowing discrimination between interacting and non-
interacting cases. Using the EPSPS PCA, we were able to isolate cells harboring a 
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specific antibody:antigen pair from a mock library of cells that contained a 1000-fold 
excess of cells coexpressing a non-interacting antibody:antigen pair. With further 
development, our EPSPS PCA could become a powerful antibody engineering tool 
that because of its simplicity makes antibody development an option for virtually any 
standard molecular biology lab. 
Results 
The aroA gene is essential for growth of SHuffle T7 Express cells on minimal 
media. Wild-type E. coli cells express EPSPS endogenously which allows them to 
grow on minimal media [182, 183]. In order to use in vivo EPSP synthase activity as a 
fitness filter, we first generated aroA knockouts in the SHuffle strain background 
(SHuffle ∆aroA). SHuffle ∆aroA cells showed no detectable growth when cultured on 
M9 minimal media agar confirming previous studies that found that EPSP synthase 
was required for survival under these conditions (Figure 4.4a). Complementation with 
EPSP synthase, expressed from either pBAD34-EPSPS or pET21b-EPSPS, restored 
viability to SHuffle ∆aroA cells on M9 agar (Figure 4.4a). The high level of EPSPS 
expression from the T7 driven pET21b vector appears to be mildly toxic to the cells as 
they grow slightly less dense compared to those complemented with pBAD34-EPSPS. 
SHuffle ∆aroA cells expressing plasmid encoded EPSPS exhibited higher levels of 
resistance to the antimicrobial agent glyphosate when compared to the wild-type 
SHuffle strain. SHuffle ∆aroA cells complemented with the aroA gene were observed 
to grow on concentrations of glyphosate reaching as high as 5 mM while wild-type 
SHuffle cells failed to survive on M9 minimal agar supplemented with greater than 
1mM glyphosate. 
 A previous study reported that complementary EPSPS fragments, one 
composed of residues 1-235 of S. typhimurium EPSPS and the other composed of 
residues 236-427 of S. typhimurium EPSPS, could complement aroA knockouts if 
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fused to interacting domains of a split intein.  As inactivity of the fragments resulting 
from the genetic dissection of the full-length gene is paramount to a robust PCA 
selection, we sought to determine if E. coli EPSPS dissected into two analogous 
polypeptide fragments lacked EPSPS activity. Additionally, we sought to prove that 
the fragments would not spontaneously reassemble into functional EPSPS when 
coexpressed in SHuffle ∆aroA cells. Therefore, we constructed one vector for 
expressing the fragment consisting of residues 1-235 of E. coli EPSPS (EPSPSN235), 
and a second vector for expressing the fragment composed of residues 236-427 of 
EPSP synthase (EPSPSC236). Neither the expression of the fragments by themselves 
nor the coexpression of both EPSPS fragments conferred survival upon SHuffle 
∆aroA cells when cultured on minimal media (Figure 4.4a).  
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Figure 4.4 Complementation of EPSP synthase enzyme in SHuffle T7 express 
cells. (a) SHuffle T7 Express (SHuffle) or SHuffle T7 Express with the aroA deleted 
(∆aroA) expressing the full-length EPSP synthase enzyme (EPSPS), the N terminal 
EPSP synthase fragment (EPSPSN235), the C terminal EPSP synthase split fragment 
(EPSPSC236), or both split fragments (EPSPSN235 + EPSPSC236) were streaked and 
cultured on M9 minimal media agar. Proteins were expressed from either the pBAD34 
(arabinose inducible) vector or pET21b (b) Selective spot plating of serially diluted 
SHuffle T7 express (SHuffle), SHuffle T7 express ∆aroA (SHuffle ∆aroA) cells, and 
SHuffle T7 Express ∆aroA cells carrying the pBAD24-EPSPS (SHuffle ∆aroA + 
pAroA). SHuffle T7 express was plated as a positive control while SHuffle T7 express 
∆aroA cells without a plasmid were plated as a negative control.  
 
EPSP synthase activity reconstituted with basic leucine zipper interactions. 
Having demonstrated that the previously reported EPSPS fragments EPSPSN235 and 
EPSPSC236 do not possess EPSPS activity, we sought to confirm that fusing the 
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fragments to a known interacting pair would result in functional complementation of 
EPSPS in the SHuffle ∆aroA strain background. As an initial test of this concept, we 
chose to fuse the EPSPS fragments to the basic region leucine zipper (bZIP) domains 
of c-Fos (FosLZ) and c-Jun (JunLZ) (Figure 4.5a). The interaction between leucine 
zipper domains is strong and well-characterized [184-186] and is often used as a 
model interaction to validate protein-protein interaction reporters and PCAs [88, 187, 
188]. SHuffle ∆aroA cells expressing FosLZ- EPSPSN235 (FosLZ fused to N 
terminally EPSPSN235) and JunLZ-EPSPSC236 (JunLZ domain fused to the C terminus 
of EPSPSC236) showed a selective advantage over cells that coexpressed the unfused 
fragments when plated on M9 minimal media agar (Figure 4.5b).  While EPSPS 
complementation facilitated by the FosLZ:JunLZ interaction resulted in restoration of 
cell viability, SHuffle ∆aroA cells expressing FosLZ:JunLZ assembled EPSP synthase 
are less viable than wild-type SHuffle T7 Express cells (Figure 4.5b).  
 
 
 103 
Figure 4.5 FosLZ-JunLZ mediated reconstitution of split EPSP synthase 
fragments. (a) Schematic representation of FosLZ:JunLZ oligomerization mediated 
reactivation of EPSPS. FosLZ is fused to the N terminus of an EPSPS fragment 
composed of residues 1-235 (EPSPSN235) by means of a flexible linker 
(Ala(Ser)3(Asn)10) and coexpressed with JunLZ fused to the C terminus of the 
complementary EPSPS fragment composed of residues 236-427 (EPSPSC236). The 
interaction between FosLZ and JunLZ leucine zippers bring the fragments within a 
functional radius within which they can form an active enzyme (b) Selective spot 
plating of serially diluted SHuffle ∆aroA cells carrying plasmids pET21b- EPSPSN235 
and pBAD34- EPSPSC236 (N235 + C236) encoding the two complementary EPSPS 
fragments unfused, or SHuffle ∆aroA cells transformed with pET21b- FosLZ-
EPSPSN235 and pBAD34- EPSPSC236-JunLZ, coding for FosLZ-EPSPSN235 and 
EPSPSC236-JunLZ interacting hybrid protein pair (SHuffle ∆aroA Fos+ Jun). 
Additional controls plated were empty SHuffle and SHuffle ∆aroA cells. 
 
Rational design and characterization of a functional cyclonal-EPSPS fusion for 
PCA. Following the observation that the EPSP synthase-based PCA faithfully reports 
FosLZ:JunLZ heterodimerization, we set forth to determine whether this system could 
be adapted to identify antibody:antigen binding pairs. The requisite folding and 
assembly processes required for the correct biosynthesis of a functional cyclonal 
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presents several challenges. Cyclonals are tetrameric and require stable disulfide bond 
formation for their proper assembly and function. Therefore, one of the most crucial 
design considerations is the location of the EPSPS fragment in its fusion with the 
cyclonal.  
There are four conceivable positions where an EPSP synthase fragment may be 
fused to a cyclonal of interest. These include the amino and carboxyl terminus of the 
light chain and the amino and carboxyl terminus of the heavy chain. The position of 
the EPSPS fusion must meet three critical criteria (Figure 4.7): (1) Allow for correct 
assembly of the IgG tetramer via disulfide bonding (2) Not interfere with antigen 
binding, and (3) Enable the split fragments to reassemble upon antigen:cyclonal 
interaction. Fusion to the N terminus of either cyclonal chain could potentially 
interfere with antigen binding since the binding pocket (formed by the six CDR loops) 
is structurally adjacent to the N terminus of both chains. However, these N terminal 
fusions should not interfere with heavy chain-heavy chain assembly (e.g. disulfide 
bonding) as the heavy chain cysteines within the hinge region (C226 and C229) should 
be completely free to participate in disulfide bonding. The C terminus of the light 
chain is distal to the antigen binding surface at N terminus of the cyclonal. Therefore 
EPSPS fusions to the C terminus of the light chain should also avoid interference with 
antigen recognition. Fusion to the C terminus of the heavy chain, however, would 
most likely position the fused EPSPS fragment too far from the antigen binding 
surface to functionally reconstitute enzymatic activity without the use of a long linker. 
Therefore, fusing an EPSPS fragment C terminally to the cyclonal light chain struck 
the best balance between positioning the fusion as close as possible to the antigen 
binding region while having minimal interference with binding and full-length 
cyclonal assembly.  One possible disadvantage to fusing an EPSPS fragment to the C 
terminus of the light chain would be interference with heavy chain/light chain 
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assembly as the final cysteine at the C terminus of light chain participates in interchain 
disulfide bonding with C220 of the heavy chain. Nevertheless, a C terminal fusion to 
the light chain still represents the most rational option. 
To determine if cyclonal-EPSPS fusions retained binding activity, we 
constructed a vector that coded for the expression of the EPSPSN235 fragment 
genetically fused to the C terminus of the anti-MBP mFab/hFc cyclonal light chain 
(IgL-aMBP-EPSPSN235). The gene coding for the full-length anti-MBP mFab/hFc 
heavy chain (IgH-aMBP) was cloned into the same cistron to generate a bicistronic 
expression vector. The cyclonal- EPSPSN235 fusion was then expressed in SHuffle 
∆aroA cells Next, the binding activity of the crude lysate prepared from these cells 
was measured by ELISA (Figure 4.6). Soluble lysate containing anti-MBP- 
EPSPSN235 showed 20-fold greater binding activity against MBP when compared with 
lysate containing anti-HAG- EPSPSN235, a non-specific cyclonal-EPSPS fusion. 
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Figure 4.6 Characterization of cyclonal-EPSPS fusions. Binding activity of soluble 
cell extract containing the anti-MBP cyclonal-EPSPS fusion was measured by ELISA. 
Extracts were normalized by total protein content. EPSPSN235 is genetically fused to 
the C terminus of the light chain. The anti-MBP cyclonal-EPSPS fusion was expressed 
from pMAZ360-cIgG-aMBP-mFab/hFc(L)-EPSPSN235 in SHuffle ∆aroA cells. Anti-
HAG IgG expressed from pMAZ360-cIgG-aHAG-mFab/hFc in SHuffle ∆aroA cells 
was used as a negative control. 
 
Protein fragment complementation of EPSPS reports antibody:antigen binding. 
Having demonstrated that the anti-MBP cyclonal-EPSPS fusion retains binding 
activity, we sought to prove that EPSPS complementation could report antigen binding 
in vivo. The gene for MBP, the target antigen, was fused to the complementary 
fragment of EPSPSN235, EPSPSC236. SHuffle ∆aroA coexpressing the anti-MBP 
cyclonal- EPSPSN235:MBP- EPSPSC236 PCA pair were tested for EPSPS 
complementation on M9 minimal agar plates supplemented with arabinose and IPTG 
for induction of protein expression. EPSPS complementation facilitated by 
antigen:cyclonal binding restored viability to SHuffle ∆aroA cells even when diluted 
10,000 fold (Figure 4.7). The binding of anti-MBP:MBP appears comparable to that 
of FosLZ:JunLZ as reported by the EPSPS PCA system. No detectable growth was 
observed when anti-MBP- EPSPSN235 was co-expressed with a non-specific antigen, 
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JunLZ, further establishing the specificity of the assay (Figure 4.7).  
 
 
Figure 4.7 Split EPSP synthase selection for antibody:antigen interactions. (a) 
Schematic representation of EPSP synthase PCA based selection for antibody:antigen 
binding. The cyclonal light chain is fused to the N terminus of the EPSPSN235 fragment 
(residues 1-235) by means of a flexible linker (Ala(Ser)3(Asn)10) and coexpressed with 
a protein antigen fused to the C terminus of the complementary EPSPS fragment, 
EPSPSC236 (residues 236-427).The interaction between a specific antibody:antigen pair 
facilitates reconstitution of EPSPS activity and confers growth on minimal media  (b) 
Spot plating of serially diluted SHuffle ∆aroA cells carrying plasmids pMAZ360-
cIgG-aMBP-mFab/hFc(LC)-LN10-EPSPS(N)235 and pBAD34-EPSPSC236- MBP 
(anti-MBP + MBP) encoding the matching antibody-antigen pair, or SHuffle ∆aroA 
cells transformed with pMAZ360-cIgG-aMBP-mFab/hFc(LC)-LN10-EPSPS(N)235 
and pBAD34- EPSPSC236-JunLZ, coding for a non-specific pair (SHuffle ∆aroA anti-
MBP + Jun). SHuffle and SHuffle ∆aroA cells were plated as negative controls.  
Having confirmed that the anti-MBP cyclonal:MBP pair enabled growth of 
SHuffle ∆aroA cells in the split EPSPS-based PCA, we aimed to prove that this assay 
is robust and applicable to a wide-range of cyclonal:antigen pairs. Replacing the anti-
MBP cyclonal:MBP pair with two different cognate pairs, namely anti-HAG:HAG and 
Humira (anti-TNFα):TNFα yielded a similar growth advantage on minimal media 
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when compared with non-binding pairs. Furthermore, we also investigated 
supplementing the minimal media agar with the EPSP synthase inhibitor glyphosate as 
a means of applying additional selective pressure within the context of the EPSPS 
PCA. We found that cells expressing strongly interacting cyclonal:antigen pairs were 
in fact resistant to glyphosate up to at least 0.2 mM (200 µM) (Figure 4.8).   
 
 
Figure 4.8  Extension of EPSPS PCA selection to therapeutic antibodies  Selective 
spot plating of serially diluted SHuffle ∆aroA cells carrying plasmids coding for the 
anti-HAG-mFab/hFc-EPSPSN235 and EPSPSC236-HAG antibody-antigen pair (anti-
HAG + HAG), pMAZ360-cIgG-aHAG-mFab/hFc(LC)-LN10-EPSPS(N)235 and 
pBAD34-EPSPSC236- HAG, and SHuffle ∆aroA cells transformed with pMAZ360-
cIgG-Humira(LC)-LN10-EPSPSN235 and pBAD34- EPSPSC236-TNFα, encoding the 
matching Humira -EPSPSN235 and EPSPSC236- TNFα antibody-antigen pair (anti-
TNFa + TNFa). SHuffle ∆aroA cells transformed with plasmids coding for 
mismatched pairs anti-MBP-mFab/hFc-EPSPSN235 and EPSPSC236-HAG (anti-MBP + 
HAG) or anti-MBP-mFab/hFc-EPSPSN235 and EPSPSC236- TNFα, (anti-MBP + 
TNFα) served as negative controls.  
 
EPSPS PCA facilitates the isolation of cognate cyclonal:antigen pair from a mock 
library. Our preliminary results prove that the EPSPS PCA reliably reports 
antibody:antigen binding in vivo within SHuffle ∆aroA. However, our ultimate 
objective is to apply the strategy to isolating specific cyclonal:antigen pairs from 
diverse libraries, thereby enabling the rapid discovery of highly specific antibodies. 
Toward this goal, we designed a mock library experiment to test if cells expressing 
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matching cyclonal:antigen pairs could be selected from a pool of cells in which non-
interacting pairs are overrepresented.  Cells carrying split-EPSPS PCA plasmids for 
expressing anti-MBP- EPSPSN235 and EPSPSC236-MBP, and cells expressing anti-
MBP- EPSPSN235 and EPSPSC236-JunLZ were mixed at a ratio of 1:1000. The cell 
mixture was cultured on minimal media and colonies picked at random were analyzed 
for the identity of the antigen (EPSPSC236 fusion partner).  The cell mixture was 
cultured on Lysogeny broth (LB) agar in parallel as a control for the mock library. 
Analysis of 26 randomly selected colonies revealed that each carried the cognate pair 
when the mock library was selected on M9 minimal agar. In contrast, none of the 26 
colonies selected from the LB agar control plate harbored the specific anti-MBP:MBP 
pair, which suggests that selection for viability on minimal media favors the matched 
cyclonal:antigen pair. A second trial of the same experiment revealed similar results in 
which ~77% (20/26) of colonies picked from the minimal media plate contained the 
interacting pair whereas none of the colonies analyzed from the LB plate carried that 
pair (Figure 4.9). 
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Figure 4.9 Isolation of cognate antibody:antigen interaction from mock library 
using EPSPS PCA selection. (a) SHuffle ∆aroA cells were transformed with the 
cognate plasmid pair, pMAZ360-cIgG-aMBP-mFab/hFc(LC)-LN10-EPSPSN235 and 
pBAD34-EPSPSC236- MBP, or a non-specific pair pMAZ360-cIgG-aMBP-
mFab/hFc(LC)-LN10-EPSPSN235 and pBAD34-EPSPSC236- JunLZ. Cells were 
normalized by A600 and mixed at a 1:1000 matched pair:unmatched pair ratio to make 
the mock library. The mock library was then plated on M9 minimal media agar 
supplemented with arabinose (0.4% w/v) and IPTG (1mM). The mock library was also 
plated on LB agar supplemented with arabinose (0.4% w/v) and IPTG (1mM) as a 
control. Single colonies were analyzed for the presence of either EPSPSC236- JunLZ or 
EPSPSC236- MBP gene by PCR. (b) Number of occurrences of each antigen after PCR 
analysis of single colonies. 26 colonies were analyzed from control and selection 
plates. 
 
Discussion  
We have successfully developed a survival selection that reports specific 
binding of full-length IgG antibodies to their target antigens within the cytoplasm 
engineered bacterial cells. Our results constitute the first example of a simple selection 
in which bacterial cells are used to report such interactions between full-length IgG 
antibodies and their antigens in vivo. While several laboratories have developed 
survival selections as a means to both report and identify specific binding between an 
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antigen and antibody fragments, none of these strategies to date have been applied to 
full-length IgGs. To achieve this milestone, we developed a version of the protein 
fragment complementation assay in which cell viability is predicated on EPSPS 
activity that in turn relies upon the specific intracellular interaction of a full-length IgG 
and its cognate antigen. This adaptation of the assay is made possible through the use 
of the redox engineered E. coli SHuffle strain which we showed in previous work 
permits the expression of active and correctly assembled IgG antibodies within its 
cytoplasm. 
 We first confirmed that EPSPS activity, essential for growth on minimal 
media agar, is a selectable phenotype for the E. coli SHuffle strain as cells with a 
genomic deletion of the aroA gene were not viable unless its product EPSPS was 
complemented exogenously from a plasmid.  Essentiality of EPSPS for growth on 
minimal media was previously shown for wild-type E. coli cells, and had not been 
confirmed in redox-engineered cells. Through further experiments, we validated 
EPSPS as a suitable PCA reporter by showing that cells expressing inactive EPSPS 
fragments as fusions to the strongly interacting leucine zipper pair FosLZ and JunLZ, 
possess a selective advantage over those cells expressing the fragments alone or as 
fusions to non-interacting protein pairs. Interestingly, while EPSPS PCAs have been 
shown to report homodimerization between leucine zippers and interactions between 
split inteins, this is the first study describing the use of an EPSPS PCA to report 
heterodimeric interactions in bacteria.  
The PCA was then adapted for use with cyclonals by first rationally designing 
a cyclonal fusion to the N terminal fragment of EPSPS via the C terminus light chain. 
First, we confirmed that the first cyclonal fusion, anti-MBP-EPSPSN235, retained MBP 
binding activity. Next, we further extended our variation on the EPSPS PCA by 
showing that our model IgG:antigen case, anti-MBP:MBP, restores cell growth to 
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Shuffle ∆aroA cells on M9 minimal media. Though we conceptualized our fusion 
constructs by rational design and achieved positive results, we did not test all possible 
orientations. An empirical approach may reveal more optimal designs. It would be 
prudent to test alternate designs in the future.  
Two additional IgG:antigen pairs were shown to facilitate reconstitution of 
functional EPSPS and restore growth to Shuffle ∆aroA cells on minimal media. 
Importantly, it is significant that complementation was demonstrated using a diverse 
collection of antigens derived from very different sources. Our results show that the 
EPSPS PCA is compatible with a peptide antigen derived from a viral coat protein 
(HAG), a native E. coli protein (MBP), and a therapeutically relevant human derived 
antigen (TNFα). In addition, the Humira:TNFα and anti-HAG:HAG pairs conferred 
tolerance to glyphosate upon SHuffle ∆aroA cells. This is crucial as glyphosate 
resistance will likely play an important role as we develop the assay for cyclonal 
selection and affinity maturation. The selective pressure provided by glyphosate would 
be integral in implementing any directed evolution strategy to engineer the biophysical 
properties of an antibody of interest. Additionally, we demonstrated a proof-of-
concept selection by enriching cells expressing the anti-MBP:MBP pair from a mock 
library in which cells expressing non-interacting pairs were 1000 times more 
abundant.  The selection represented a ~700 fold enrichment of the anti-MBP:MBP 
expressing cells in one step. 
Our work has explored the molecular versatility of the EPSPS PCA. Several 
studies have exploited EPSPS PCAs for the purposes of engineering glyphosate 
resistance, however, none as of yet has explored the possibility of using it as a tool to 
report binding interactions. Notably all previous studies involving an EPSPS PCA 
were more focused on studying properties of the EPSPS enzyme itself and not protein-
protein interactions as we have done here. The archive of information accumulated as 
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a result of nearly four decades of studies focused solely on EPSPS includes structural, 
kinetic, biochemical, and phylogenic data which could be leveraged in the future to 
improve and refine the PCA. 
To date all other E. coli based isolation strategies have involved IgG export to 
the periplasm, fluorescently conjugated antigens, fluorescence-activated cell sorting, 
and/or panning on immobilized antigen [92, 93, 95].  Our EPSPS PCA represents the 
simplest protocol for identifying IgG:antigen binding as it only requires 
transformation, protein expression, and cell culture on selective media, which are all 
standard techniques performed by molecular and cellular biologists. We are able to 
report antibody reactivity without special ex vivo preparation of the antigen, rigorous 
washing or panning steps, laborious technical methods, or specialized equipment. We 
believe that our study is the first step on the way to a technique that would expand 
access to antibody development technology. 
Materials and Methods 
Plasmid construction. All cloning was performed using standard techniques. To 
construct vectors for the expression of EPSP synthase, total DNA was extracted from 
SHuffle T7 express using a DNeasy® Blood and Tissue kit (Qiagen). The full-length 
aroA gene was then amplified using the purified genomic DNA as a template by PCR 
using primers that added a 5’ NdeI restriction site and a HindIII restriction site at the 
3’ end. The product was then ligated with pET21b using the NdeI and HindIII 
restriction sites to generate pET21b-EPSPS. To construct the pBAD34-EPSPS vector, 
the aroA gene was amplified with flanking NcoI and SphI restriction sites and then 
inserted into the NcoI/SphI site of pBAD34. The pBAD24-EPSPS (pAroA) vector was 
created similarly by cloning aroA into the NcoI/SphI site of pBAD24. 
 A DNA sequence for the N terminal split fragment of EPSPS homologous to 
the one reported by Chen et al. composed of EPSPS residues 1-235 (EPSPSN235) was 
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generated by amplifying from the start codon to nucleotide 705 (nucleotides 1-705) of 
the aroA gene. The resulting product was cloned into the NdeI/HindIII site of pET21b 
creating pET21b- EPSPSN235. Nucleotides 706-1281 of aroA were PCR amplified to 
create the gene for the C terminal fragment of EPSPS (EPSPSC236), which is composed 
by residues 236-427 of EPSPS, and ligated between NcoI and SphI restriction sites of 
pBAD34 resulting in the expression vector pBAD34-EPSPSC236 .  
In order to produce the sequence for a MBP fusion to EPSPSC236, DNA 
encoding EPSPS residues 236-427 was amplified from pAroA inserting a NcoI site at 
the 5’ end and a sequence overlap coding for part of a flexible linker at the 3’ end of 
the PCR product. The MBP gene was amplified from pMAL-c5X (NEB) with primers 
that added an overlap to the 5’ of MBP and a 3’ SalI site. EPSPSC236 coding sequence 
was fused to 5’ end of MBP by overlap extension PCR creating a genetic fusion of 
two genes with the overlap coding for a flexible linker, ASSSNNNNNNNNNN 
(LN10), followed by a KpnI site resulting in a gene that codes for EPSPSC236-LN10-
MBP. The EPSPSC236-LN10-MBP fusion was cloned into the NcoI/SalI site of 
pBAD34 to create pBAD34-EPSPSC236- MBP. The HAG peptide DNA insert was 
generated through annealing complementary oligonucleotides that encoded KpnI and 
SalI overhangs at the 5’ and 3’ ends respectively. The gene for human TNFα was PCR 
amplified using plasmid pBAD34-hsTNFa_EcOPT which encodes a codon optimized 
version of the gene. Both HAG and TNFα genes were cloned into the KpnI/SalI site of 
pBAD34-EPSPSC236- MBP yielding pBAD34-EPSPSC236- HAG and pBAD34-
EPSPSC236- hsTNFα, respectively.  
To clone vectors for the expression of cyclonal-EPSPS N235 fragment fusions, 
the anti-HAG and anti-MBP mFab/hFc light chain genes (IgL) were first amplified 
from pMAZ360-cIgG-aHAG-mFab/hFc and pMAZ360-cIgG-aMBP-mFab/hFc 
vectors. The light chain genes were then genetically fused via a LN10 linker to 
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EPSPSN235 by overlap extension creating IgL-LN10- EPSPSN235. The anti-HAG 
mFab/hFc light chain- EPSPSN235 fusion was cloned into pMAZ360-cIgG-aHAG via 
the NdeI and HindIII sites creating pMAZ360-cIgG-aHAG-mFab/hFc(LC)-LN10- 
EPSPSN235. The anti-aMBP mFab/hFc light chain- EPSPSN235 fusion was ligated into 
the NdeI/HindIII site of pMAZ360-cIgG-aMBP-mFab/hFc thereby generating the 
vector pMAZ360-cIgG-aMBP-mFab/hFc(LC)-LN10-EPSPSN235. Genes encoding the 
heavy and light chains of the anti-TNFα antibody Humira were amplified from 
pETDuet-cIgG-aTNF. DNA for N terminal fragment of EPSPS was amplified by PCR 
using pBAD34-EPSPS as the template. The light chain was genetically fused to 
EPSPSN235 by overlap extension PCR. The light chain Humira-LN10- EPSPSN235 gene 
was cloned into cyclonal expression vector pMAZ360-cIgG between the NdeI and 
HindIII restriction sites in order to make an intermediate product pMAZ360-IgL-
Humira-LN10- EPSPSN235. The plasmid pMAZ360-cIgG-Humira(LC)-LN10- EPSPS-
N235 was produced by ligating the Humira heavy chain sequence into the NheI/XhoI 
site of pMAZ360-IgL-Humira-LN10- EPSPSN235.  
Selective growth assays. For initial determination of in vivo EPSP synthase activity, 
SHuffle ∆aroA  cells harboring control vectors, vectors for expression of  EPSP 
synthase, EPSP synthase fragments,  or EPSPS PCA fusions were grown overnight  in 
Lysogeny broth (LB) medium supplemented with 100 µg/ml carbenicillin for pET21 
or 34 µg/ml pBAD34 vectors at 30 C. Cells from overnight culture were harvested by 
centrifugation and approximately 109 cells of each strain were washed using M9 
minimal medium by centrifugation at 16, 000xg to remove traces of LB and then 
normalized to 2.5 (A600).  The cells were serially diluted 10-fold in M9 media. A 
volume of 5 µl of cells from each dilution were cultured on solid M9 minimal Agar 
containing 1 mM IPTG, 0.4% Arabinose, and 0-5 mM glyphosate at 30ºC for 72-96 h. 
Images of selection plates were produced using the GelDoc or the ChemiDoc XRS+ 
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molecular imager. 
Protein expression. SHuffle T7 Express cells carrying plasmids form cyclonal- 
EPSPSN235 expression were cultured in LB media supplemented with 100 µg/ml 
ampicillin at 30°C overnight. Overnights were subcultured in 3-5 mL LB with 100 
µg/ml ampicillin at 30°C to mid-log phase (0.6-0.8 A600). Protein expression was 
induced with 1 mM IPTG at 30°C for 12-18 h.  
Enzyme-linked immunosorbent assay (ELISA). Costar 96-well ELISA plates 
(Corning) were coated overnight at 4°C with 50 µl of 4µg/ml 1 MBP5 (New England 
Biolabs), in 0.05 M sodium carbonate buffer (pH 9.6). After blocking with 3% (w/v) 
milk in PBST (PBSTM) for 1–3 h at room temperature, the plates were washed four 
times with PBS buffer and incubated with serially diluted soluble fractions of crude 
cell lysates for 1 h at room temperature. IgG-containing samples were quantified by 
the Bradford assay and an equivalent amount of total protein (typically 8–64 mg) was 
applied to the plate. After washing four times with the same buffer, 50 µl of 1:5,000-
diluted rabbit anti-human IgG (Fc) antibody–HRP conjugate (Pierce) antibodies in 
PBSTM was added to each well for 1 h. The 96 well Plates were washed six times 
with PBST. After the final wash, 200 µl SigmaFAST™ OPD solution (Sigma-
Aldrich) was added and incubated within each well in the dark for 30 min. The HRP 
reaction was then terminated by the addition of 50 µl 3 M H2SO4 to the wells. 
Following reaction quenching, the absorbance of each well was measured at 492 nm. 
Protein analysis. Cells expressing recombinant proteins were harvested by 
centrifugation (4,000g, 4°C) and resuspended in PBS, Halt protease inhibitor, and 5 
mM EDTA. Cells were lysed by sonication on ice using a Branson sonifier 450 (Duty 
cycle 30% Output control 3) using four repetitions of 30 sec each. The insoluble 
fraction was removed by centrifugation (21,000g, 4°C) and the supernatant collected 
as the soluble fraction. 
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Mock library selection. SHuffle ∆aroA transformed with pMAZ360-cIgG-aMBP-
EPSPSN235 and pBAD34-EPSPSC336-JunLZ or pMAZ360-cIgG-aMBP-EPSPSN235 and 
pBAD34-EPSPSC336-MBP were cultured overnight in 5 mL LB supplemented with 
ampicillin (100 µg/ml), chloramphenicol (34 µg/mL), and spectinomycin (25 µg/ml) 
at 30°C. SHuffle cells were harvested by centrifugation and the LB media was 
decanted. Cells were then washed twice with minimal media to remove traces of LB. 
Cells from overnight culture were normalized to A600 = 2.5 in M9 minimal media. 
SHuffle ∆aroA harboring pMAZ360-cIgG-aMBP-EPSPSN235 and pBAD34-
EPSPSC336-MBP were diluted 10-fold with normalized SHuffle ∆aroA cells carrying 
the pMAZ360-cIgG-aMBP-EPSPSN235 and pBAD34-EPSPSC336-JunLZ plasmid in 
minimal media. 
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CHAPTER 5 
PROSPECTUS FOR BACTERIA-ENABLED CYCLONAL ENGINEERING 
Introduction 
Shortening the process and development time for monoclonal antibodies has 
long been a goal of antibody engineers. Additionally, greater control of discovery, 
affinity maturation, and engineering of mAb properties has been desired. Data 
presented in the previous chapters demonstrate that we have made progress toward 
these goals. We have proved that we can rapidly produce and engineer both antigen 
and effector activity using cyclonal technology. We also showed that selecting high 
affinity full-length antibodies from combinatorial libraries using simple E. coli-based 
survival assays is possible. Our focus in the near future will be on improving the 
efficiency of production in SHuffle cells and adaption of the cyclonal technology to 
select antibodies against diverse antigens in an attempt to completely bypass 
immunization. In this chapter experimental designs aimed at addressing these 
challenges will be proposed. 
Discussion  
Improvements on cyclonal expression system. Previous studies have found that 
placing antibody light and heavy chains under the control of separate promoters can 
greatly enhance full-length antibody assembly in E. coli by balancing the expression 
of the heavy and light chains[94]. Our current bicistronic constructs place expression 
of the HC and the LC under the control of the same promoter. Expression data we 
have collected so far suggest that the total expression of heavy chain is not optimally 
balanced with total light chain expression as we observe a large excess of monomeric 
light chain when cyclonals are expressed within the cytoplasm of SHuffle. We 
hypothesize that this imbalance is a result of the second gene in the cistron being 
transcribed less efficiently than the first. As such, we could apply this strategy to our 
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system in an attempt to improve the assembly efficiency of heavy and light chains into 
full-length antibodies. We will first clone dual promoter constructs using several 
diverse promoters. We will then clone HC and LC sequences such that each is under 
the control of its own promoter. These constructs will be used to transform SHuffle 
cells. IgGs will be expressed cytoplasmically in SHuffle cells and assembly will be 
assayed by western blot. The assembly efficiency will be compared to that of the same 
IgG expressed from the original bicistronic construct. Assembly efficiency of IgGs 
expressed in SHuffle cells from separate cistron and bicistronic constructs will also be 
evaluated by Coomassie staining after resolution of Protein A-purified IgG samples by 
SDS-PAGE. The Coomassie stained gels will be analyzed by densitometry to compare 
the assembly efficiency in the different experimental cases.  
Promoter engineering could also be combined with other available strategies to 
enhance full-length IgG expression in our system. Engineering the translation 
initiation region, 5’ untranslated region (UTR) engineering, ribosome binding site 
(RBS) engineering, and strain engineering, have all been used successfully to increase 
IgG production in periplasmic systems. Any of these strategies could also be applied 
in SHuffle [94, 189-191]. 
Affinity maturation of selected cyclonals. Interestingly, The CDR-H3 of the GTK 
clone selected in Chapter 3 departs from the observed preferences for anti-GCN4 
binders reported in previous works and appears to have the weakest affinity for GCN4 
as measured by ELISA. This provides an opportunity to explore the application of the 
CAT-Ag selection to antibody affinity maturation. Clone GTK is specific for GCN4 
but has low affinity and therefore is a good candidate to use as a starting point for 
affinity maturation in a second round of selection. To test this, we could generate a 
second round cyclonal library by error prone PCR mutagenesis of the GTK cyclonal or 
by targeting another CDR, most likely CDR-L3, for mutagenesis. The library would 
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then be selected at a higher concentration range of Cm (30-50 μg/ml). If a higher 
affinity variant of GTK can be selected this would be yet another step in proving the 
utility of the CAT-Ag selection strategy. 
 Reprogramming antigen specificity of an existing antibody toward a new 
antigen. We have demonstrated that the CAT reporter can select for antibody antigen 
binding within SHuffle cells. To further show the utility of the CAT-Ag reporter 
strategy, we will attempt to select and evolve an antibody against a new antigen. We 
identified two criteria to select a suitable antigen-(1) the antigen should be small (<10 
kDa) and (2) the antigen should be similar to antigen for which we already possess a 
specific antibody. We chose criterion (2) hypothesizing that we would have a better 
chance of finding an antigen specific antibody if we selected a library generated from 
a well-characterized antibody against an antigen that is similar to the cognate antigen 
of the well-characterized antibody. The two criteria led us to select the basic leucine 
zipper domain FosLZ as our target as it is homologous to Gcn4LZ, an antigen for 
which we have a cyclonal, and it is relatively small (~8 kDa).  
 
Figure 5.1 Characterization of CAT-FosLZ antigen for library selection. Selective 
plating of SHuffle cells with plasmids for CAT-Fos (spTorA-CAT-Fos) and CAT-Fos 
fusions with a defective Tat signal peptide that impedes translocation (spTorA(KK)-
CAT-Fos) are indicated. SHuffle cells were serially diluted in LB media and 5 µl was 
plated on LB-agar supplemented with 0 or 20 µg/ml chloramphenicol, 0.4 % 
arabinose, and 1mM IPTG. 
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In order to determine if Fos is a suitable antigen, we constructed two CAT-Fos 
fusions, one with a functional Tat export signal (spTorA-CAT-Fos) and the other with 
a defective Tat export signal (spTorA (KK)-CAT-Fos). SHuffle T7 express cells were 
transformed with these constructs alone or co-transformed with the anti-Gcn4 
antibody. Cells expressing CAT-Fos preceded by a functional export signal were not 
resistant to chloramphenicol (Figure 5.1). Coexpressing the anti-Gcn4 antibody was 
not sufficient to give chloramphenicol resistance, as presumably it cannot retain 
spTorA-CAT-Fos within the cytoplasm. However, when CAT-Fos is retained within 
the cytoplasm due to a defective Tat export signal peptide (spTorA(KK)), SHuffle 
cells were resistant to chloramphenicol (Figure 5.1). These results support moving 
forward with Fos as a target antigen. We have also constructed a similar CAT-Ag 
reporter fusion using the leucine zipper domain of c-Jun (JunLZ). While we have not 
confirmed its compatibility with the CAT reporter system, we anticipate that the CAT-
JunLZ reporter will behave similar to the other leucine zippers.  
The randomized 3-residue and 4-residue libraries we constructed in Chapter 3 
could be selected for JunLZ and FosLZ binders. In addition, der Maur et al. reported 
successfully selecting JunLZ binders from a library with encoding 6 randomized 
residues within CDR-H3 [133]. We could use the CAT selection system to perform a 
similar selection. Therefore, we have designed library construction strategies to 
generate cyclonals with 5 and 6-residues randomized within CDR-H3. We would use 
the NDT degenerate codon as we selected a greater number of positive hits from the 
NDT library when compared with the NNK library despite the NNK library being 
much larger.  We would select these libraries in parallel with the 3-residue and 4-
residue CDR-H3 libraries against both FosLZ and JunLZ. A successful specificity 
switch to one or both of the antigens would further validate the CAT-Ag selection for 
antibody engineering applications. 
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Construction of a naïve cyclonal library. Attempting to select for more diverse 
antigens would almost certainly require an IgG library much more diverse that the 
CDR-H3 libraries we have previously proposed.  In order to construct a large naïve 
cyclonal library, we would use the scFv Tomlinson I and J libraries, which were 
constructed using stable human VH and VL frameworks [192, 193]. In addition to these 
libraries, we also possess a separate naïve scFv library created in the lab of Dr. Pierre 
Martineau[194] that has been optimized for expression in E. coli. We would amplify 
the VH and VL genes from these libraries by PCR and genetically fuse the amplified 
VH and VL sequences with human constant heavy chain and light chain domains, 
respectively. We would then analyze the diversity of the newly created IgG library by 
sequencing. Finally, we would clone this library into vectors for selection with the 
EPSPS and CAT selection systems. 
Selection from a naïve library. The compatibility of globular antigens with the CAT 
selection has yet to be determined. However, we showed that the EPSPS PCA can 
report binding between cyclonals and antigens ranging from the HAG peptide to MBP 
(~43 kDa). As such, we will test the EPSPS PCA against larger antigens that may not 
be compatible with the CAT-Ag selection. 
 To demonstrate the utility of the EPSPS PCA described in Chapter 4, we 
would select an IgG against a clinically relevant antigen, namely, the extracellular 
domain of the B-cell surface protein CD20. CD20 is an integral membrane phosphor-
protein that is expressed on the surface of ~90% of all B-cell lymphomas and is not 
found on any other cell type, making it an excellent target for immunotherapy [195]. 
As a result, the “blockbuster” anti-CD20 antibody Rituximab (Rituxan) has been 
widely used to treat non-Hodgkin’s lymphoma and leukemia since its approval in 
1997. Last year, Genentech won FDA approval of a new mAb, Obinutuzumab 
(Gazyva), which also targets CD20. This indicates that CD20 continues to be a 
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relevant antigen for monoclonal antibody development.  
The extracellular loop of CD20 (exCD20) is the epitope for all currently 
available anti-CD20 antibodies[195]. Therefore, we would select our library against 
this epitope. Soluble expression of exCD20 in E. coli has been reported[196]. 
Therefore, we would co-transform the IgG libraries generated above with a vector 
encoding an exCD20-EPSPS fusion. We would select the library on M9 minimal 
media. The growth phenotype of selected cells would then be confirmed by back 
transforming DNA from the selected clones into fresh SHuffle cells. Once confirmed, 
we would express the selected IgGs and measure exCD20 binding activity by ELISA.  
To further improve the binding affinity of the selected IgGs against exCD20, 
we would perform additional rounds of selection. This would be accomplished by 
generating a new library based upon the selected IgG clones by random mutagenesis 
of VH and VL genes or by DNA shuffling [70, 71]. We would then select the new library 
at increasing levels of glyphosate to select for IgG mutants that exhibit higher affinity 
for exCD20 as compared to the parent. We would also determine binding kinetics of 
the selected IgG clones by surface plasmon resonance (SPR). 
Recently, there has been a great effort to develop broadly neutralizing 
antibodies (bnAbs) against viral pathogens. Broadly neutralizing antibodies (bnAbs) 
are those that can neutralize many different viral serotypes. Of particular interest are 
those against increasing virulent influenza strains that could be used to protect the 
population in the event of a pandemic. Recent studies have found that these broadly 
neutralizing antibodies recognize a conserved epitope in stem region of HA region 
near the fusion peptide [197, 198]. These antibodies, termed anti-fusogenic antibodies, 
inhibit the membrane fusion event vital for host cell infection. Interestingly, 
production of anti-fusogenic antibodies was elicited in mice by immunization with a 
mutant version of green fluorescent protein (GFP), which was engineered to mimic the 
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structure of the stem region of the influenza A virus[199]. We propose using this same 
protein to select broadly neutralizing antibodies against the influenza virus. We would 
synthesize DNA to encode a GFPHAmut-EPSPS fusion and co-transform this 
construct and the naive IgG libraries into SHuffle. We could then select for anti-viral 
antibodies as described for exCD20. 
Summation 
E. coli has proved to be a useful platform for producing and engineering 
antibodies.  Plückthun and Skerra showed that E. coli possessed the capacity to 
produce specific antibody fragments[62]. The Winter lab demonstrated that bacteria 
and engineered bacteriophage could be used to screen large libraries for specific 
antibodies[74]. Yansura and colleagues at Genentech proved that full-length 
monoclonal antibodies could be expressed in E. coli[94]. Building upon the work by 
the Yansura group, Georgiou and coworkers developed an E. coli-based screen for 
isolating full-length IgG antibodies from combinatorial libraries[93]. Each advance 
further supplemented the toolkit available to develop antibodies crucial to research and 
the treatment of disease. Our work has similarly contributed to this growing body of 
techniques by adding a simple system that could potentially be used from discovery to 
final production without requiring immunization, or a complementary organism (e.g. 
phage, myeloma cells), antigen purification, or additional equipment (e.g. flow 
cytometer). The rapid production offered by the cyclonal platform could prove 
advantageous in the future for producing antibodies in response to epidemics as 
antibody therapies are often used as front-line treatments. Our work opens up the 
possibility that antibody development could be carried out in one system thereby 
allowing reliable affinity reagents to reach researchers more quickly and more cost-
effectively for critical experiments. Finally, with further development we envision our 
system being a transformative platform for discovery and engineering of antibodies for 
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use in life-saving therapies. 
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